The    O
4    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
,    O
palmatine    B-Alkaloid114712692
,    O
NADPH    O
,    O
and    O
H+    O
,    O
whereas    O
its    O
3    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
,    O
corydaline    B-Alkaloid114712692
,    O
and    O
NADP+    O
.    O

Pericine    B-Alkaloid114712692

Nornicotine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
found    O
in    O
various    O
plants    O
including    O
"    O
Nicotiana    O
"    O
,    O
the    O
tobacco    O
plant    O
.    O

Nornicotine    B-Alkaloid114712692

Altemicidin    B-Alkaloid114712692
is    O
monoterpene    O
alkaloid    O
first    O
identified    O
in    O
isolates    O
from    O
marine    O
actinomycetes    O
(    O
specifically    O
Streptomyces    O
sioyaensis    O
)    O
in    O
1989    O
.    O

Complex    O
formation    O
may    O
be    O
the    O
reason    O
why    O
tomatine    O
has    O
a    O
much    O
lower    O
oral    O
toxicity    O
than    O
other    O
glycoalkaloids    B-Alkaloid114712692
.    O

The    O
symptoms    O
of    O
acute    O
tomatine    O
poisoning    O
in    O
animals    O
are    O
similar    O
to    O
the    O
symptoms    O
of    O
poisoning    O
by    O
solanine    B-Alkaloid114712692
,    O
a    O
potato    O
glycoalkaloid    B-Alkaloid114712692
.    O

Human    O
ingestion    O
of    O
solanidine    O
also    O
occurs    O
via    O
the    O
consumption    O
of    O
the    O
glycoalkaloids    B-Alkaloid114712692
,    O
α-solanine    B-Alkaloid114712692
and    O
α-chaconine    B-Alkaloid114712692
,    O
present    O
in    O
potatoes    O
.    O

This    O
wild    O
species    O
contains    O
leptine    O
glycoalkaloid    B-Alkaloid114712692
which    O
make    O
it    O
resistant    O
to    O
the    O
Colorado    O
potato    O
beetle    O
(    O
"    O
Leptinotarsa    O
decemlineata    O
"    O
)    O
,    O
a    O
pest    O
of    O
potato    O
crops    O
.    O

In    O
a    O
2014    O
paper    O
a    O
group    O
first    O
demonstrated    O
the    O
immunomodulatory    O
potential    O
of    O
DMT    O
and    O
5-MeO-DMT    B-Alkaloid114712692
through    O
the    O
Sigma-1    O
receptor    O
of    O
human    O
immune    O
cells    O
.    O

5-MeO-DMT    B-Alkaloid114712692

5-MeO-DMT    B-Alkaloid114712692

It    O
is    O
the    O
4-hydroxy    O
counterpart    O
of    O
5-MeO-DMT    B-Alkaloid114712692
,    O
or    O
the    O
5-methoxy    O
counterpart    O
of    O
psilocin    O
.    O

5-MeO-DMT    B-Alkaloid114712692

Presence    O
of    O
the    O
hallucinogenic    O
tryptamines    O
5-MeO-DMT    B-Alkaloid114712692
,    O
bufotenine    B-Alkaloid114712692
and    O
dimethyltryptamine    B-Alkaloid114712692
,    O
and    O
supposedly    O
the    O
beta-carboline    B-Alkaloid114712692
6-MeO    O
-    O
harmane    O
has    O
been    O
confirmed    O
in    O
"    O
M.    O
pruriens    O
"    O
,    O
apparently    O
the    O
only    O
thoroughly    O
researched    O
species    O
thus    O
far    O
.    O

5-MeO-DMT    B-Alkaloid114712692
,    O
one    O
of    O
the    O
psychedelic    O
tryptamines    O
found    O
in    O
velvet    O
bean    O
(    O
"    O
M.    O
pruriens    O
"    O
)    O
in    O
trace    O
quantities    O
.    O

On    O
January    O
17    O
,    O
2017    O
,    O
in    O
Jackson    O
Hole    O
,    O
Wyoming    O
,    O
after    O
drinking    O
heavily    O
,    O
Hardison    O
and    O
two    O
other    O
men    O
consumed    O
a    O
substance    O
believed    O
by    O
the    O
Teton    O
County    O
,    O
Wyoming    O
coroner    O
to    O
be    O
the    O
psychedelic    O
drug    O
5-MeO-DMT    B-Alkaloid114712692
.    O

While    O
at    O
least    O
one    O
strain    O
showed    O
an    O
extremely    O
strong    O
occurrence    O
of    O
N,N-DMT    B-Alkaloid114712692
as    O
the    O
sole    O
alkaloid    O
,    O
other    O
strains    O
indicated    O
the    O
presence    O
of    O
5-MeO-DMT    B-Alkaloid114712692
as    O
well    O
.    O

oxaline    B-Alkaloid114712692
.    O

Isoteolin    B-Alkaloid114712692
(    O
isoboldine    O
)    O

methyllycaconitine    B-Alkaloid114712692

Methyllycaconitine    B-Alkaloid114712692
,    O
a    O
nicotinic    O
acetylcholine    O
receptor    O
antagonist    O

Panicudine    B-Alkaloid114712692

Raucaffrinoline    B-Alkaloid114712692
is    O
an    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
isolated    O
from    O
the    O
leaves    O
of    O
"    O
Rauvolfia    O
yunnanensis    O
"    O
.    O

A    O
generally    O
recognized    O
pharmacophore    O
model    O
for    O
cocaine    O
and    O
phenyltropane    B-Alkaloid114712692
comprises    O
two    O
electrostatic    O
interactions    O
of    O
the    O
basic    O
nitrogen    O
and    O
the    O
ester    O
group    O
of    O
the    O
C-2    O
substituent    O
,    O
and    O
one    O
hydrophobic    O
interaction    O
of    O
the    O
C-3    O
aryl    O
group    O
.    O

(    O
–)-2β-Carbomethoxy-3β-(4-ethylphenyl)tropane    O
(    O
RTI-"4229"-83    O
)    O
is    O
a    O
phenyltropane    B-Alkaloid114712692
derivative    O
which    O
represents    O
a    O
rare    O
example    O
of    O
an    O
SDRI    O
or    O
serotonin    O
-    O
dopamine    O
reuptake    O
inhibitor    O
,    O
a    O
drug    O
which    O
inhibits    O
the    O
reuptake    O
of    O
the    O
neurotransmitters    O
serotonin    O
and    O
dopamine    O
,    O
while    O
having    O
little    O
or    O
no    O
effect    O
on    O
the    O
reuptake    O
of    O
the    O
related    O
neurotransmitter    O
noradrenaline    O
.    O

RTI(-"4229")-353    O
is    O
a    O
phenyltropane    B-Alkaloid114712692
derived    O
drug    O
which    O
acts    O
as    O
an    O
SSRI    O
.    O

Another    O
stimulant    O
,    O
the    O
phenyltropane    B-Alkaloid114712692
derivative    O
RTI-126    O
,    O
was    O
banned    O
from    O
27    O
December    O
2012    O
.    O

Dichloropane    O
(    O
(    O
−)-2β-Carbomethoxy-3β-(3,4-dichlorophenyl)tropane    O
,    O
RTI-111    O
,    O
O-401    O
)    O
is    O
a    O
stimulant    O
of    O
the    O
phenyltropane    B-Alkaloid114712692
class    O
that    O
acts    O
as    O
a    O
serotonin    O
–    O
norepinephrine    O
–    O
dopamine    O
reuptake    O
inhibitor    O
(    O
SNDRI    O
)    O
with    O
IC50    O
values    O
of    O
3.13    O
,    O
0.79    O
and    O
18    O
nM    O
,    O
respectively    O
.    O

They    O
are    O
derived    O
from    O
berberine    B-Alkaloid114712692
,    O
tetrahydroberberine    O
,    O
protopine    B-Alkaloid114712692
and    O
benzophenanthridine    O
in    O
Papaveroideae    O
,    O
and    O
from    O
spirobenzylisoquinoline    O
and    O
cularine    O
in    O
Fumarioideae    O
,    O
as    O
well    O
as    O
from    O
other    O
groups    O
that    O
give    O
them    O
pharmacological    O
properties    O
:    O
derivatives    O
of    O
aporphine    B-Alkaloid114712692
,    O
morphinan    O
,    O
pavine    B-Alkaloid114712692
,    O
isopavine    B-Alkaloid114712692
,    O
narceine    B-Alkaloid114712692
and    O
rhoeadine    B-Alkaloid114712692
.    O

Chelidonine    B-Alkaloid114712692
(    O
from    O
Snowberries    O
)    O

Penicillium    O
clavigerum    O
is    O
a    O
fungus    O
species    O
of    O
the    O
genus    O
of    O
"    O
Penicillium    O
"    O
which    O
produces    O
fumigaclavine    O
A    O
and    O
fumigaclavine    B-Alkaloid114712692
B    I-Alkaloid114712692

Tazopsine    B-Alkaloid114712692

Bulbocapnine    B-Alkaloid114712692

Bulbocapnine    B-Alkaloid114712692

Human    O
ingestion    O
of    O
solanidine    O
also    O
occurs    O
via    O
the    O
consumption    O
of    O
the    O
glycoalkaloids    B-Alkaloid114712692
,    O
α-solanine    B-Alkaloid114712692
and    O
α-chaconine    B-Alkaloid114712692
,    O
present    O
in    O
potatoes    O
.    O

Eburnamonine    B-Alkaloid114712692

KT5720    B-Alkaloid114712692

Veratridine    O
is    O
a    O
derivative    O
,    O
the    O
3-veratroate    O
ester    O
,    O
of    O
veracevine    B-Alkaloid114712692
,    O
which    O
belongs    O
to    O
the    O
class    O
of    O
C    O
-    O
nor    O
-    O
D    O
-    O
homosteroidal    O
alkaloids    O
.    O

DHICA    B-Alkaloid114712692

The    O
leaves    O
of    O
"    O
Annona    O
muricata    O
"    O
contain    O
annonamine    B-Alkaloid114712692
,    O
which    O
is    O
an    O
aporphine    B-Alkaloid114712692
-    O
class    O
alkaloid    O
featuring    O
a    O
quaternary    O
ammonium    O
group    O
.    O

Narceine    B-Alkaloid114712692
,    O
a    O
lesser    O
known    O
but    O
related    O
opium    O
alkaloid    O
.    O

Species    O
identified    O
in    O
Nigeria    O
contains    O
several    O
types    O
of    O
alkaloids    O
including    O
benzophenanthridines    O
(    O
nitidine    B-Alkaloid114712692
,    O
dihydronitidine    O
,    O
oxynitidine    O
,    O
fagaronine    B-Alkaloid114712692
,    O
dihydroavicine    O
,    O
chelerythrine    B-Alkaloid114712692
,    O
dihydrochelerythrine    O
,    O
methoxychelerythrine    O
,    O
norchelerythrine    O
,    O
oxychelerythrine    O
,    O
decarine    O
and    O
fagaridine    O
)    O
,    O
furoquinoline    B-Alkaloid114712692
(    O
dictamine    O
,    O
8-methoxydictamine    O
,    O
skimmianine    O
,    O
3-dimethylallyl-4-methoxy-2-quinolone    O
)    O
,    O
carbazoles    O
(    O
3-methoxycarbazole    O
,    O
glycozoline    O
)    O
,    O
aporphine    B-Alkaloid114712692
(    O
berberine    B-Alkaloid114712692
,    O
tembetarine    O
,    O
magnoflorine    B-Alkaloid114712692
,    O
M    O
-    O
methyl    O
-    O
corydine    O
)    O
,    O
canthinones    O
(    O
6-canthinone    O
)    O
,    O
acridones    O
(    O
1-hydroxy-3-methoxy-10-methylacridon-9-one    O
,    O
1-hydroxy-10-methylacridon-9-one    O
,    O
zanthozolin    O
)    O
,    O
and    O
aromatic    O
and    O
aliphatic    O
amides    O
.    O

Tabernanthine    B-Alkaloid114712692

"    O
Pholiotina    O
cyanopus    O
"    O
is    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
baeocystin    B-Alkaloid114712692
,    O
norbaeocystin    B-Alkaloid114712692
and    O
aeruginascin    B-Alkaloid114712692
.    O

Research    O
has    O
indicated    O
that    O
the    O
alkaloid    O
dehydrocorybulbine    B-Alkaloid114712692
(    O
DHCB    O
)    O
,    O
extracted    O
from    O
the    O
roots    O
of    O
the    O
plant    O
,    O
can    O
be    O
helpful    O
in    O
reducing    O
neuropathic    O
pain    O
.    O

K252a    B-Alkaloid114712692

K252a    B-Alkaloid114712692

Himbacine    B-Alkaloid114712692

File    O
:    O
Carpaine    B-Alkaloid114712692

Boldine    B-Alkaloid114712692
.    O

The    O
major    O
psychoactive    O
ingredients    O
–    O
arecoline    B-Alkaloid114712692
(    O
a    O
muscarinic    O
receptor    O
partial    O
agonist    O
)    O
and    O
arecaidine    B-Alkaloid114712692
(    O
a    O
GABA    O
reuptake    O
inhibitor    O
)    O
–    O
are    O
responsible    O
for    O
the    O
euphoric    O
effect    O
.    O

Solanine    B-Alkaloid114712692

They    O
also    O
contain    O
small    O
amounts    O
of    O
solanine    B-Alkaloid114712692
,    O
a    O
toxic    O
alkaloid    O
found    O
in    O
potato    O
leaves    O
and    O
other    O
plants    O
in    O
the    O
nightshade    O
family    O
.    O

Like    O
all    O
parts    O
of    O
the    O
plant    O
except    O
the    O
tubers    O
,    O
the    O
fruit    O
contain    O
the    O
toxic    O
alkaloid    O
solanine    B-Alkaloid114712692
and    O
are    O
therefore    O
unsuitable    O
for    O
consumption    O
.    O

The    O
fruits    O
have    O
no    O
value    O
to    O
gardeners    O
as    O
the    O
fruits    O
are    O
inedible    O
as    O
they    O
are    O
filled    O
with    O
solanine    B-Alkaloid114712692
,    O
which    O
causes    O
severe    O
illnesses    O
.    O

Mitragynine    B-Alkaloid114712692
pseudoindoxyl    I-Alkaloid114712692

The    O
resulting    O
brew    O
may    O
contain    O
the    O
powerful    O
psychedelic    O
drug    O
DMT    B-Alkaloid114712692
and    O
MAO    O
inhibiting    O
harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
,    O
which    O
are    O
necessary    O
to    O
make    O
the    O
DMT    O
orally    O
active    O
.    O

Natural    O
variations    O
in    O
plant    O
alkaloid    O
content    O
and    O
profiles    O
also    O
affect    O
the    O
final    O
concentration    O
of    O
alkaloids    O
in    O
the    O
brew    O
,    O
and    O
the    O
physical    O
act    O
of    O
cooking    O
may    O
also    O
serve    O
to    O
modify    O
the    O
alkaloid    O
profile    O
of    O
harmala    B-Alkaloid114712692
alkaloids    O
.    O

However    O
,    O
evidence    O
indicates    O
that    O
harmala    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
act    O
only    O
on    O
MAO    O
-    O
A    O
,    O
in    O
a    O
reversible    O
way    O
similar    O
to    O
moclobemide    O
(    O
an    O
antidepressant    O
that    O
does    O
not    O
require    O
dietary    O
restrictions    O
)    O
.    O

Harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
are    O
MAO    O
-    O
inhibiting    O
"beta"-carboline    B-Alkaloid114712692
.    O

Original    O
measurements    O
for    O
a    O
series    O
of    O
intramolecular    O
amine    O
-    O
carbonyl    O
ketone    O
interactions    O
observed    O
in    O
crystals    O
of    O
compounds    O
bearing    O
both    O
functionalities    O
—    O
e.g    O
.    O
,    O
methadone    O
and    O
protopine    B-Alkaloid114712692
,    O
images    O
at    O

This    O
argemone    O
resin    O
contains    O
berberine    B-Alkaloid114712692
and    O
protopine    B-Alkaloid114712692
.    O

Pukateine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
found    O
in    O
the    O
bark    O
of    O
the    O
New    O
Zealand    O
tree    O
"    O
Laurelia    O
novae    O
-    O
zelandiae    O
"    O
(    O
"    O
Pukatea    O
"    O
)    O
.    O

Pukateine    B-Alkaloid114712692

Some    O
of    O
Shulgin    O
's    O
noteworthy    O
discoveries    O
include    O
compounds    O
of    O
the    O
2C    O
family    O
(    O
such    O
as    O
2C-B    B-Alkaloid114712692
)    O
and    O
compounds    O
of    O
the    O
DOx    O
family    O
(    O
such    O
as    O
DOM    O
)    O
.    O

25B    O
-    O
NBOH    O
(    O
2C    O
-    O
B    O
-    O
NBOH    O
,    O
NBOH-2C    O
-    O
B    O
)    O
is    O
a    O
derivative    O
of    O
the    O
phenethylamine    O
derived    O
hallucinogen    O
2C-B    B-Alkaloid114712692
which    O
has    O
been    O
sold    O
as    O
a    O
designer    O
drug    O
.    O

βk-2C    O
-    O
B    O
(    O
beta    O
-    O
keto    O
2C    O
-    O
B    O
,    O
bk-2C    O
-    O
B    O
)    O
is    O
a    O
psychedelic    O
drug    O
which    O
is    O
structurally    O
related    O
to    O
2C-B    B-Alkaloid114712692
and    O
BOB    O
and    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
.    O

2C-B    B-Alkaloid114712692
(    O
or    O
Nexus    O
)    O
,    O
a    O
psychedelic    O
drug    O
of    O
the    O
2C    O
family    O

In    O
November    O
2013    O
,    O
Baggaley    O
was    O
arrested    O
by    O
Australian    O
Federal    O
Police    O
and    O
charged    O
with    O
various    O
counts    O
of    O
conspiracy    O
to    O
import    O
a    O
commercial    O
quantity    O
of    O
a    O
border    O
-    O
controlled    O
drug    O
into    O
Australia    O
,    O
conspiracy    O
to    O
manufacture    O
and    O
produce    O
a    O
prohibited    O
drug    O
(    O
2C-B    B-Alkaloid114712692
a    O
psychedelic    O
drug    O
)    O
,    O
the    O
manufacture    O
and    O
production    O
of    O
a    O
prohibited    O
drug    O
and    O
one    O
count    O
of    O
supplying    O
a    O
large    O
commercial    O
quantity    O
of    O
a    O
prohibited    O
drug    O
.    O

2C-B    B-Alkaloid114712692

After    O
moving    O
to    O
Brighton    O
,    O
Hardison    O
illegally    O
manufactured    O
three    O
class    O
A    O
drugs    O
:    O
2C-B    B-Alkaloid114712692
,    O
DMT    B-Alkaloid114712692
,    O
and    O
LSD    O
.    O

:    O
C04AE02    O
Nicergoline    B-Alkaloid114712692

Commercially    O
available    O
organobromine    O
pharmaceuticals    O
include    O
the    O
vasodilator    O
nicergoline    B-Alkaloid114712692
,    O
the    O
sedative    O
brotizolam    O
,    O
the    O
anticancer    O
agent    O
pipobroman    O
,    O
and    O
the    O
antiseptic    O
merbromin    O
.    O

Cotinine    O
was    O
developed    O
as    O
an    O
antidepressant    O
as    O
a    O
fumaric    O
acid    O
salt    O
,    O
cotinine    O
fumarate    O
,    O
to    O
be    O
sold    O
under    O
the    O
brand    O
name    O
Scotine    B-Alkaloid114712692
but    O
it    O
was    O
never    O
marketed    O
.    O

CYP2A6    O
is    O
the    O
primary    O
enzyme    O
responsible    O
for    O
the    O
oxidation    O
of    O
nicotine    O
and    O
cotinine    B-Alkaloid114712692
.    O

cotinine    B-Alkaloid114712692
(    O
metabolite    O
of    O
nicotine    O
)    O

Pleiocarpamine    B-Alkaloid114712692
is    O
a    O
natural    O
anticholinergic    O
alkaloid    O
.    O

spirotryprostatin    B-Alkaloid114712692
B    I-Alkaloid114712692
,    O
via    O
the    O
Ganesan    O
approach    O

Following    O
the    O
success    O
of    O
these    O
drugs    O
,    O
semi    O
-    O
synthetic    O
"    O
vinca    O
"    O
alkaloids    O
were    O
produced    O
:    O
vinorelbine    B-Alkaloid114712692
(    O
used    O
in    O
the    O
treatment    O
of    O
non    O
-    O
small    O
-    O
cell    O
lung    O
cancer    O
)    O
,    O
vindesine    B-Alkaloid114712692
,    O
and    O
vinflunine    B-Alkaloid114712692
.    O

If    O
the    O
condition    O
is    O
associated    O
with    O
spasm    O
of    O
the    O
esophagus    O
,    O
antispasmodic    O
medications    O
such    O
as    O
butylscopolamine    B-Alkaloid114712692
can    O
be    O
used    O
.    O

Hyoscine    B-Alkaloid114712692
butylbromide    I-Alkaloid114712692
,    O
an    O
antispasmodic    O
,    O
is    O
also    O
indicated    O
in    O
biliary    O
colic    O
.    O

Such    O
spasms    O
can    O
be    O
controlled    O
with    O
medication    O
such    O
as    O
butylscopolamine    B-Alkaloid114712692
,    O
although    O
most    O
patients    O
eventually    O
adjust    O
to    O
the    O
irritation    O
and    O
the    O
spasms    O
go    O
away    O
.    O

Important    O
industries    O
include    O
beef    O
,    O
dairy    O
,    O
grains    O
and    O
duboisia    O
,    O
used    O
in    O
the    O
production    O
of    O
the    O
antispasmodic    O
drug    O
butylscopolamine    B-Alkaloid114712692
.    O

Other    O
reasons    O
for    O
its    O
shamanic    O
use    O
are    O
the    O
comparatively    O
high    O
levels    O
of    O
beta-carboline    B-Alkaloid114712692
,    O
including    O
the    O
harmala    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
harman    O
and    O
norharman    B-Alkaloid114712692
.    O

Harmine    B-Alkaloid114712692
,    O
also    O
known    O
as    O
telepathine    B-Alkaloid114712692
,    O
is    O
a    O
fluorescent    O
harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
belonging    O
to    O
the    O
beta-carboline    B-Alkaloid114712692
family    O
of    O
compounds    O
.    O

Isolated    O
from    O
the    O
plant    O
"    O
Peganum    O
harmala    O
"    O
,    O
harmine    O
is    O
an    O
indole    O
alkaloid    O
with    O
the    O
pyrido[3,4-b]indole    O
ring    O
structure    O
that    O
is    O
characteristic    O
of    O
the    O
β-carboline    B-Alkaloid114712692
alkaloids    O
.    O

Harmaline    B-Alkaloid114712692
is    O
a    O
fluorescent    O
psychoactive    O
indole    O
alkaloid    O
from    O
the    O
group    O
of    O
harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
and    O
beta-carboline    B-Alkaloid114712692
.    O

Nostocarboline    O
is    O
a    O
beta-carboline    B-Alkaloid114712692
isolated    O
from    O
freshwater    O
cyanobacterium    O
.    O

The    O
efficacy    O
of    O
a    O
full    O
agonist    O
is    O
by    O
definition    O
100%    O
,    O
a    O
neutral    O
antagonist    O
has    O
0%    O
efficacy    O
,    O
and    O
an    O
inverse    O
agonist    O
has    O
A    O
receptor    O
]    O
]    O
.    O
Agonists    O
for    O
the    O
GABAA    O
receptor    O
(    O
such    O
as    O
benzodiazepines    O
)    O
create    O
a    O
sedative    O
effect    O
,    O
whereas    O
inverse    O
agonists    O
have    O
anxiogenic    O
effects    O
(    O
for    O
example    O
,    O
Ro15    O
-    O
4513    O
)    O
or    O
even    O
convulsive    O
effects    O
(    O
certain    O
beta-carboline    B-Alkaloid114712692
)    O
.    O

Harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
are    O
MAO    O
-    O
inhibiting    O
"beta"-carboline    B-Alkaloid114712692
.    O

Presence    O
of    O
the    O
hallucinogenic    O
tryptamines    O
5-MeO-DMT    B-Alkaloid114712692
,    O
bufotenine    B-Alkaloid114712692
and    O
dimethyltryptamine    B-Alkaloid114712692
,    O
and    O
supposedly    O
the    O
beta-carboline    B-Alkaloid114712692
6-MeO    O
-    O
harmane    O
has    O
been    O
confirmed    O
in    O
"    O
M.    O
pruriens    O
"    O
,    O
apparently    O
the    O
only    O
thoroughly    O
researched    O
species    O
thus    O
far    O
.    O

The    O
Jerusalem    O
cherry    O
's    O
poison    O
is    O
primarily    O
solanocapsine    B-Alkaloid114712692
,    O
which    O
is    O
similar    O
to    O
other    O
alkaloids    O
found    O
in    O
their    O
genus    O
,    O
such    O
as    O
solanine    B-Alkaloid114712692
and    O
atropine    O
.    O

Disease    O
associated    O
with    O
consumption    O
of    O
PAs    O
is    O
known    O
as    O
pyrrolizidine    B-Alkaloid114712692
alkaloidosis    I-Alkaloid114712692
.    O

Hasubanan    B-Alkaloid114712692
is    O
an    O
alkaloid    O
with    O
the    O
chemical    O
formula    O
of    O
C16H21N.    O
It    O
forms    O
the    O
central    O
core    O
of    O
a    O
class    O
of    O
alkaloids    O
known    O
collectively    O
as    O
hasubanans    O
.    O

Mitraphylline    B-Alkaloid114712692

Indolizidine    O
is    O
a    O
heterocyclic    O
chemical    O
compound    O
that    O
forms    O
the    O
central    O
core    O
of    O
the    O
indolizidine    O
alkaloids    O
such    O
as    O
swainsonine    B-Alkaloid114712692
and    O
castanospermine    B-Alkaloid114712692
.    O

#    O
The    O
drugs    O
cyclandelate    O
and    O
homatropine    B-Alkaloid114712692
are    O
esters    O
of    O
mandelic    O
acid    O
.    O

In    O
addition    O
to    O
corticosteroids    O
,    O
topical    O
cycloplegics    O
,    O
such    O
as    O
atropine    O
or    O
homatropine    B-Alkaloid114712692
,    O
may    O
be    O
used    O
.    O

The    O
butterflies    O
also    O
congregate    O
with    O
other    O
danaiines    O
to    O
sip    O
from    O
the    O
sap    O
of    O
"    O
Crotalaria    O
"    O
,    O
"    O
Heliotropium    O
"    O
and    O
other    O
plants    O
which    O
provide    O
the    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
which    O
they    O
sequester    O
.    O

Common    O
defenses    O
include    O
:    O
cardiac    O
glycosides    O
(    O
or    O
cardenolides    O
)    O
,    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
,    O
pyrazines    O
and    O
histamines    O
.    O

Many    O
genera    O
also    O
accumulate    O
quinolizidine    O
alkaloids    O
,    O
ammodendrine    O
-    O
type    O
piperidine    B-Alkaloid114712692
alkaloids    O
,    O
and    O
macrocyclic    O
pyrrolizidine    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
.    O

Thesinine    B-Alkaloid114712692
is    O
a    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
first    O
isolated    O
from    O
"    O
Thesium    O
minkwitzianum    O
"    O
from    O
which    O
it    O
derives    O
its    O
name    O
.    O

Pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
(    O
PAs    O
)    O
florosenine    O
,    O
otosenine    O
,    O
and    O
floridanine    O
.    O

In    O
contemporary    O
times    O
,    O
"    O
P.    O
aurea    O
"    O
is    O
not    O
much    O
used    O
due    O
to    O
its    O
saturated    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
which    O
can    O
cause    O
liver    O
veno    O
-    O
occlusive    O
disease    O
upon    O
metabolism    O
.    O

Many    O
compounds    O
,    O
such    O
as    O
PAHs    O
,    O
aromatic    O
amines    O
,    O
aflatoxin    O
and    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
,    O
may    O
form    O
reactive    O
oxygen    O
species    O
catalyzed    O
by    O
cytochrome    O
P450    O
.    O

The    O
host    O
plants    O
of    O
this    O
species    O
almost    O
always    O
carry    O
toxins    O
known    O
as    O
Pyrrolizidine    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
.    O

Pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692

Aasen´s    O
research    O
areas    O
include    O
determination    O
of    O
the    O
absolute    O
configurations    O
of    O
racemic    O
drugs    O
,    O
isolation    O
,    O
structural    O
determination    O
and    O
syntheses    O
of    O
natural    O
products    O
,    O
"    O
e.g.    O
"    O
carotenoids    O
and    O
pyrrolizidine    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
,    O
mass    O
spectrometry    O
of    O
specifically    O
deuterium    O
-    O
labelled    O
wax    O
esters    O
,    O
fatty    O
acids    O
and    O
triglycerides    O
,    O
and    O
identification    O
and    O
syntheses    O
of    O
flavour    O
constituents    O
from    O
tobacco    O
and    O
other    O
plants    O
.    O

Like    O
other    O
"    O
Petasites    O
"    O
species    O
,    O
fuki    O
contains    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
(    O
PAs    O
)    O
which    O
have    O
been    O
associated    O
with    O
cumulative    O
damage    O
to    O
the    O
liver    O
and    O
tumor    O
formation    O
.    O

Pyrrolizidine    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
(    O
PAs    B-Alkaloid114712692
)    O
,    O
sometimes    O
referred    O
to    O
as    O
necine    B-Alkaloid114712692
bases    I-Alkaloid114712692
,    O
are    O
a    O
group    O
of    O
naturally    O
occurring    O
alkaloids    O
based    O
on    O
the    O
structure    O
of    O
pyrrolizidine    B-Alkaloid114712692
.    O

It    O
was    O
shown    O
that    O
PKCε    O
translocates    O
from    O
the    O
cytosolic    O
to    O
the    O
particulate    O
fraction    O
upon    O
RIPC    O
induction    O
and    O
that    O
the    O
protection    O
conferred    O
by    O
RIPC    O
can    O
be    O
inhibited    O
with    O
the    O
PKC    O
inhibitor    O
chelerythrine    B-Alkaloid114712692

Alkaloids    O
have    O
a    O
wide    O
range    O
of    O
pharmacological    O
activities    O
including    O
antimalarial    O
(    O
"    O
e.g.    O
"    O
quinine    O
)    O
,    O
antiasthma    O
(    O
"    O
e.g.    O
"    O
ephedrine    O
)    O
,    O
anticancer    O
(    O
"    O
e.g.    O
"    O
homoharringtonine    B-Alkaloid114712692
)    O
,    O
cholinomimetic    O
(    O
"    O
e.g.    O
"    O
galantamine    B-Alkaloid114712692
)    O
,    O
vasodilatory    O
(    O
"    O
e.g.    O
"    O
vincamine    B-Alkaloid114712692
)    O
,    O
antiarrhythmic    O
(    O
"    O
e.g.    O
"    O
quinidine    O
)    O
,    O
analgesic    O
(    O
"    O
e.g.    O
"    O
morphine    O
)    O
,    O
antibacterial    O
(    O
"    O
e.g.    O
"    O
chelerythrine    B-Alkaloid114712692
)    O
,    O
and    O
antihyperglycemic    O
activities    O
(    O
"    O
e.g.    O
"    O
piperine    O
)    O
.    O

Ageliferin    B-Alkaloid114712692

"N"-Ethyltryptamine    B-Alkaloid114712692

It    O
is    O
a    O
source    O
of    O
jervine    B-Alkaloid114712692
and    O
cyclopamine    B-Alkaloid114712692
,    O
teratogens    O
which    O
can    O
cause    O
prolonged    O
gestation    O
associated    O
with    O
birth    O
defects    O
such    O
as    O
holoprosencephaly    O
and    O
cyclopia    O
in    O
animals    O
such    O
as    O
sheep    O
,    O
horses    O
,    O
and    O
other    O
mammals    O
that    O
graze    O
upon    O
it    O
.    O

Solbec    O
Pharmaceuticals    O
attempted    O
to    O
develop    O
Coramsine    B-Alkaloid114712692
,    O
a    O
1:1    O
mixture    O
of    O
the    O
alkaloids    O
solamargine    B-Alkaloid114712692
and    O
solasonine    B-Alkaloid114712692
extracted    O
from    O
"    O
Solanum    O
linnaeanum    O
"    O
,    O
as    O
a    O
cancer    O
drug    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
(R,S)-norcoclaurine    B-Alkaloid114712692
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
(    O
R    O
,    O
S)-coclaurine    O
.    O

Viminol    B-Alkaloid114712692

Studies    O
of    O
"    O
Senecio    O
"    O
and    O
"    O
Crotalaria    O
"    O
alkaloids    O
that    O
opened    O
two    O
fields    O
of    O
study    O
:    O
pyrrolizidine    B-Alkaloid114712692
and    O
large    O
-    O
ring    O
diester    O
chemistry    O
.    O

Pyrrolizidine    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
(    O
PAs    B-Alkaloid114712692
)    O
,    O
sometimes    O
referred    O
to    O
as    O
necine    B-Alkaloid114712692
bases    I-Alkaloid114712692
,    O
are    O
a    O
group    O
of    O
naturally    O
occurring    O
alkaloids    O
based    O
on    O
the    O
structure    O
of    O
pyrrolizidine    B-Alkaloid114712692
.    O

Dopachrome    B-Alkaloid114712692

More    O
commonly    O
,    O
it    O
is    O
used    O
in    O
combination    O
with    O
two    O
similar    O
compounds    O
,    O
dihydroergocornine    B-Alkaloid114712692
and    O
dihydroergocristine    B-Alkaloid114712692
.    O

Pancratistatin    B-Alkaloid114712692

10-Hydroxy    B-Alkaloid114712692
Lycopodium    I-Alkaloid114712692
alkaloids    I-Alkaloid114712692
(    O
2013    O
)    O
,    O

File    O
:    O
Voacamine    O
chemical    O
Voacamine    B-Alkaloid114712692

From    O
left    O
:    O
bromoform    O
,    O
a    O
brominated    O
bisphenol    O
,    O
dibromoindigo    O
(    O
Tyrian    O
purple    O
)    O
,    O
and    O
the    O
antifeedant    O
tambjamine    B-Alkaloid114712692
B    I-Alkaloid114712692

"    O
Corydalis    O
ambigua    O
"    O
contains    O
a    O
variety    O
of    O
alkaloids    O
including    O
corynoline    B-Alkaloid114712692
,    O
acetylcorynoline    B-Alkaloid114712692
d-corydalin    I-Alkaloid114712692
,    O
dl-tetrahydropalmatine    B-Alkaloid114712692
,    O
protopine    B-Alkaloid114712692
,    O
tetrahydrocoptisine    O
,    O
dl    O
-    O
tetrahydrocoptisine    O
,    O
d    O
-    O
corybulbine    O
and    O
allo-crytopine    B-Alkaloid114712692
.    O

Lyngbyatoxin    B-Alkaloid114712692

The    O
flora    O
includes    O
gramine    B-Alkaloid114712692
plants    O
and    O
shrubs    O
such    O
as    O
the    O
taya    O
-    O
taya    O
(    O
"    O
Caesalpinia    O
spinosa    O
"    O
)    O
,    O
the    O
quishuar    O
(    O
"    O
Buddleja    O
coriacea    O
"    O
)    O
,    O
and    O
the    O
cantuta    O
(    O
"    O
Cantua    O
buxifolia    O
"    O
)    O
which    O
was    O
considered    O
sacred    O
by    O
the    O
Incas    O
.    O

Some    O
"    O
Phalaris    O
"    O
species    O
contain    O
gramine    B-Alkaloid114712692
,    O
which    O
can    O
cause    O
brain    O
damage    O
,    O
other    O
organ    O
damage    O
,    O
central    O
nervous    O
system    O
damage    O
and    O
death    O
in    O
sheep    O
.    O

18-Methoxycoronaridine    B-Alkaloid114712692

18-Methoxycoronaridine    B-Alkaloid114712692

Cordycepin    B-Alkaloid114712692
(    O
3'-deoxyadenosine    O
)    O

The    O
inhibitory    O
effects    O
on    O
monoamine    O
oxidase    O
allows    O
dimethyltryptamine    B-Alkaloid114712692
(DMT)    I-Alkaloid114712692
,    O
the    O
psychoactively    O
prominent    O
chemical    O
in    O
the    O
mixture    O
,    O
to    O
bypass    O
the    O
extensive    O
first    O
-    O
pass    O
metabolism    O
it    O
undergoes    O
upon    O
ingestion    O
;    O
allowing    O
a    O
psychologically    O
active    O
quantity    O
of    O
the    O
chemical    O
to    O
exist    O
in    O
the    O
brain    O
for    O
a    O
perceivable    O
period    O
of    O
time    O
.    O

DMT    B-Alkaloid114712692

More    O
recounts    O
of    O
Dr.    O
Sack    O
's    O
experiences    O
-    O
including    O
experimentation    O
with    O
mescaline    O
,    O
psilocybin    O
,    O
LSD    O
,    O
and    O
probably    O
DMT    B-Alkaloid114712692
-    O
have    O
been    O
compared    O
in    O
his    O
novel    O
Hallucinations    O
(    O
book    O
)    O
.    O

The    O
controlled    O
drugs    O
to    O
which    O
it    O
was    O
alleged    O
that    O
AET    O
was    O
substantially    O
similar    O
were    O
the    O
tryptamine    O
analogues    O
dimethyltryptamine    B-Alkaloid114712692
(    O
DMT    O
)    O
and    O
diethyltryptamine    O
(    O
DET    O
)    O
.    O

In    O
1969    O
,    O
Canada    O
added    O
Part    O
IV    O
to    O
its    O
Food    O
and    O
Drugs    O
Act    O
,    O
placing    O
a    O
set    O
of    O
"    O
restricted    O
substances    O
,    O
"    O
including    O
LSD    O
,    O
DMT    B-Alkaloid114712692
,    O
and    O
MDA    O
,    O
under    O
federal    O
control    O
.    O

This    O
includes    O
"    O
infusion    O
of    O
the    O
roots    O
"    O
of    O
"    O
Mimosa    O
tenuiflora    O
"    O
(    O
M.    O
hostilis    O
;    O
which    O
contains    O
DMT    B-Alkaloid114712692
)    O
and    O
"    O
beverages    O
"    O
made    O
from    O
psilocybin    O
mushrooms    O
.    O

That    O
case    O
involved    O
a    O
seizure    O
by    O
U.S.    O
Customs    O
and    O
Border    O
Protection    O
of    O
several    O
drums    O
of    O
DMT    B-Alkaloid114712692
-    O
containing    O
liquid    O
.    O

(    O
...    O
)    O
Neither    O
the    O
crown    O
(    O
fruit    O
,    O
mescal    O
button    O
)    O
of    O
the    O
Peyote    O
cactus    O
nor    O
the    O
roots    O
of    O
the    O
plant    O
Mimosa    O
hostilis    O
nor    O
Psilocybe    O
mushrooms    O
themselves    O
are    O
included    O
in    O
Schedule    O
1    O
,    O
but    O
only    O
their    O
respective    O
principles    O
,    O
Mescaline    O
,    O
DMT    B-Alkaloid114712692
and    O
Psilocybin    O
.    O
"    O

dimethyltryptamine    B-Alkaloid114712692
(    O
DMT    O
)    O

This    O
is    O
one    O
of    O
the    O
purest    O
natural    O
sources    O
of    O
the    O
psychedelic    O
drug    O
dimethyltryptamine    B-Alkaloid114712692
,    O
also    O
known    O
as    O
DMT    O
,    O
which    O
occurs    O
as    O
the    O
predominant    O
alkaloid    O
throughout    O
the    O
plant    O
.    O

In    O
the    O
case    O
of    O
tryptamine    O
and    O
serotonin    O
these    O
then    O
become    O
the    O
dimethylated    O
indolethylamines    O
dimethyltryptamine    B-Alkaloid114712692
(    O
DMT    O
)    O
and    O
bufotenine    B-Alkaloid114712692
.    O

He    O
personally    O
tested    O
hundreds    O
of    O
drugs    O
,    O
mainly    O
analogues    O
of    O
various    O
phenethylamines    O
(    O
family    O
containing    O
MDMA    O
,    O
mescaline    O
,    O
and    O
the    O
2C    O
family    O
)    O
,    O
and    O
tryptamines    O
(    O
family    O
containing    O
DMT    B-Alkaloid114712692
and    O
psilocin    O
)    O
.    O

dimethyltryptamine    B-Alkaloid114712692

He    O
credits    O
his    O
use    O
of    O
the    O
psychedelic    O
drug    O
DMT    B-Alkaloid114712692
for    O
"    O
swerv[ing    O
his    O
]    O
career    O
toward    O
a    O
search    O
for    O
the    O
connections    O
between    O
mathematics    O
and    O
the    O
experience    O
of    O
the    O
Logos    O
"    O
.    O

Dimethyltryptamine-"N    O
"-    O
oxide    O
(    O
DMT-"N    O
"-    O
oxide    O
)    O
is    O
a    O
dimethyltryptamine    B-Alkaloid114712692
metabolite    O
.    O

Hancock    O
gave    O
a    O
TEDx    O
lecture    O
titled    O
"    O
The    O
War    O
on    O
Consciousness    O
"    O
,    O
in    O
which    O
he    O
described    O
his    O
use    O
of    O
ayahuasca    B-Alkaloid114712692
,    O
an    O
amazonian    O
brew    O
containing    O
a    O
hallucinogenic    O
compound    O
DMT    B-Alkaloid114712692
,    O
and    O
argued    O
that    O
adults    O
should    O
be    O
allowed    O
to    O
responsibly    O
use    O
it    O
for    O
self    O
-    O
improvement    O
and    O
spiritual    O
growth    O
.    O

Scientifically    O
,    O
these    O
visions    O
can    O
be    O
described    O
as    O
hallucinations    O
induced    O
by    O
DMT    B-Alkaloid114712692
,    O
the    O
active    O
hallucinogenic    O
compound    O
in    O
the    O
brew    O
.    O

The    O
resulting    O
brew    O
may    O
contain    O
the    O
powerful    O
psychedelic    O
drug    O
DMT    B-Alkaloid114712692
and    O
MAO    O
inhibiting    O
harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
,    O
which    O
are    O
necessary    O
to    O
make    O
the    O
DMT    O
orally    O
active    O
.    O

Traditional    O
ayahuasca    O
brews    O
are    O
usually    O
made    O
with    O
"    O
Banisteriopsis    O
caapi    O
"    O
as    O
an    O
MAOI    O
,    O
although    O
dimethyltryptamine    B-Alkaloid114712692
sources    O
and    O
other    O
admixtures    O
vary    O
from    O
region    O
to    O
region    O
.    O

This    O
inhibition    O
of    O
MAO    O
-    O
A    O
allows    O
DMT    B-Alkaloid114712692
to    O
diffuse    O
unmetabolized    O
past    O
the    O
membranes    O
in    O
the    O
stomach    O
and    O
small    O
intestine    O
,    O
and    O
eventually    O
cross    O
the    O
blood    O
–    O
brain    O
barrier    O
(    O
which    O
,    O
by    O
itself    O
,    O
requires    O
no    O
MAO    O
-    O
A    O
inhibition    O
)    O
to    O
activate    O
receptor    O
sites    O
in    O
the    O
brain    O
.    O

Neither    O
the    O
crown    O
(    O
fruit    O
,    O
mescal    O
button    O
)    O
of    O
the    O
Peyote    O
cactus    O
nor    O
the    O
roots    O
of    O
the    O
plant    O
Mimosa    O
hostilis    O
nor    O
Psilocybe    O
mushrooms    O
themselves    O
are    O
included    O
in    O
Schedule    O
1    O
,    O
but    O
only    O
their    O
respective    O
principals    O
,    O
mescaline    O
,    O
DMT    B-Alkaloid114712692
,    O
and    O
psilocin    O
.    O

Mescaline    O
and    O
many    O
of    O
indole    O
alkaloids    O
(    O
such    O
as    O
psilocybin    O
,    O
dimethyltryptamine    B-Alkaloid114712692
and    O
ibogaine    B-Alkaloid114712692
)    O
have    O
hallucinogenic    O
effect    O
.    O
Morphine    O
and    O
codeine    O
are    O
strong    O
narcotic    O
pain    O
killers    O
.    O

Presence    O
of    O
the    O
hallucinogenic    O
tryptamines    O
5-MeO-DMT    B-Alkaloid114712692
,    O
bufotenine    B-Alkaloid114712692
and    O
dimethyltryptamine    B-Alkaloid114712692
,    O
and    O
supposedly    O
the    O
beta-carboline    B-Alkaloid114712692
6-MeO    O
-    O
harmane    O
has    O
been    O
confirmed    O
in    O
"    O
M.    O
pruriens    O
"    O
,    O
apparently    O
the    O
only    O
thoroughly    O
researched    O
species    O
thus    O
far    O
.    O

The    O
pineal    O
gland    O
is    O
a    O
light    O
sensitive    O
gland    O
that    O
produces    O
the    O
hormone    O
melatonin    O
which    O
regulates    O
sleep    O
and    O
waking    O
up    O
,    O
and    O
is    O
also    O
postulated    O
to    O
be    O
the    O
production    O
site    O
of    O
the    O
psychedelic    O
dimethyltryptamine    B-Alkaloid114712692
,    O
the    O
only    O
known    O
hallucinogen    O
endogenous    O
to    O
the    O
human    O
body    O
.    O

Szára    O
was    O
the    O
first    O
to    O
scientifically    O
study    O
the    O
psychotropic    O
effects    O
of    O
"N,N"-Dimethyltryptamine    B-Alkaloid114712692
(    O
DMT    O
)    O
,    O
performing    O
research    O
with    O
volunteers    O
in    O
the    O
mid-1950s    O
.    O

Among    O
other    O
achievements    O
,    O
Szára    O
and    O
his    O
colleagues    O
characterized    O
the    O
biochemistry    O
of    O
the    O
first    O
three    O
psychedelic    O
cogeners    O
of    O
tryptamine    O
:    O
dimethyl-    O
,    O
diethyl-    O
,    O
and    O
dipropyl    O
-    O
tryptamine    O
(    O
DMT    B-Alkaloid114712692
,    O
DET    O
,    O
and    O

N,N-Dimethyltryptamine    B-Alkaloid114712692

N,N-Dimethyltryptamine    B-Alkaloid114712692
,    O
1.15%    O

The    O
mature    O
inner    O
bark    O
of    O
this    O
species    O
contains    O
the    O
compound    O
NN-Dimethyltryptamine    B-Alkaloid114712692
(    O
0.4%    O
)    O
and    O
other    O
substituted    O
tryptamines    O
that    O
are    O
components    O
of    O
the    O
South    O
American    O
visionary    O
medicine    O
Ayahuasca    B-Alkaloid114712692
.    O

Gracie    O
and    O
Zarkov    O
were    O
pseudonymous    O
writers    O
who    O
documented    O
their    O
use    O
of    O
dimethyltryptamine    B-Alkaloid114712692
and    O
other    O
psychedelic    O
tryptamines    O
and    O
phenethylamines    O
.    O

After    O
moving    O
to    O
Brighton    O
,    O
Hardison    O
illegally    O
manufactured    O
three    O
class    O
A    O
drugs    O
:    O
2C-B    B-Alkaloid114712692
,    O
DMT    B-Alkaloid114712692
,    O
and    O
LSD    O
.    O

While    O
at    O
least    O
one    O
strain    O
showed    O
an    O
extremely    O
strong    O
occurrence    O
of    O
N,N-DMT    B-Alkaloid114712692
as    O
the    O
sole    O
alkaloid    O
,    O
other    O
strains    O
indicated    O
the    O
presence    O
of    O
5-MeO-DMT    B-Alkaloid114712692
as    O
well    O
.    O

Allopumiliotoxins    B-Alkaloid114712692
are    O
a    O
structural    O
division    O
in    O
the    O
pumiliotoxin    O
-    O
A    O
class    O
of    O
alkaloids    O
.    O

Tetrahydroharmol    B-Alkaloid114712692

The    O
ryanodine    O
receptors    O
are    O
named    O
after    O
the    O
plant    O
alkaloid    O
ryanodine    B-Alkaloid114712692
,    O
to    O
which    O
they    O
show    O
a    O
high    O
affinity    O
.    O

Ryanodine    B-Alkaloid114712692
locks    O
the    O
RyRs    O
at    O
half    O
-    O
open    O
state    O
at    O
nanomolar    O
concentrations    O
,    O
yet    O
fully    O
closes    O
them    O
at    O
micromolar    O
concentration    O
.    O

The    O
project    O
was    O
centered    O
on    O
,    O
but    O
not    O
restricted    O
to    O
,    O
the    O
use    O
of    O
anabasine    B-Alkaloid114712692
(    O
an    O
alkaloid    O
)    O
,    O
scopolamine    O
and    O
mescaline    O
.    O

Prior    O
to    O
the    O
development    O
of    O
a    O
wide    O
range    O
of    O
relatively    O
low    O
-    O
toxic    O
synthetic    O
pesticides    O
,    O
some    O
alkaloids    O
,    O
such    O
as    O
salts    O
of    O
nicotine    O
and    O
anabasine    B-Alkaloid114712692
,    O
were    O
used    O
as    O
insecticides    O
.    O

Concentrate    O
of    O
poppy    O
straw    O
,    O
processed    O
poppy    B-Alkaloid114712692
straw    I-Alkaloid114712692

The    O
poppy    O
seed    O
harvest    O
can    O
be    O
a    O
by    O
-    O
product    O
of    O
opium    O
poppy    O
cultivation    O
for    O
opium    O
,    O
poppy    B-Alkaloid114712692
straw    I-Alkaloid114712692
,    O
or    O
both    O
opium    O
and    O
poppy    O
straw    O
.    O

After    O
the    O
war    O
production    O
picked    O
up    O
again    O
,    O
with    O
poppy    B-Alkaloid114712692
straw    I-Alkaloid114712692
imported    O
from    O
Turkey    O
and    O
Yugoslavia    O
to    O
produce    O
morphine    O
and    O
other    O
opiates    O
.    O

"N"-Methylconiine    B-Alkaloid114712692

Pergolide    O
(    O
trade    O
names    O
Permax    O
,    O
Prascend    O
)    O
is    O
an    O
ergoline    B-Alkaloid114712692
-    O
based    O
dopamine    O
receptor    O
agonist    O
used    O
in    O
some    O
countries    O
for    O
the    O
treatment    O
of    O
Parkinson    O
's    O
disease    O
(    O
PD    O
)    O
.    O

Ergoline    B-Alkaloid114712692
derivatives    O
(    O
lysergamides    B-Alkaloid114712692
)    O
are    O
probably    O
responsible    O
for    O
the    O
entheogenic    O
activity    O
.    O

The    O
seeds    O
,    O
vines    O
,    O
flowers    O
,    O
and    O
leaves    O
contain    O
ergoline    B-Alkaloid114712692
alkaloids    O
,    O
and    O
have    O
been    O
used    O
for    O
centuries    O
by    O
many    O
Mexican    O
Native    O
American    O
cultures    O
as    O
an    O
entheogen    O
;    O
R.    O
Gordon    O
Wasson    O
has    O
argued    O
that    O
the    O
hallucinogenic    O
seeds    O
used    O
by    O
the    O
Aztecs    O
under    O
the    O
Nahuatl    O
name    O
"    O
tlitliltzin    O
"    O
,    O
were    O
the    O
seeds    O
of    O
"    O
I.    O
tricolor    O
"    O
.    O

Acetergamine    O
is    O
a    O
organic    O
chemical    O
compound    O
;    O
specifically    O
it    O
is    O
a    O
derivative    O
of    O
ergoline    B-Alkaloid114712692
,    O
making    O
it    O
a    O
member    O
of    O
the    O
ergotamine    O
family    O
of    O
compounds    O
.    O

Ergoline    B-Alkaloid114712692
:    O

The    O
ergoline    B-Alkaloid114712692
alkaloids    O
found    O
in    O
"    O
Convolvulaceae    O
"    O
are    O
produced    O
by    O
a    O
seed    O
-    O
transmitted    O
epiphytic    O
clavicipitaceous    O
fungus    O
.    O

-Lysergic    B-Alkaloid114712692
acid    I-Alkaloid114712692
α-hydroxyethylamide    I-Alkaloid114712692
(    O
LSH    B-Alkaloid114712692
,    O
LAH    B-Alkaloid114712692
)    O
,    O
also    O
known    O
as    O
-lysergic    B-Alkaloid114712692
acid    I-Alkaloid114712692
methyl    I-Alkaloid114712692
carbinolamide    I-Alkaloid114712692
,    O
is    O
an    O
alkaloid    O
of    O
the    O
ergoline    B-Alkaloid114712692
family    O
,    O
and    O
occurs    O
in    O
various    O
species    O
in    O
the    O
"    O
Convolvulaceae    O
"    O
(    O
morning    O
glory    O
)    O
family    O
and    O
some    O
species    O
of    O
fungi    O
.    O

Ergoline    B-Alkaloid114712692

Like    O
those    O
of    O
"    O
Argyreia    O
nervosa    O
"    O
,    O
the    O
seeds    O
of    O
"    O
A.    O
cuneata    O
"    O
contain    O
various    O
ergoline    B-Alkaloid114712692
alkaloids    O
such    O
as    O
chanoclavines    O
and    O
lysergic    O
acid    O
amides    O
.    O

Ergot    O
alkaloids    O
/    O
Ergopeptine    B-Alkaloid114712692
alkaloids    O
–    O

Ergocryptine    O
("'β-ergocryptine    B-Alkaloid114712692
)    O
is    O
an    O
ergoline    B-Alkaloid114712692
alkaloid    O
.    O

Lisuride    O
(    O
Dopergin    O
,    O
Proclacam    O
,    O
Revanil    O
)    O
is    O
an    O
antiparkinson    O
agent    O
of    O
the    O
iso    O
-    O
ergoline    O
class    O
,    O
chemically    O
related    O
to    O
the    O
dopaminergic    O
ergoline    B-Alkaloid114712692
Parkinson    O
's    O
drugs    O
.    O

Dihydroergocryptine    O
(    O
DHEC    O
,    O
trade    O
names    O
Almirid    O
,    O
Cripar    O
)    O
is    O
a    O
dopamine    O
agonist    O
of    O
the    O
ergoline    B-Alkaloid114712692
chemical    O
class    O
that    O
is    O
used    O
as    O
an    O
antiparkinson    O
agent    O
.    O

A    O
related    O
reaction    O
,    O
a    O
Prins    O
-    O
Pinacol    O
cascade    O
which    O
produces    O
a    O
tetrahydrofuran    O
,    O
has    O
also    O
been    O
used    O
extensively    O
by    O
the    O
Overman    O
group    O
,    O
for    O
example    O
in    O
the    O
total    O
synthesis    O
of    O
(    O
magellanine    B-Alkaloid114712692
,    O
a    O
"    O
Lycopodium    O
"    O
alkaloid    O
.    O

Also    O
related    O
are    O
TAN-1057    B-Alkaloid114712692
A    I-Alkaloid114712692
and    O
TAN-1057    O
B    O
,    O
isolated    O
from    O
the    O
same    O
bacteria    O
.    O

DMT    O
is    O
produced    O
in    O
many    O
species    O
of    O
plants    O
often    O
in    O
conjunction    O
with    O
its    O
close    O
chemical    O
relatives    O
5-MeO-DMT    B-Alkaloid114712692
and    O
bufotenin    B-Alkaloid114712692
(    O
5-OH    O
-    O
DMT    O
)    O
.    O

DMT    O
is    O
also    O
found    O
as    O
a    O
minor    O
alkaloid    O
in    O
bark    O
,    O
pods    O
,    O
and    O
beans    O
of    O
"    O
Anadenanthera    O
peregrina    O
"    O
and    O
"    O
Anadenanthera    O
colubrina    O
"    O
used    O
to    O
make    O
Yopo    O
and    O
Vilca    O
snuff    O
in    O
which    O
bufotenin    B-Alkaloid114712692
is    O
the    O
main    O
active    O
alkaloid    O
.    O

In    O
Australia    O
,    O
many    O
invasive    O
species    O
,    O
such    O
as    O
cane    O
toads    O
and    O
rabbits    O
,    O
have    O
spread    O
rapidly    O
due    O
to    O
a    O
lack    O
of    O
competition    O
and    O
a    O
lack    O
of    O
adaptations    O
to    O
cane    O
toad    O
bufotenine    B-Alkaloid114712692
on    O
the    O
part    O
of    O
potential    O
predators    O
.    O

Bufotenin    B-Alkaloid114712692

In    O
the    O
case    O
of    O
tryptamine    O
and    O
serotonin    O
these    O
then    O
become    O
the    O
dimethylated    O
indolethylamines    O
dimethyltryptamine    B-Alkaloid114712692
(    O
DMT    O
)    O
and    O
bufotenine    B-Alkaloid114712692
.    O

Beside    O
plants    O
,    O
alkaloids    O
are    O
found    O
in    O
certain    O
types    O
of    O
fungi    O
,    O
such    O
as    O
psilocybin    O
in    O
the    O
fungus    O
of    O
the    O
genus    O
"    O
Psilocybe    O
"    O
,    O
and    O
in    O
animals    O
,    O
such    O
as    O
bufotenin    B-Alkaloid114712692
in    O
the    O
skin    O
of    O
some    O
toads    O
.    O

Bufotenin    B-Alkaloid114712692
,    O
an    O
alkaloid    O
from    O
some    O
toads    O
,    O
contains    O
an    O
indole    O
core    O
and    O
is    O
produced    O
in    O
living    O
organisms    O
from    O
the    O
amino    O
acid    O
tryptophan    O
.    O

Presence    O
of    O
the    O
hallucinogenic    O
tryptamines    O
5-MeO-DMT    B-Alkaloid114712692
,    O
bufotenine    B-Alkaloid114712692
and    O
dimethyltryptamine    B-Alkaloid114712692
,    O
and    O
supposedly    O
the    O
beta-carboline    B-Alkaloid114712692
6-MeO    O
-    O
harmane    O
has    O
been    O
confirmed    O
in    O
"    O
M.    O
pruriens    O
"    O
,    O
apparently    O
the    O
only    O
thoroughly    O
researched    O
species    O
thus    O
far    O
.    O

Vindesine    B-Alkaloid114712692
is    O
an    O
anti    O
-    O
mitotic    O
vinca    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
used    O
in    O
chemotherapy    O
.    O

Vindesine    B-Alkaloid114712692
—    O
used    O
to    O
treat    O
leukaemia    O
,    O
lymphoma    O
,    O
melanoma    O
,    O
breast    O
cancer    O
,    O
and    O
lung    O
cancer    O
.    O

It    O
is    O
an    O
amide    O
of    O
pelargonic    O
acid    O
(    O
n    O
-    O
nonanoic    O
acid    O
)    O
and    O
vanillyl    B-Alkaloid114712692
amine    I-Alkaloid114712692
.    O

Conolidine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
.    O

In    O
livestock    O
it    O
is    O
caused    O
by    O
chronic    O
poisoning    O
with    O
swainsonine    B-Alkaloid114712692
from    O
locoweed    O
.    O

Swainsonine    B-Alkaloid114712692

Indolizidine    O
is    O
a    O
heterocyclic    O
chemical    O
compound    O
that    O
forms    O
the    O
central    O
core    O
of    O
the    O
indolizidine    O
alkaloids    O
such    O
as    O
swainsonine    B-Alkaloid114712692
and    O
castanospermine    B-Alkaloid114712692
.    O

Nonetheless    O
,    O
he    O
believed    O
it    O
was    O
poisonous    O
(    O
in    O
fact    O
,    O
the    O
plant    O
and    O
raw    O
fruit    O
do    O
have    O
low    O
levels    O
of    O
tomatine    B-Alkaloid114712692
,    O
but    O
are    O
not    O
generally    O
dangerous    O
;    O
see    O
below    O
)    O
.    O

Leaves    O
,    O
stems    O
,    O
and    O
green    O
unripe    O
fruit    O
of    O
the    O
tomato    O
plant    O
contain    O
small    O
amounts    O
of    O
the    O
toxic    O
alkaloid    O
tomatine    B-Alkaloid114712692
.    O

Slaframine    B-Alkaloid114712692
is    O
an    O
indolizidine    O
alkaloidal    O
mycotoxin    O
that    O
generally    O
causes    O
salivation    O
(    O
slobbers    O
)    O
in    O
most    O
animals    O
.    O

lycoctonine    B-Alkaloid114712692

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
16-epivellosimine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
vinorine    B-Alkaloid114712692
.    O

Yuremamine    B-Alkaloid114712692
is    O
a    O
phytoindole    O
alkaloid    O
which    O
was    O
isolated    O
and    O
identified    O
from    O
the    O
bark    O
of    O
"    O
Mimosa    O
tenuiflora    O
"    O
in    O
2005    O
.    O

Solenopsin    B-Alkaloid114712692
is    O
an    O
alkaloid    O
with    O
the    O
molecular    O
formula    O
C17H35N    O
found    O
in    O
the    O
venom    O
of    O
fire    O
ants    O
(    O
"    O
Solenopsis    O
"    O
)    O
.    O

Cheilanthifoline    B-Alkaloid114712692
,    O
an    O
alkaloid    O
found    O
in    O
"    O
Corydalis    O
dubia    O
"    O

The    O
reaction    O
has    O
been    O
used    O
to    O
synthesize    O
quinine    O
,    O
colchicine    O
,    O
sarain    O
,    O
morphine    O
,    O
stigmatellin    O
,    O
eudistomin    O
,    O
oseltamivir    O
,    O
strychnine    O
,    O
and    O
nupharamine    B-Alkaloid114712692
.    O

In    O
addition    O
to    O
nicotine    O
,    O
tobacco    O
smoke    O
contains    O
small    O
amounts    O
of    O
the    O
alkaloids    O
anatabine    B-Alkaloid114712692
,    O
anabasine    B-Alkaloid114712692
,    O
nornicotine    B-Alkaloid114712692
,    O
N    O
-    O
methylanabasine    O
,    O
anabaseine    O
,    O
nicotine    O
N'-oxide    O
,    O
myosmine    B-Alkaloid114712692
,    O
β-nicotyrine    O
,    O
cotinine    B-Alkaloid114712692
,    O
and    O
2,3'-bipyridyl    O
.    O

A    O
variety    O
of    O
modifications    O
to    O
the    O
basic    O
ergoline    O
are    O
seen    O
in    O
nature    O
,    O
for    O
example    O
agroclavine    B-Alkaloid114712692
,    O
elymoclavine    B-Alkaloid114712692
,    O
lysergol    B-Alkaloid114712692
.    O

Neurine    B-Alkaloid114712692

Harmalol    B-Alkaloid114712692
is    O
a    O
bioactive    O
beta-carboline    B-Alkaloid114712692
and    O
a    O
member    O
of    O
the    O
harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
.    O

The    O
β-carboline    O
alkaloids    O
include    O
harmine    O
,    O
harmaline    B-Alkaloid114712692
,    O
harman    O
and    O
harmalol    B-Alkaloid114712692
.    O

Birnbaumins    B-Alkaloid114712692
are    O
a    O
pair    O
of    O
alkaloids    O
and    O
toxic    O
yellow    O
pigment    O
compounds    O
first    O
isolated    O
from    O
the    O
flowerpot    O
parasol    O
mushroom    O
.    O

Kevin    O
plays    O
a    O
character    O
named    O
"    O
Johnny    O
C    O
"    O
,    O
a    O
singer    O
who    O
becomes    O
addicted    O
to    O
OxyContin    B-Alkaloid114712692
and    O
loses    O
his    O
family    O
and    O
job    O
as    O
a    O
Christian    O
music    O
star    O
.    O

Dihydrocodeine    O
,    O
oxymorphol    O
,    O
oxycodone    B-Alkaloid114712692
,    O
oxymorphone    O
,    O
metopon    O
and    O
possibly    O
other    O
derivatives    O
of    O
morphine    O
and/or    O
hydromorphone    O
also    O
are    O
found    O
in    O
trace    O
amounts    O
in    O
opium    O
.    O

Eight    O
varieties    O
of    O
"    O
Epipactis    O
helleborine    O
"    O
in    O
central    O
Europe    O
(    O
Lower    O
Silesia    O
,    O
Poland    O
)    O
had    O
their    O
nectar    O
studied    O
and    O
they    O
were    O
found    O
to    O
contain    O
naturally    O
occurring    O
oxycodone    B-Alkaloid114712692
(    O
as    O
well    O
as    O
another    O
narcotic    O
like    O
opioid    O
)    O
in    O
minute    O
amounts    O
.    O

Back    O
in    O
school    O
,    O
A.J.    O
pressures    O
Jason    O
to    O
steal    O
Oxycontin    B-Alkaloid114712692
from    O
a    O
pharmacy    O
and    O
bring    O
it    O
to    O
his    O
house    O
for    O
a    O
party    O
.    O

Oxycodone    B-Alkaloid114712692
,    O
not    O
available    O
intravenously    O
in    O
U.S.    O

There    O
,    O
Téa    O
finds    O
out    O
that    O
Dani    O
has    O
been    O
taking    O
Oxycontin    B-Alkaloid114712692
pills    O
,    O
which    O
caused    O
her    O
to    O
have    O
an    O
overdose    O
at    O
the    O
club    O
.    O

Crohn    O
committed    O
suicide    O
by    O
a    O
drug    O
overdose    O
on    O
oxycodone    B-Alkaloid114712692
and    O
benzodiazepines    O
at    O
the    O
age    O
of    O
66    O
.    O

Other    O
drugs    O
that    O
have    O
been    O
associated    O
with    O
toxic    O
leukoencephalopathy    O
in    O
much    O
more    O
rare    O
occurrences    O
include    O
psychoactive    O
drug    O
2C    O
-    O
E    O
(    O
"    O
Europa    O
"    O
)    O
,    O
oxycodone    B-Alkaloid114712692
,    O
cocaine    O
,    O
and    O
methadone    O
.    O

Oxycodone    B-Alkaloid114712692
is    O
the    O
main    O
active    O
ingredient    O
in    O
various    O
oral    O
pain    O
relief    O
medications    O
.    O

In    O
April    O
2013    O
,    O
Victor    O
reappears    O
in    O
Llanview    O
after    O
Danielle    O
overdoses    O
on    O
oxycontin    B-Alkaloid114712692
at    O
the    O
opening    O
of    O
Blair    O
's    O
new    O
nightclub    O
,    O
"    O
Shelter    O
"    O
.    O

In    O
January    O
2017    O
,    O
Everett    O
,    O
with    O
a    O
high    O
rate    O
of    O
opioid    O
abuse    O
,    O
sued    O
Purdue    O
Pharma    O
,    O
claiming    O
that    O
the    O
company    O
's    O
gross    O
negligence    O
in    O
the    O
distribution    O
of    O
OxyContin    B-Alkaloid114712692
harmed    O
its    O
citizens    O
.    O

Fraser    O
-    O
Pryce    O
served    O
a    O
six    O
-    O
month    O
ban    O
from    O
athletics    O
after    O
a    O
urine    O
sample    O
taken    O
at    O
the    O
2010    O
Shanghai    O
Diamond    O
League    O
meeting    O
was    O
found    O
to    O
contain    O
Oxycodone    B-Alkaloid114712692
.    O

Following    O
Boogaard    O
and    O
Rypien    O
's    O
deaths    O
,    O
NHL    O
commissioner    O
Gary    O
Bettman    O
told    O
media    O
that    O
the    O
league    O
would    O
look    O
into    O
their    O
substance    O
abuse    O
and    O
behavioural    O
issue    O
programs    O
–    O
initiatives    O
that    O
both    O
players    O
had    O
been    O
involved    O
with    O
(    O
Boogaard    O
's    O
death    O
was    O
due    O
to    O
a    O
lethal    O
combination    O
of    O
alcohol    O
and    O
oxycodone    B-Alkaloid114712692
)    O
.    O

At    O
one    O
point    O
,    O
she    O
was    O
kicked    O
out    O
of    O
her    O
home    O
by    O
her    O
mother    O
for    O
,    O
according    O
to    O
police    O
,    O
smoking    O
OxyContin    B-Alkaloid114712692
.    O

In    O
2011    O
,    O
the    O
couple    O
's    O
son    O
Andrew    O
died    O
of    O
an    O
OxyContin    B-Alkaloid114712692
overdose    O
at    O
the    O
now    O
closed    O
Sunset    O
Plaza    O
Drive    O
sober    O
living    O
facility    O
in    O
California    O
.    O

Opioids    O
include    O
substances    O
such    O
as    O
morphine    O
,    O
heroin    O
,    O
codeine    O
and    O
oxycodone    B-Alkaloid114712692
.    O

Buprenorphine    O
sublingual    O
preparations    O
are    O
often    O
used    O
to    O
manage    O
opioid    O
dependence    O
(    O
that    O
is    O
,    O
dependence    O
on    O
heroin    O
,    O
oxycodone    B-Alkaloid114712692
,    O
hydrocodone    O
,    O
morphine    O
,    O
oxymorphone    O
,    O
fentanyl    O
or    O
other    O
opioids    O
)    O
.    O

In    O
2011    O
,    O
crack    O
cocaine    O
was    O
the    O
most    O
commonly    O
used    O
illicit    O
hard    O
drug    O
in    O
Vancouver    O
,    O
followed    O
by    O
injected    O
prescription    O
opioids    O
(    O
such    O
as    O
fentanyl    O
and    O
OxyContin    B-Alkaloid114712692
)    O
,    O
heroin    O
,    O
crystal    O
methamphetamine    O
(    O
usually    O
injected    O
rather    O
than    O
smoked    O
)    O
,    O
and    O
cocaine    O
(    O
also    O
usually    O
injected    O
)    O
.    O

Examples    O
of    O
opioids    O
are    O
:    O
morphine    O
,    O
heroin    O
,    O
tramadol    O
,    O
oxycodone    B-Alkaloid114712692
,    O
and    O
methadone    O
.    O

David    O
did    O
take    O
creative    O
license    O
on    O
some    O
realities    O
,    O
such    O
as    O
making    O
"    O
Little    O
Man    O
's    O
"    O
mother    O
addicted    O
to    O
OxyContin    B-Alkaloid114712692
and    O
dying    O
of    O
an    O
overdose    O
.    O

In    O
"    O
The    O
Boys    O
Who    O
Died    O
in    O
Their    O
Sleep    O
"    O
,    O
Ellison    O
raps    O
,    O
under    O
his    O
alias    O
Captain    O
Murphy    O
,    O
about    O
"    O
being    O
comfortable    O
in    O
a    O
cloud    O
where    O
nothing    O
ever    O
happens    O
"    O
,    O
while    O
naming    O
Oxycotin    B-Alkaloid114712692
,    O
Vicodin    O
and    O
Xanax    O
.    O

codeine    O
or    O
oxycodone    B-Alkaloid114712692

On    O
October    O
19    O
,    O
2009    O
,    O
Adam    O
was    O
arrested    O
,    O
and    O
charged    O
by    O
the    O
DEA    O
in    O
North    O
Reading    O
,    O
MA    O
for    O
possession    O
of    O
2,000    O
oxycodone    B-Alkaloid114712692
pills    O
with    O
intent    O
to    O
distribute    O
.    O

Drummer    O
Sean    O
Kinney    O
said    O
in    O
a    O
2005    O
interview    O
that    O
Staley    O
had    O
told    O
Kinney    O
that    O
he    O
was    O
high    O
on    O
heroin    O
and    O
marijuana    O
during    O
the    O
recordings    O
of    O
"    O
Down    O
in    O
a    O
Hole    O
"    O
and    O
"    O
Angry    O
Chair    O
"    O
as    O
well    O
as    O
taking    O
oxycodone    B-Alkaloid114712692
for    O
back    O
pain    O
.    O

She    O
was    O
found    O
dead    O
in    O
her    O
home    O
on    O
the    O
shore    O
of    O
Lake    O
James    O
,    O
on    O
the    O
morning    O
of    O
September    O
22    O
of    O
a    O
drug    O
overdose    O
from    O
a    O
combination    O
of    O
the    O
painkillers    O
codeine    O
and    O
oxycodone    B-Alkaloid114712692
.    O

After    O
U.S.    O
Track    O
Nationals    O
in    O
2015    O
,    O
Lea    O
tested    O
positive    O
for    O
noroxycodone    O
,    O
a    O
metabolite    O
of    O
oxycodone    B-Alkaloid114712692
found    O
in    O
Percocet    O
which    O
is    O
a    O
substance    O
on    O
the    O
USADA    O
banned    O
list    O
.    O

Hyperkatifeia    O
and    O
Opioid    O
-    O
induced    O
hyperalgesia    O
can    O
be    O
seen    O
with    O
long    O
-    O
term    O
use    O
of    O
elicit    O
street    O
opioids    O
e.g.    O
heroin    O
and    O
prescription    O
opioids    O
e.g.    O
hydrocodone    O
and    O
oxycodone    B-Alkaloid114712692
during    O
withdrawal    O
.    O

He    O
admits    O
in    O
"    O
Cleanso    O
"    O
that    O
not    O
only    O
does    O
he    O
use    O
cocaine    O
,    O
but    O
also    O
huffs    O
paint    O
,    O
uses    O
crystal    O
meth    O
,    O
heroin    O
,    O
pain    O
pills    O
,    O
and    O
OxyContin    B-Alkaloid114712692
before    O
stating    O
,    O
"    O
I    O
do    O
it    O
all    O
.    O
"    O

Hinck    O
introduced    O
a    O
bill    O
to    O
encourage    O
best    O
practices    O
and    O
greater    O
responsibility    O
in    O
the    O
dispensing    O
and    O
prescribing    O
of    O
addictive    O
painkillers    O
like    O
OxyContin    B-Alkaloid114712692
;    O
that    O
bill    O
has    O
now    O
been    O
enacted    O
as    O
Resolve    O
,    O
To    O
Reduce    O
Opioid    O
Overprescription    O
,    O
Overuse    O
and    O
Abuse    O
.    O

Synthesis    O
of    O
morphine    O
-    O
like    O
alkaloids    O
in    O
chemistry    O
describes    O
the    O
total    O
synthesis    O
of    O
the    O
natural    O
morphinan    O
class    O
of    O
alkaloids    O
that    O
includes    O
codeine    O
,    O
morphine    O
,    O
oripavine    O
,    O
and    O
thebaine    B-Alkaloid114712692
and    O
the    O
closely    O
related    O
semisynthetic    O
analogs    O
buprenorphine    O
,    O
hydrocodone    O
,    O
isocodeine    O
,    O
naltrexone    O
,    O
naloxone    O
,    O
nalbuphine    O
,    O
and    O
oxycodone    B-Alkaloid114712692
.    O

On    O
February    O
2    O
,    O
2012    O
,    O
the    O
Drug    O
Enforcement    O
Administration    O
again    O
suspended    O
the    O
license    O
of    O
the    O
firm    O
's    O
Lakeland    O
distribution    O
center    O
to    O
distribute    O
controlled    O
substances    O
on    O
charges    O
that    O
it    O
had    O
allowed    O
four    O
Florida    O
pharmacies    O
to    O
purchase    O
excessive    O
amounts    O
of    O
controlled    O
substances    O
,    O
in    O
particular    O
oxycodone    B-Alkaloid114712692
.    O

In    O
February    O
2012    O
,    O
Joseph    O
Rannazzisi    O
,    O
chief    O
of    O
the    O
Drug    O
Enforcement    O
Administration    O
’s    O
Office    O
of    O
Diversion    O
Control    O
,    O
issued    O
immediate    O
suspension    O
orders    O
against    O
Cardinal    O
's    O
supply    O
of    O
oxycodone    B-Alkaloid114712692
to    O
suspected    O
pill    O
mills    O
.    O

µ-Opioid    O
receptor    O
agonists    O
are    O
a    O
set    O
of    O
euphoriants    O
that    O
include    O
drugs    O
such    O
as    O
heroin    O
,    O
morphine    O
,    O
codeine    O
,    O
oxycodone    B-Alkaloid114712692
,    O
and    O
fentanyl    O
.    O

Analgesics    O
include    O
paracetamol    O
(    O
known    O
in    O
North    O
America    O
as    O
acetaminophen    O
or    O
simply    O
APAP    O
)    O
,    O
the    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
drugs    O
(    O
NSAIDs    O
)    O
such    O
as    O
the    O
salicylates    O
,    O
and    O
opioid    O
drugs    O
such    O
as    O
morphine    O
and    O
oxycodone    B-Alkaloid114712692
.    O

Morphine    O
,    O
the    O
archetypal    O
opioid    O
,    O
and    O
other    O
opioids    O
(    O
e.g.    O
,    O
codeine    O
,    O
oxycodone    B-Alkaloid114712692
,    O
hydrocodone    O
,    O
dihydromorphine    O
,    O
pethidine    O
)    O
all    O
exert    O
a    O
similar    O
influence    O
on    O
the    O
cerebral    O
opioid    O
receptor    O
system    O
.    O

Thebaine    B-Alkaloid114712692
is    O
used    O
in    O
the    O
synthesis    O
of    O
many    O
painkillers    O
such    O
as    O
oxycodone    B-Alkaloid114712692
.    O

On    O
February    O
26    O
,    O
2017    O
,    O
Elam    O
was    O
arrested    O
in    O
Miami    O
,    O
Florida    O
for    O
possession    O
of    O
a    O
126.2    O
grams    O
of    O
marijuana    O
and    O
3.1    O
grams    O
of    O
oxycodone    B-Alkaloid114712692
.    O

In    O
an    O
interview    O
in    O
early    O
2010    O
,    O
Wilson    O
stated    O
he    O
had    O
been    O
addicted    O
to    O
oxycontin    B-Alkaloid114712692
and    O
other    O
painkillers    O
for    O
at    O
least    O
10    O
years    O
.    O

White    O
and    O
Morris    O
influenced    O
Danny    O
Shelley    O
,    O
an    O
OxyContin    B-Alkaloid114712692
addict    O
,    O
to    O
carry    O
out    O
their    O
plot    O
.    O

Tropisetron    B-Alkaloid114712692
(    O
INN    O
)    O
is    O
a    O
serotonin    O
5-HT3    O
receptor    O
antagonist    O
used    O
mainly    O
as    O
an    O
antiemetic    O
to    O
treat    O
nausea    O
and    O
vomiting    O
following    O
chemotherapy    O
,    O
although    O
it    O
has    O
been    O
used    O
experimentally    O
as    O
an    O
analgesic    O
in    O
cases    O
of    O
fibromyalgia    O
.    O

It    O
is    O
marketed    O
by    O
Novartis    O
in    O
Europe    O
,    O
Australia    O
,    O
New    O
Zealand    O
,    O
Japan    O
,    O
South    O
Korea    O
and    O
the    O
Philippines    O
as    O
Navoban    B-Alkaloid114712692
,    O
but    O
is    O
not    O
available    O
in    O
the    O
U.S.    O
It    O
is    O
also    O
available    O
from    O
Novell    O
Pharmaceutical    O
Laboratories    O
and    O
marketed    O
in    O
several    O
Asian    O
countries    O
as    O
Setrovel    B-Alkaloid114712692
.    O

Tropisetron    B-Alkaloid114712692

Spirotryprostatin    B-Alkaloid114712692
A    I-Alkaloid114712692
is    O
an    O
indolic    O
alkaloid    O
from    O
the    O
2,5-Diketopiperazine    O
class    O
of    O
natural    O
products    O
found    O
in    O
the    O
"    O
Aspergillus    O
fumigatus    O
"    O
fungus    O
.    O

A    O
neurotoxin    O
called    O
homobatrachotoxin    B-Alkaloid114712692
found    O
in    O
the    O
birds    O
'    O
skin    O
and    O
feathers    O
causes    O
numbness    O
and    O
tingling    O
in    O
those    O
touching    O
the    O
bird    O
.    O

This    O
genus    O
of    O
beetle    O
is    O
known    O
to    O
have    O
high    O
levels    O
of    O
batrachotoxin    B-Alkaloid114712692
and    O
is    O
believed    O
to    O
be    O
a    O
possible    O
toxin    O
source    O
for    O
Pitohui    O
and    O
Blue    O
-    O
capped    O
ifrit    O
birds    O
in    O
New    O
Guinea    O
.    O

The    O
combined    O
brachial    O
secretion    O
and    O
saliva    O
of    O
recently    O
captured    O
wild    O
lorises    O
was    O
shown    O
to    O
contain    O
batrachotoxin    B-Alkaloid114712692
,    O
which    O
were    O
not    O
found    O
in    O
slow    O
lorises    O
held    O
in    O
captivity    O
for    O
more    O
than    O
a    O
year    O
.    O

Batrachotoxin    B-Alkaloid114712692

batrachotoxin    B-Alkaloid114712692

The    O
total    O
synthesis    O
of    O
(    O
neothiobinupharidine    B-Alkaloid114712692
,    O
a    O
bioactive    O
alkaloid    O
isolated    O
from    O
Nuphar    O
pumila    O
(    O
the    O
small    O
yellow    O
pond    O
-    O
lily    O
)    O
was    O
accomplished    O
in    O
eight    O
steps    O
employing    O
two    O
moles    O
of    O
3-bromofuran    O
.    O

Lamellarins    B-Alkaloid114712692
are    O
a    O
group    O
of    O
pyrrole    O
alkaloids    O
first    O
isolated    O
in    O
1985    O
from    O
the    O
marine    O
mollusk    O
"    O
Lamellaria    O
"    O
in    O
the    O
waters    O
of    O
Palau    O
.    O

"    O
Corydalis    O
ambigua    O
"    O
contains    O
a    O
variety    O
of    O
alkaloids    O
including    O
corynoline    B-Alkaloid114712692
,    O
acetylcorynoline    B-Alkaloid114712692
d-corydalin    I-Alkaloid114712692
,    O
dl-tetrahydropalmatine    B-Alkaloid114712692
,    O
protopine    B-Alkaloid114712692
,    O
tetrahydrocoptisine    O
,    O
dl    O
-    O
tetrahydrocoptisine    O
,    O
d    O
-    O
corybulbine    O
and    O
allo-crytopine    B-Alkaloid114712692
.    O

Guvacine    B-Alkaloid114712692

Kifunensine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
originally    O
isolated    O
from    O
"    O
Kitasatosporia    O
kifunense    O
"    O
,    O
an    O
actinobacterium    O
(    O
formerly    O
called    O
an    O
actinomycete    O
)    O
.    O

Mesembrenone    B-Alkaloid114712692
,    O
an    O
alkaloid    O
from    O
the    O
herb    O
"    O
Sceletium    O
tortuosum    O
"    O
(    O
Kanna    O
)    O
.    O

delphinine    B-Alkaloid114712692

Rhazine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
isolated    O
from    O
"    O
Alstonia    O
boonei    O
"    O
,    O
a    O
tree    O
of    O
West    O
Africa    O
.    O

File    O
:    O
Toxiferine    O
Toxiferine    B-Alkaloid114712692

2,4,6-trimethoxyamphetamine    O
(    O
TMA-6    B-Alkaloid114712692
)    O

trimethoxyamphetamine    B-Alkaloid114712692
(    O
TMA    O
)    O

2,4,5-trimethoxyamphetamine    B-Alkaloid114712692
(    O
TMA-2    O
)    O

It    O
is    O
similar    O
in    O
structure    O
to    O
TMA-2    B-Alkaloid114712692
.    O

Matrine    B-Alkaloid114712692
and    O
matrine    B-Alkaloid114712692
oxide    I-Alkaloid114712692
,    O
quinolizidine    O
alkaloids    O
found    O
in    O
the    O
roots    O

AZD0328    B-Alkaloid114712692
is    O
an    O
experimental    O
drug    O
.    O

Pavine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
found    O
in    O
poppy    O
species    O
.    O

Though    O
this    O
method    O
has    O
never    O
been    O
explored    O
with    O
5-MeO    O
-    O
DMT    O
,    O
it    O
has    O
been    O
used    O
successfully    O
for    O
changing    O
DET    O
into    O
4-HO    O
-    O
DET    O
and    O
4-PO-DET    B-Alkaloid114712692
,    O
both    O
of    O
which    O
had    O
never    O
before    O
been    O
found    O
in    O
nature    O
.    O

Polyfothine    B-Alkaloid114712692
is    O
an    O
anticholinergic    O
alkaloid    O
.    O

Oliveroline    B-Alkaloid114712692
is    O
an    O
anti    O
-    O
cholinergic    O
aporphine    B-Alkaloid114712692
alkaloid    O
.    O

#    O
Etorphine    B-Alkaloid114712692

Activation    O
of    O
this    O
receptor    O
produces    O
strong    O
analgesia    O
and    O
release    O
of    O
met    O
-    O
enkephalin    O
;    O
a    O
number    O
of    O
widely    O
used    O
opioid    O
agonists    O
,    O
such    O
as    O
the    O
μ    O
agonist    O
etorphine    B-Alkaloid114712692
and    O
the    O
κ    O
agonist    O
bremazocine    O
,    O
have    O
been    O
shown    O
to    O
act    O
as    O
agonists    O
for    O
this    O
effect    O
(    O
even    O
in    O
the    O
presence    O
of    O
antagonists    O
to    O
their    O
more    O
well    O
known    O
targets    O
)    O
,    O
while    O
buprenorphine    O
has    O
been    O
shown    O
to    O
act    O
as    O
an    O
epsilon    O
antagonist    O
.    O

Etorphine    B-Alkaloid114712692
(    O
a.k.a    O
.    O
Immobilon    O
or    O
M99    O
)    O
,    O
a    O
veterinary    O
tranquilizer    O

Immediately    O
after    O
the    O
siege    O
,    O
Western    O
media    O
speculated    O
widely    O
as    O
to    O
the    O
identity    O
of    O
the    O
substance    O
that    O
was    O
used    O
to    O
end    O
the    O
siege    O
,    O
and    O
chemicals    O
such    O
as    O
the    O
tranquilizer    O
diazepam    O
(    O
Valium    O
)    O
,    O
the    O
anticholinergic    O
BZ    O
,    O
the    O
highly    O
potent    O
oripavine    O
-    O
derived    O
Bentley    O
-    O
series    O
opioid    O
etorphine    B-Alkaloid114712692
,    O
another    O
highly    O
potent    O
opioid    O
,    O
such    O
as    O
a    O
fentanyl    O
or    O
an    O
analogue    O
thereof    O
,    O
such    O
as    O
3-methylfentanil    O
,    O
and    O
the    O
anaesthetic    O
halothane    O
were    O
proposed    O
.    O

Several    O
commonly    O
used    O
opioid    O
drugs    O
including    O
etorphine    B-Alkaloid114712692
and    O
buprenorphine    O
have    O
been    O
demonstrated    O
to    O
bind    O
to    O
nociceptin    O
receptors    O
,    O
but    O
this    O
binding    O
is    O
relatively    O
insignificant    O
compared    O
to    O
their    O
activity    O
at    O
other    O
opioid    O
receptors    O
in    O
the    O
acute    O
setting    O
(    O
however    O
the    O
non    O
-    O
analgesic    O
NOPr    O
antagonist    O
SB-612,111    O
was    O
demonstrated    O
to    O
potentiate    O
the    O
therapeutic    O
benefits    O
of    O
morphine    O
)    O
.    O

Etorphine    B-Alkaloid114712692

Pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
sequestration    I-Alkaloid114712692

Dihydroergocryptine    O
is    O
a    O
mixture    O
of    O
two    O
very    O
similar    O
compounds    O
,    O
alpha-    O
and    O
"beta"-dihydroergocryptine    B-Alkaloid114712692
(    O
epicriptine    O
)    O
at    O
a    O
ratio    O
of    O
2:1    O
.    O

Malouetine    B-Alkaloid114712692
is    O
an    O
aminosteroid    O
neuromuscular    O
blocking    O
agent    O
and    O
antinicotinic    O
alkaloid    O
isolated    O
from    O
"    O
Malouetia    O
"    O
spp    O
.    O

He    O
named    O
the    O
newly    O
discovered    O
chemical    O
compound    O
as    O
"    O
Ajmaline    B-Alkaloid114712692
"    O
,    O
after    O
his    O
mentor    O
Hakim    O
Ajmal    O
Khan    O
who    O
was    O
one    O
of    O
the    O
illustrious    O
practitioners    O
of    O
Unani    O
system    O
of    O
medicine    O
in    O
South    O
Asia    O
.    O

Vomilenine    B-Alkaloid114712692
is    O
an    O
intermediate    O
chemical    O
in    O
the    O
biosynthesis    O
of    O
ajmaline    B-Alkaloid114712692
.    O

Class    O
Ia    O
—    O
Fast    O
sodium    O
channels    O
(    O
quinidine    O
,    O
ajmaline    B-Alkaloid114712692
,    O
procainamide    O
,    O
disopyramide    O
)    O

In    O
1982    O
,    O
seven    O
people    O
in    O
Santa    O
Clara    O
County    O
,    O
California    O
were    O
diagnosed    O
with    O
Parkinsonism    O
after    O
having    O
used    O
MPPP    O
contaminated    O
with    O
MPTP    B-Alkaloid114712692
.    O

In    O
addition    O
,    O
recent    O
evidence    O
shows    O
that    O
inhibition    O
of    O
SIRT2    O
protects    O
against    O
MPTP    B-Alkaloid114712692
-    O
induced    O
neuronal    O
loss    O
in    O
vivo    O
.    O

It    O
is    O
unlikely    O
that    O
the    O
tetrahydropyridine    O
byproducts    O
that    O
may    O
be    O
formed    O
during    O
the    O
synthesis    O
of    O
PEPAP    O
are    O
neurotoxic    O
in    O
the    O
same    O
way    O
as    O
the    O
MPPP    O
byproduct    O
MPTP    B-Alkaloid114712692
.    O

Omigapil    O
also    O
rescues    O
rat    O
oligodendrocytes    O
from    O
AMPA    O
receptor    O
excitotoxicity    O
and    O
rat    O
embryonic    O
mesencephalic    O
(    O
midbrain    O
)    O
dopaminergic    O
cells    O
from    O
toxicity    O
by    O
MPP+/MPTP    B-Alkaloid114712692
.    O

The    O
appearance    O
of    O
parkinsonism    O
in    O
a    O
group    O
of    O
drug    O
addicts    O
in    O
the    O
early    O
1980s    O
who    O
consumed    O
a    O
contaminated    O
batch    O
of    O
the    O
synthetic    O
opiate    O
MPPP    O
led    O
to    O
the    O
discovery    O
of    O
the    O
chemical    O
MPTP    B-Alkaloid114712692
as    O
an    O
agent    O
that    O
causes    O
parkinsonism    O
in    O
non    O
-    O
human    O
primates    O
as    O
well    O
as    O
in    O
humans    O
.    O

At    O
NIMH    O
,    O
he    O
came    O
up    O
with    O
the    O
false    O
neurotransmitter    O
theory    O
to    O
explain    O
the    O
action    O
of    O
drugs    O
such    O
as    O
monoamine    O
oxidase    O
inhibitors    O
,    O
and    O
studied    O
the    O
relationship    O
between    O
the    O
neurotoxin    O
MPTP    B-Alkaloid114712692
and    O
Parkinson    O
's    O
disease    O
.    O

-Lysergic    B-Alkaloid114712692
acid    I-Alkaloid114712692
α-hydroxyethylamide    I-Alkaloid114712692
(    O
LSH    B-Alkaloid114712692
,    O
LAH    B-Alkaloid114712692
)    O
,    O
also    O
known    O
as    O
-lysergic    B-Alkaloid114712692
acid    I-Alkaloid114712692
methyl    I-Alkaloid114712692
carbinolamide    I-Alkaloid114712692
,    O
is    O
an    O
alkaloid    O
of    O
the    O
ergoline    B-Alkaloid114712692
family    O
,    O
and    O
occurs    O
in    O
various    O
species    O
in    O
the    O
"    O
Convolvulaceae    O
"    O
(    O
morning    O
glory    O
)    O
family    O
and    O
some    O
species    O
of    O
fungi    O
.    O

The    O
lignan    O
sesamin    O
,    O
the    O
N    O
-    O
isobutylamide    O
γ-sanshool    O
,    O
the    O
acridone    O
alkaloids    O
1-hydroxy-3-methoxy    O
-    O
N    O
-    O
methylacridone    O
,    O
arborinine    O
,    O
xanthoxoline    O
and    O
1-hydroxy-3-methoxyacridone    O
can    O
also    O
be    O
extracted    O
from    O
the    O
bark    O
as    O
well    O
as    O
the    O
alkaloids    O
oblongine    O
,    O
tembetarine    O
and    O
magnoflorine    B-Alkaloid114712692
and    O
the    O
flavonoid    O
hesperidin    O
.    O

"    O
Pholiotina    O
cyanopus    O
"    O
is    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
baeocystin    B-Alkaloid114712692
,    O
norbaeocystin    B-Alkaloid114712692
and    O
aeruginascin    B-Alkaloid114712692
.    O

Oreobeiline    B-Alkaloid114712692
is    O
an    O
isolate    O
of    O
"    O
Beilschmiedia    O
"    O
with    O
anti    O
-    O
acetylcholinesterase    O
,    O
anti    O
-    O
alpha    O
-    O
glucosidase    O
,    O
anti    O
-    O
leishmanial    O
,    O
and    O
anti    O
-    O
fungal    O
activities    O
.    O

The    O
molecule    O
whose    O
synthesis    O
Altom    O
was    O
attempting    O
to    O
complete    O
,    O
—    O
aspidophytine    B-Alkaloid114712692
,    O
one    O
of    O
the    O
two    O
sub    O
-    O
units    O
of    O
haplophytine    O
—    O
was    O
subsequently    O
completed    O
by    O
postdoctoral    O
research    O
associates    O
and    O
published    O
in    O
the    O
Journal    O
of    O
the    O
American    O
Chemical    O
Society    O
in    O
1999    O
.    O

Evoxine    B-Alkaloid114712692
(    O
haploperine    B-Alkaloid114712692
)    O
is    O
a    O
furoquinoline    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
with    O
hypnotic    O
and    O
sedative    O
effects    O
.    O

Gigantine    O
was    O
first    O
discovered    O
along    O
with    O
Macromerine    B-Alkaloid114712692
in    O
1967    O
.    O

In    O
addition    O
,    O
analysis    O
of    O
residues    O
from    O
ceramic    O
vessels    O
has    O
found    O
traces    O
of    O
theobromine    B-Alkaloid114712692
and    O
caffeine    O
in    O
early    O
formative    O
vessels    O
from    O
Puerto    O
Escondido    O
,    O
Honduras    O
(    O
1100–900    O
BC    O
)    O
and    O
in    O
middle    O
formative    O
vessels    O
from    O
Colha    O
,    O
Belize    O
(    O
600–400    O
BC    O
)    O
using    O
similar    O
techniques    O
to    O
those    O
used    O
to    O
extract    O
chocolate    O
residues    O
from    O
four    O
classic    O
period    O
(    O
around    O
400    O
AD    O
)    O
vessels    O
from    O
a    O
tomb    O
at    O
the    O
Maya    O
archaeological    O
site    O
of    O
Rio    O
Azul    O
.    O

Many    O
genes    O
were    O
identified    O
as    O
coding    O
for    O
flavonoids    O
,    O
aromatic    O
terpenes    O
,    O
theobromine    B-Alkaloid114712692
and    O
many    O
other    O
metabolites    O
involved    O
in    O
cocoa    O
flavor    O
and    O
quality    O
traits    O
,    O
among    O
which    O
a    O
relatively    O
high    O
proportion    O
code    O
for    O
polyphenols    O
,    O
which    O
constitute    O
up    O
to    O
8%    O
of    O
cacao    O
pods    O
dry    O
weight    O
.    O

However    O
,    O
the    O
fruit    O
is    O
poisonous    O
,    O
containing    O
,    O
amongst    O
other    O
substances    O
,    O
the    O
alkaloids    O
theobromine    B-Alkaloid114712692
and    O
caffeine    O
,    O
as    O
well    O
as    O
an    O
extremely    O
bitter    O
terpene    O
.    O

He    O
finished    O
second    O
to    O
the    O
French    O
colt    O
Trepan    O
,    O
but    O
was    O
awarded    O
the    O
race    O
when    O
the    O
winner    O
tested    O
positive    O
for    O
theobromine    B-Alkaloid114712692
,    O
a    O
banned    O
substance    O
.    O

Fresh    O
leaves    O
contain    O
about    O
4%    O
caffeine    O
,    O
as    O
well    O
as    O
related    O
compounds    O
including    O
theobromine    B-Alkaloid114712692
.    O

Other    O
alkaloids    O
possess    O
psychotropic    O
(    O
"    O
e.g.    O
"    O
psilocin    O
)    O
and    O
stimulant    O
activities    O
(    O
"    O
e.g.    O
"    O
cocaine    O
,    O
caffeine    O
,    O
nicotine    O
,    O
theobromine    B-Alkaloid114712692
)    O
,    O
and    O
have    O
been    O
used    O
in    O
entheogenic    O
rituals    O
or    O
as    O
recreational    O
drugs    O
.    O

This    O
group    O
includes    O
terpene    O
-    O
like    O
and    O
steroid    O
-    O
like    O
alkaloids    O
,    O
as    O
well    O
as    O
purine    O
-    O
like    O
alkaloids    O
such    O
as    O
caffeine    O
,    O
theobromine    B-Alkaloid114712692
,    O
theacrine    B-Alkaloid114712692
and    O
theophylline    O
.    O

Most    O
alkaloids    O
are    O
weak    O
bases    O
,    O
but    O
some    O
,    O
such    O
as    O
theobromine    B-Alkaloid114712692
and    O
theophylline    O
,    O
are    O
amphoteric    O
.    O

The    O
active    O
ingredients    O
,    O
like    O
those    O
of    O
the    O
related    O
yerba    O
mate    O
and    O
guayusa    O
plants    O
,    O
are    O
actually    O
caffeine    O
and    O
theobromine    B-Alkaloid114712692
,    O
and    O
the    O
vomiting    O
either    O
was    O
learned    O
or    O
resulted    O
from    O
the    O
great    O
quantities    O
in    O
which    O
they    O
drank    O
the    O
beverage    O
coupled    O
with    O
fasting    O
.    O

Content    O
verification    O
tests    O
yielded    O
the    O
presence    O
of    O
Theobromine    B-Alkaloid114712692
,    O
an    O
essential    O
cocoa    O
component    O
;    O
chromatography    O
and    O
UV    O
tests    O
detected    O
ions    O
of    O
cocoa    O
's    O
chemical    O
components    O
.    O

The    O
toxin    O
orellanine    B-Alkaloid114712692
was    O
later    O
recovered    O
from    O
the    O
species    O
.    O

Moser    O
was    O
also    O
interested    O
in    O
the    O
toxicity    O
of    O
the    O
Agaricales    O
,    O
and    O
was    O
—    O
with    O
his    O
students    O
—    O
involved    O
with    O
research    O
on    O
the    O
toxin    O
orellanine    B-Alkaloid114712692
.    O

Affinisine    B-Alkaloid114712692

5-Bromo-DMT    B-Alkaloid114712692

File:(+    O
)    O
Stephacidin    O
Stephacidin    B-Alkaloid114712692
A    O

Active    O
substance    O
:    O
galantamine    B-Alkaloid114712692
)    O

He    O
directed    O
an    O
R&D    O
program    O
for    O
galantamine    B-Alkaloid114712692
derivatives    O
.    O

Alkaloids    O
have    O
a    O
wide    O
range    O
of    O
pharmacological    O
activities    O
including    O
antimalarial    O
(    O
"    O
e.g.    O
"    O
quinine    O
)    O
,    O
antiasthma    O
(    O
"    O
e.g.    O
"    O
ephedrine    O
)    O
,    O
anticancer    O
(    O
"    O
e.g.    O
"    O
homoharringtonine    B-Alkaloid114712692
)    O
,    O
cholinomimetic    O
(    O
"    O
e.g.    O
"    O
galantamine    B-Alkaloid114712692
)    O
,    O
vasodilatory    O
(    O
"    O
e.g.    O
"    O
vincamine    B-Alkaloid114712692
)    O
,    O
antiarrhythmic    O
(    O
"    O
e.g.    O
"    O
quinidine    O
)    O
,    O
analgesic    O
(    O
"    O
e.g.    O
"    O
morphine    O
)    O
,    O
antibacterial    O
(    O
"    O
e.g.    O
"    O
chelerythrine    B-Alkaloid114712692
)    O
,    O
and    O
antihyperglycemic    O
activities    O
(    O
"    O
e.g.    O
"    O
piperine    O
)    O
.    O

So    O
,    O
galantamine    B-Alkaloid114712692
and    O
homoaporphines    O
do    O
not    O
contain    O
isoquinoline    O
fragment    O
,    O
but    O
are    O
,    O
in    O
general    O
,    O
attributed    O
to    O
isoquinoline    O
alkaloids    O
.    O

It    O
is    O
reported    O
that    O
"    O
I.    O
amancaes    O
"    O
contains    O
the    O
alkaloid    O
substances    O
galantamine    B-Alkaloid114712692
and    O
narcissidine    O
.    O

Cryogenine    B-Alkaloid114712692

Phellodendrine    B-Alkaloid114712692

Epoxyagroclavine    B-Alkaloid114712692
is    O
an    O
ergot    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
made    O
by    O
permafrost    O
"    O
Penicillium    O
"    O
.    O

All    O
parts    O
of    O
"    O
Datura    O
"    O
plants    O
contain    O
dangerous    O
levels    O
of    O
anticholinergic    O
tropane    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
and    O
may    O
be    O
fatal    O
if    O
ingested    O
by    O
humans    O
,    O
livestock    O
,    O
or    O
pets    O
.    O

Increased    O
dosages    O
result    O
in    O
more    O
prominent    O
central    O
opioid    O
effects    O
(    O
and    O
anticholingeric    O
effects    O
when    O
the    O
formulation    O
also    O
contains    O
a    O
tropane    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
)    O
.    O

The    O
biosynthesis    O
of    O
the    O
tropane    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
,    O
however    O
,    O
is    O
still    O
uncertain    O
.    O

However    O
,    O
the    O
tropane    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
responsible    O
for    O
both    O
the    O
medicinal    O
and    O
hallucinogenic    O
properties    O
are    O
fatally    O
toxic    O
in    O
only    O
slightly    O
higher    O
amounts    O
than    O
the    O
medicinal    O
dosage    O
,    O
and    O
careless    O
use    O
often    O
results    O
in    O
hospitalizations    O
and    O
deaths    O
.    O

All    O
parts    O
of    O
"    O
Datura    O
"    O
plants    O
contain    O
dangerous    O
levels    O
of    O
the    O
tropane    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
atropine    O
,    O
hyoscyamine    O
,    O
and    O
scopolamine    O
,    O
which    O
are    O
classified    O
as    O
deliriants    O
,    O
or    O
anticholinergics    O
.    O

Plants    O
of    O
the    O
Solanaceae    O
family    O
contain    O
various    O
anticholinergic    O
tropane    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
,    O
such    O
as    O
scopolamine    O
,    O
atropine    O
,    O
and    O
hyoscyamine    O
.    O

All    O
parts    O
of    O
"    O
Datura    O
"    O
plants    O
contain    O
dangerous    O
levels    O
of    O
tropane    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
(    O
highly    O
poisonous    O
)    O
and    O
may    O
be    O
fatal    O
if    O
ingested    O
by    O
humans    O
or    O
other    O
animals    O
,    O
including    O
livestock    O
and    O
pets    O
.    O

"    O
Brugmansia    O
"    O
are    O
rich    O
in    O
scopolamine    O
(    O
hyoscine    O
)    O
,    O
hyoscyamine    O
,    O
and    O
several    O
other    O
tropane    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
.    O

Ergovaline    B-Alkaloid114712692

Ample    O
research    O
on    O
the    O
cycad    O
hypothesis    O
found    O
a    O
component    O
of    O
the    O
seeds    O
,    O
cycasin    B-Alkaloid114712692
,    O
was    O
a    O
potent    O
toxin    O
;    O
it    O
was    O
discovered    O
in    O
the    O
1950s    O
.    O

Unlike    O
"    O
Metroxylon    O
"    O
palms    O
(    O
discussed    O
above    O
)    O
,    O
cycads    O
are    O
highly    O
poisonous    O
:    O
most    O
parts    O
of    O
the    O
plant    O
contain    O
the    O
neurotoxins    O
cycasin    B-Alkaloid114712692
and    O
BMAA    O
.    O

demecolcine    B-Alkaloid114712692
(    O
INN    O
)    O

Akuammine    B-Alkaloid114712692

Alseroxylon    B-Alkaloid114712692
(    O
Rautensin    B-Alkaloid114712692
,    O
Rauwiloid    B-Alkaloid114712692
)    O
is    O
a    O
norepinephrine    O
reuptake    O
inhibitor    O
that    O
has    O
been    O
investigated    O
in    O
the    O
treatment    O
of    O
hypertension    O
and    O
angina    O
pectoris    O
and    O
as    O
a    O
sedative    O
in    O
psychoses    O
.    O

The    O
primary    O
function    O
of    O
pigments    O
in    O
plants    O
is    O
photosynthesis    O
,    O
which    O
uses    O
the    O
green    O
pigment    O
chlorophyll    O
along    O
with    O
several    O
red    O
and    O
yellow    O
pigments    O
including    O
porphyrins    O
,    O
carotenoids    O
,    O
anthocyanins    O
and    O
betalain    B-Alkaloid114712692
.    O

The    O
flowers    O
are    O
funnel    O
-    O
shaped    O
and    O
range    O
from    O
7    O
mm    O
to    O
40    O
mm    O
and    O
more    O
in    O
length    O
and    O
in    O
diameter    O
,    O
from    O
white    O
and    O
greenish    O
to    O
yellow    O
,    O
pink    O
and    O
red    O
in    O
colour    O
,    O
often    O
with    O
a    O
darker    O
mid    O
-    O
stripe    O
;    O
the    O
reddish    O
hues    O
are    O
due    O
to    O
betalain    B-Alkaloid114712692
pigments    O
as    O
usual    O
for    O
Caryophyllales    O
.    O

This    O
fruit    O
is    O
one    O
of    O
the    O
few    O
to    O
have    O
indicaxanthin    O
,    O
a    O
betalain    B-Alkaloid114712692
,    O
a    O
type    O
of    O
plant    O
pigment    O
antioxidant    O
.    O

Eight    O
betaxanthin    B-Alkaloid114712692
(    O
indicaxanthin    O
,    O
vulgaxanthin    O
-    O
I    O
,    O
miraxanthin    O
-    O
I    O
,    O
-II    O
,    O
-III    O
,    O
-IV    O
,    O
-V    O
and    O
-VI    O
)    O
can    O
be    O
isolated    O
from    O
"    O
M.    O
jalapa    O
"    O
flowers    O
.    O

Also    O
a    O
synthetic    O
dye    O
was    O
named    O
"    O
amaranth    O
"    O
for    O
its    O
similarity    O
in    O
color    O
to    O
the    O
natural    O
amaranth    O
pigments    O
known    O
as    O
betalain    B-Alkaloid114712692
.    O

Ergocryptine    O
("'β-ergocryptine    B-Alkaloid114712692
)    O
is    O
an    O
ergoline    B-Alkaloid114712692
alkaloid    O
.    O

Alkaloids    O
present    O
in    O
the    O
fresh    O
plant    O
or    O
the    O
dried    O
root    O
included    O
atropine    O
,    O
hyoscyamine    O
,    O
scopolamine    O
(    O
hyoscine    O
)    O
,    O
scopine    B-Alkaloid114712692
,    O
cuscohygrine    B-Alkaloid114712692
,    O
apoatropine    O
,    O
3-alpha    O
-    O
tigloyloxytropane    O
,    O
3-alpha,6-beta    O
-    O
ditigloyloxytropane    O
and    O
belladonnines    O
.    O

Allopumiliotoxin    B-Alkaloid114712692
267A    I-Alkaloid114712692

desomorphine    B-Alkaloid114712692
(    O
INN    O
)    O

#    O
Desomorphine    B-Alkaloid114712692

Nicomorphine    O
(    O
morphine    O
dinicotinate    O
)    O
,    O
dipropanoylmorphine    O
(    O
morphine    O
dipropionate    O
)    O
,    O
desomorphine    B-Alkaloid114712692
(    O
di    O
-    O
hydro    O
-    O
desoxy    O
-    O
morphine    O
)    O
,    O
methyldesorphine    O
,    O
acetylpropionylmorphine    O
,    O
dibenzoylmorphine    O
,    O
diacetyldihydromorphine    O
,    O
and    O
several    O
others    O
are    O
also    O
derived    O
from    O
morphine    O
.    O

Desomorphine    B-Alkaloid114712692

Isovaleramide    B-Alkaloid114712692
is    O
an    O
organic    O
compound    O
with    O
the    O
formula    O
(    O
CH3)2CHCH2C(O)NH2    O
.    O

Samandaridine    B-Alkaloid114712692
is    O
an    O
extremely    O
toxic    O
alkaloid    O
produced    O
by    O
the    O
skin    O
glands    O
of    O
various    O
salamanders    O
.    O

Mitragynine    B-Alkaloid114712692

Mitragynine    B-Alkaloid114712692

Rodiasine    B-Alkaloid114712692
is    O
a    O
cyclic    O
bisbenzylisoquinoline    O
alkaloid    O
that    O
was    O
first    O
isolated    O
from    O
the    O
South    O
American    O
greenheart    O
tree    O
"    O
Chlorocardium    O
rodiei    O
"    O
.    O

Mesembrine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
present    O
in    O
"    O
Sceletium    O
tortuosum    O
"    O
(    O
kanna    O
)    O
.    O

Cycloclavine    B-Alkaloid114712692
is    O
an    O
ergot    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
.    O

Aspidospermidine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
isolated    O
from    O
plants    O
in    O
the    O
genus    O
"    O
Aspidosperma    O
"    O
.    O

Anonaine    B-Alkaloid114712692

Ipecacuanha    O
contains    O
the    O
alkaloids    O
emetine    O
(    O
methylcephaeline    O
)    O
and    O
cephaeline    B-Alkaloid114712692
.    O

It    O
is    O
the    O
base    O
chemical    O
structure    O
of    O
various    O
alkaloids    O
in    O
the    O
"    O
Rauwolfia    O
"    O
and    O
"    O
Pausinystalia    O
"    O
plant    O
genera    O
,    O
including    O
yohimbine    O
,    O
rauwolscine    O
,    O
corynanthine    O
,    O
ajmalicine    B-Alkaloid114712692
,    O
reserpine    O
,    O
deserpidine    B-Alkaloid114712692
,    O
and    O
rescinnamine    B-Alkaloid114712692
,    O
among    O
others    O
.    O

Moderil    B-Alkaloid114712692

After    O
oxidation    O
and    O
methylation    O
by    O
SAM    O
,    O
("S")-reticuline    B-Alkaloid114712692
4    O
is    O
formed    O
.    O

A    O
key    O
step    O
is    O
the    O
Grewe    O
cyclization    O
that    O
is    O
analogous    O
to    O
the    O
cyclization    O
of    O
reticuline    B-Alkaloid114712692
that    O
occurs    O
in    O
morphine    O
biosynthesis    O
.    O

Scoulerine    B-Alkaloid114712692
,    O
also    O
known    O
as    O
discretamine    B-Alkaloid114712692
and    O
aequaline    B-Alkaloid114712692
,    O
is    O
a    O
benzylisoquinoline    B-Alkaloid114712692
alkaloid    O
that    O
derives    O
from    O
reticuline    B-Alkaloid114712692
and    O
is    O
a    O
precursor    O
of    O
berberine    B-Alkaloid114712692
.    O

Riddelliine    B-Alkaloid114712692

lorajmine    B-Alkaloid114712692
(    O
INN    O
)    O

The    O
technical    O
chemistry    O
names    O
cathine    B-Alkaloid114712692
and    O
cathinone    B-Alkaloid114712692
are    O
20th    O
century    O
from    O
"    O
Catha    O
"    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    B-Alkaloid114712692
,    O
phentermine    O
,    O
mephentermine    O
,    O
bupropion    O
,    O
methoxyphenamine    O
,    O
selegiline    O
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
and    O
DOM    O
(    O
STP    O
)    O
.    O

According    O
to    O
the    O
medico    O
legal    O
report    O
of    O
NBI    O
,    O
it    O
was    O
shown    O
that    O
Fontejon    O
had    O
two    O
types    O
of    O
dangerous    O
drugs    O
in    O
her    O
body    O
:    O
MDMA    O
methylene    O
homolog    O
and    O
synthetic    O
cathinone    B-Alkaloid114712692
.    O

In    O
March    O
2010    O
,    O
the    O
ACMD    O
published    O
a    O
report    O
,    O
"    O
Consideration    O
of    O
the    O
cathinones    O
"    O
,    O
which    O
recommended    O
that    O
mephedrone    O
and    O
other    O
cathinone    B-Alkaloid114712692
should    O
be    O
made    O
illegal    O
.    O

5-Methylethylone    O
(    O
5-methyl-βk    O
-    O
MDEA    O
,    O
5ME    O
)    O
is    O
an    O
empathogen    O
,    O
stimulant    O
and    O
psychedelic    O
drug    O
of    O
the    O
amphetamine    O
,    O
phenethylamine    O
,    O
and    O
cathinone    B-Alkaloid114712692
chemical    O
classes    O
.    O

Some    O
authors    O
classify    O
as    O
pseudoalkaloids    O
such    O
compounds    O
such    O
as    O
ephedrine    O
and    O
cathinone    B-Alkaloid114712692
.    O

Cocaine    O
,    O
caffeine    O
,    O
and    O
cathinone    B-Alkaloid114712692
are    O
stimulants    O
of    O
the    O
central    O
nervous    O
system    O
.    O

Cathinone    B-Alkaloid114712692

Halostachine    B-Alkaloid114712692

For    O
instance    O
,    O
ewes    O
who    O
graze    O
on    O
corn    O
lily    O
ingest    O
cyclopamine    B-Alkaloid114712692
(    O
shown    O
)    O
and    O
veratramine    B-Alkaloid114712692
,    O
two    O
of    O
a    O
sub    O
-    O
family    O
of    O
steroids    O
where    O
the    O
C-    O
and    O
D    O
-    O
rings    O
are    O
contracted    O
and    O
expanded    O
respectively    O
via    O
a    O
biosynthetic    O
migration    O
of    O
the    O
original    O
C-13    O
atom    O
.    O

Crystalline    O
ibogaine    O
hydrochloride    O
is    O
typically    O
produced    O
by    O
semi    O
-    O
synthesis    O
from    O
voacangine    B-Alkaloid114712692
in    O
commercial    O
laboratories    O
.    O

This    O
discovery    O
was    O
stimulated    O
by    O
earlier    O
studies    O
on    O
other    O
naturally    O
occurring    O
analogues    O
of    O
ibogaine    O
such    O
as    O
coronaridine    B-Alkaloid114712692
and    O
voacangine    B-Alkaloid114712692
that    O
showed    O
these    O
compounds    O
also    O
have    O
anti    O
-    O
addictive    O
properties    O
.    O

Voacangine    B-Alkaloid114712692

:    O
C01BA08    O
Prajmaline    B-Alkaloid114712692

It    O
is    O
notable    O
for    O
its    O
concentrations    O
of    O
two    O
pyridine    O
alkaloids    O
:    O
lobeline    B-Alkaloid114712692
and    O
nicotine    O
.    O

The    O
plant    O
contains    O
a    O
number    O
of    O
toxic    O
alkaloids    O
including    O
lobelamine    O
and    O
lobeline    B-Alkaloid114712692
.    O

lobeline    B-Alkaloid114712692
(    O
INN    O
)    O

Their    O
chemical    O
structures    O
are    O
closely    O
related    O
to    O
the    O
agelasine    B-Alkaloid114712692
.    O

The    O
rhizomes    O
of    O
"    O
Coptis    O
chinensis    O
"    O
are    O
used    O
in    O
Traditional    O
Chinese    O
Medicine    O
and    O
serve    O
as    O
a    O
source    O
for    O
the    O
isoquinoline    O
alkaloids    O
berberine    B-Alkaloid114712692
,    O
palmatine    B-Alkaloid114712692
,    O
and    O
coptisine    B-Alkaloid114712692
among    O
others    O
.    O

Alkaloids    O
found    O
in    O
"    O
Scopolia    O
tangutica    O
"    O
include    O
hyoscyamine    O
,    O
scopolamine    O
,    O
anisodamine    B-Alkaloid114712692
,    O
and    O
anisodine    B-Alkaloid114712692
.    O

Rhazinilam    B-Alkaloid114712692
is    O
an    O
alkaloid    O
first    O
isolated    O
in    O
1965    O
by    O
Linde    O
from    O
the    O
"    O
Melodinus    O
australis    O
"    O
plant    O
.    O

Californidine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
with    O
the    O
molecular    O
formula    O
C21H22NO3    O
+    O
.    O

Ibogamine    B-Alkaloid114712692

In    O
other    O
species    O
high    O
levels    O
of    O
mimosine    B-Alkaloid114712692
may    O
lead    O
to    O
hair    O
loss    O
and    O
infertility    O
in    O
non    O
-    O
ruminants    O
.    O

Other    O
tropanes    O
present    O
include    O
apoatropine    O
,    O
aposcopolamine    B-Alkaloid114712692
and    O
6-hydroxyatropine    O
.    O

All    O
parts    O
of    O
the    O
plant    O
contain    O
cytisine    B-Alkaloid114712692
and    O
are    O
poisonous    O
if    O
consumed    O
.    O

The    O
fruit    O
also    O
contain    O
the    O
alkaloids    O
cytisine    B-Alkaloid114712692
,    O
N    O
-    O
methylcytisine    O
,    O
sophocarpine    O
,    O
matrine    B-Alkaloid114712692
and    O
stizolamine    O
.    O

3-Bromocytisine    O
is    O
a    O
derivative    O
of    O
the    O
toxic    O
alkaloid    O
cytisine    B-Alkaloid114712692
that    O
acts    O
as    O
a    O
highly    O
potent    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
,    O
binding    O
primarily    O
to    O
the    O
α4β2    O
and    O
α7    O
subtypes    O
.    O

Nantenine    B-Alkaloid114712692

It    O
has    O
shown    O
superiority    O
to    O
cisplatin    O
in    O
combination    O
with    O
paclitaxel    B-Alkaloid114712692
as    O
a    O
chemotherapy    O
regimen    O
in    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
(    O
NSCLC    O
)    O
adenocarcinomas    O
.    O

Bark    O
isolates    O
are    O
chemicals    O
which    O
have    O
been    O
extracted    O
from    O
bark    O
,    O
which    O
include    O
the    O
medicines    O
salicylic    O
acid    O
(    O
active    O
metabolite    O
of    O
aspirin    O
)    O
and    O
paclitaxel    B-Alkaloid114712692
(    O
Taxol    O
)    O
.    O

Phyton    O
Biotech    O
uses    O
plant    O
cell    O
culture    O
systems    O
to    O
manufacture    O
active    O
pharmaceutical    O
ingredients    O
based    O
on    O
taxanes    O
,    O
including    O
paclitaxel    B-Alkaloid114712692
and    O
docetaxel    B-Alkaloid114712692

Paclitaxel    B-Alkaloid114712692

Salinomycin    O
has    O
been    O
shown    O
by    O
Piyush    O
Gupta    O
et    O
al    O
.    O
of    O
the    O
Massachusetts    O
Institute    O
of    O
Technology    O
and    O
the    O
Broad    O
Institute    O
to    O
kill    O
breast    O
cancer    O
stem    O
cells    O
in    O
mice    O
at    O
least    O
100    O
times    O
more    O
effectively    O
than    O
the    O
anti    O
-    O
cancer    O
drug    O
paclitaxel    B-Alkaloid114712692
.    O

ANG1005    O
is    O
a    O
paclitaxel    B-Alkaloid114712692
-    O
Angiopep-2    O
conjugate    O
.    O

Florida    O
State    O
is    O
home    O
to    O
Florida    O
's    O
only    O
National    O
Laboratory    O
–    O
the    O
National    O
High    O
Magnetic    O
Field    O
Laboratory    O
and    O
is    O
the    O
birthplace    O
of    O
the    O
commercially    O
viable    O
anti    O
-    O
cancer    O
drug    O
Taxol    B-Alkaloid114712692
.    O

Chemotherapy    O
-    O
induced    O
Peripheral    O
Neuropathy    O
(    O
CIPN    O
)    O
:    O
A    O
review    O
of    O
two    O
studies    O
concluded    O
that    O
ALC    O
may    O
be    O
a    O
treatment    O
option    O
for    O
Paclitaxel    B-Alkaloid114712692
and    O
Cisplatin    O
induced    O
CIPN    O
,    O
while    O
a    O
clinical    O
trial    O
showed    O
it    O
did    O
not    O
prevent    O
CIPN    O
and    O
appeared    O
to    O
worsen    O
the    O
conditions    O
in    O
Taxane    O
therapy    O
.    O

Treating    O
embryos    O
with    O
the    O
microtubule    O
depolymerizing    O
agent    O
nocodazole    O
completely    O
blocks    O
epiboly    O
of    O
the    O
YSL    O
and    O
partially    O
blocks    O
epiboly    O
of    O
the    O
blastoderm    O
,    O
while    O
treating    O
with    O
the    O
microtubule    O
stabilizing    O
agent    O
taxol    B-Alkaloid114712692
blocks    O
epiboly    O
of    O
all    O
cell    O
layers    O
.    O

Modern    O
medicines    O
derived    O
from    O
plants    O
include    O
aspirin    O
,    O
taxol    B-Alkaloid114712692
,    O
morphine    O
,    O
quinine    O
,    O
reserpine    O
,    O
colchicine    O
,    O
digitalis    O
and    O
vincristine    O
.    O

The    O
Danishefsky    O
Taxol    O
total    O
synthesis    O
was    O
the    O
third    O
synthesis    O
of    O
taxol    B-Alkaloid114712692
,    O
a    O
highly    O
topical    O
natural    O
product    O
.    O

miR-451    O
regulates    O
the    O
drug    O
-    O
transporter    O
protein    O
P    O
-    O
glycoprotein    O
,    O
potentially    O
promoting    O
resistance    O
to    O
the    O
chemotherapy    O
drug    O
Paclitaxel    B-Alkaloid114712692
.    O

He    O
is    O
co    O
-    O
discoverer    O
of    O
Taxol    B-Alkaloid114712692
and    O
camptothecin    B-Alkaloid114712692
,    O
two    O
anti    O
-    O
cancer    O
drugs    O
considered    O
standard    O
in    O
the    O
treatment    O
to    O
fight    O
ovarian    O
,    O
breast    O
,    O
lung    O
and    O
colon    O
cancers    O
.    O

taxol    B-Alkaloid114712692
and    O
Docetaxel    B-Alkaloid114712692
both    O
are    O
still    O
used    O
in    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
ovarian    O
cancer    O
and    O
other    O
types    O
of    O
epithelial    O
cancer    O
.    O

In    O
some    O
cases    O
,    O
the    O
drug    O
itself    O
is    O
not    O
immunogenic    O
,    O
but    O
may    O
be    O
co    O
-    O
administered    O
with    O
an    O
immunogenic    O
compound    O
,    O
as    O
is    O
sometimes    O
the    O
case    O
for    O
Taxol    B-Alkaloid114712692
.    O

Taxol    B-Alkaloid114712692
is    O
a    O
drug    O
used    O
in    O
anticancer    O
therapies    O
due    O
to    O
its    O
ability    O
to    O
interfere    O
with    O
microtubule    O
assembly    O
,    O
which    O
leads    O
to    O
cell    O
cycle    O
arrest    O
.    O

The    O
total    O
synthesis    O
of    O
Taxol    B-Alkaloid114712692
is    O
considered    O
a    O
hallmark    O
in    O
organic    O
synthesis    O
.    O

This    O
method    O
has    O
been    O
used    O
in    O
natural    O
product    O
synthesis    O
of    O
Taxol    B-Alkaloid114712692
by    O
Danishefsky    O
and    O
Cortistatin    B-Alkaloid114712692
A    I-Alkaloid114712692
by    O
Shair    O
.    O

Examples    O
of    O
diterpenes    O
and    O
diterpenoids    O
are    O
cafestol    O
,    O
kahweol    O
,    O
cembrene    O
and    O
taxadiene    O
(    O
precursor    O
of    O
taxol    B-Alkaloid114712692
)    O
.    O

In    O
2007    O
preliminary    O
results    O
were    O
released    O
from    O
the    O
Phase    O
II    O
clinical    O
trial    O
of    O
intravenous    O
belinostat    O
in    O
combination    O
with    O
carboplatin    O
and    O
paclitaxel    B-Alkaloid114712692
for    O
relapsed    O
ovarian    O
cancer    O
.    O

The    O
total    O
synthesis    O
of    O
Taxol    B-Alkaloid114712692
is    O
considered    O
a    O
landmark    O
in    O
organic    O
synthesis    O
.    O

Mansukh    O
C.    O
Wani    O
,    O
cancer    O
researcher    O
,    O
discoverer    O
of    O
Taxol    B-Alkaloid114712692

Milataxel    O
(    O
MAC-321    O
,    O
TL-139    O
)    O
is    O
a    O
taxol    B-Alkaloid114712692
analog    O
.    O

Taxus    O
wallichiana    O
"    O
is    O
also    O
a    O
source    O
of    O
the    O
chemical    O
precursors    O
to    O
the    O
anticancer    O
drug    O
paclitaxel    B-Alkaloid114712692
.    O
"    O

The    O
drug    O
paclitaxel    B-Alkaloid114712692
may    O
be    O
useful    O
in    O
the    O
treatment    O
of    O
cisplatin    O
-    O
resistant    O
cancer    O
;    O
the    O
mechanism    O
for    O
this    O
activity    O
is    O
unknown    O
.    O

This    O
is    O
the    O
TAXUS    O
Express2    O
Paclitaxel    O
-    O
Eluting    O
Coronary    O
Stent    O
System    O
,    O
which    O
releases    O
paclitaxel    B-Alkaloid114712692
.    O

An    O
isolate    O
of    O
"    O
G.    O
citricarpa    O
"    O
was    O
found    O
to    O
produce    O
the    O
medically    O
important    O
compound    O
,    O
taxol    B-Alkaloid114712692
under    O
certain    O
growth    O
conditions    O
.    O

Dimethyl-4β-(2-naphthyl)piperidine-3β-carboxylate    O
(    O
"    O
'    O
DMNPC    O
)    O
is    O
a    O
piperidine    B-Alkaloid114712692
based    O
stimulant    O
drug    O
which    O
is    O
synthesised    O
from    O
arecoline    B-Alkaloid114712692
.    O

The    O
total    O
synthesis    O
of    O
a    O
number    O
of    O
natural    O
alkaloids    O
–    O
pilocarpine    O
,    O
pilozinin    O
,    O
alkaloids    O
of    O
propane    O
series    O
(    O
tropine    O
,    O
cocaine    O
)    O
,    O
arecoline    B-Alkaloid114712692
,    O
eserine    O
,    O
emetine    O
,    O
psyhotrine    O
,    O
emataliine    O
,    O
cinchonamine    O
,    O
tubocurarine    B-Alkaloid114712692
and    O
other    O
alkaloids    O
of    O
curare    O
(    O
magnolin    O
,    O
magnolamine    O
,    O
dauricine    B-Alkaloid114712692
)    O
.    O

The    O
major    O
psychoactive    O
ingredients    O
–    O
arecoline    B-Alkaloid114712692
(    O
a    O
muscarinic    O
receptor    O
partial    O
agonist    O
)    O
and    O
arecaidine    B-Alkaloid114712692
(    O
a    O
GABA    O
reuptake    O
inhibitor    O
)    O
–    O
are    O
responsible    O
for    O
the    O
euphoric    O
effect    O
.    O

Dihydroquinidine    B-Alkaloid114712692

Lythranidine    B-Alkaloid114712692

Solamargine    B-Alkaloid114712692

Geissoschizine    B-Alkaloid114712692
methyl    I-Alkaloid114712692
ether    I-Alkaloid114712692
is    O
an    O
alkalod    O
contained    O
in    O
the    O
kampo    O
medicine    O
Yokukansan    O
.    O

It    O
is    O
a    O
source    O
of    O
jervine    B-Alkaloid114712692
and    O
cyclopamine    B-Alkaloid114712692
,    O
teratogens    O
which    O
can    O
cause    O
prolonged    O
gestation    O
associated    O
with    O
birth    O
defects    O
such    O
as    O
holoprosencephaly    O
and    O
cyclopia    O
in    O
animals    O
such    O
as    O
sheep    O
,    O
horses    O
,    O
and    O
other    O
mammals    O
that    O
graze    O
upon    O
it    O
.    O

One    O
example    O
is    O
the    O
alkaloid    O
cyclopamine    B-Alkaloid114712692
,    O
produced    O
in    O
the    O
leaves    O
of    O
corn    O
lily    O
.    O

The    O
cyclopia    O
in    O
the    O
calf    O
is    O
induced    O
by    O
the    O
alkaloid    O
cyclopamine    B-Alkaloid114712692
present    O
in    O
the    O
plant    O
.    O

This    O
group    O
includes    O
terpene    O
-    O
like    O
and    O
steroid    O
-    O
like    O
alkaloids    O
,    O
as    O
well    O
as    O
purine    O
-    O
like    O
alkaloids    O
such    O
as    O
caffeine    O
,    O
theobromine    B-Alkaloid114712692
,    O
theacrine    B-Alkaloid114712692
and    O
theophylline    O
.    O

Picrinine    B-Alkaloid114712692
is    O
a    O
bio    O
-    O
active    O
alkaloid    O
from    O
"    O
Alstonia    O
boonei    O
"    O
,    O
a    O
medicinal    O
tree    O
of    O
West    O
Africa    O
.    O

Liberine    B-Alkaloid114712692
aka    O
O(2),1,9-trimethyluric    O
acid    O

Horsfiline    B-Alkaloid114712692
is    O
an    O
oxindole    O
alkaloid    O
found    O
in    O
the    O
plant    O
"    O
Horsfieldia    O
superba    O
"    O
,    O
which    O
is    O
used    O
in    O
traditional    O
herbal    O
medicine    O
.    O

Harmonyl    B-Alkaloid114712692

#    O
Methoserpidine    O
and    O
reserpine    O
and    O
Deserpidine    B-Alkaloid114712692
.    O

Фезам    O
»    O
(    O
Phezam    O
)    O
which    O
contains    O
cinnarizine    O
/    O
vinpocetine    B-Alkaloid114712692
)    O
"    O

Pharmalogical    O
neuroenhancement    O
agents    O
include    O
the    O
well    O
-    O
validated    O
nootropics    O
,    O
such    O
as    O
racetam    O
,    O
vinpocetine    B-Alkaloid114712692
,    O
and    O
phosphatidylserine    O
,    O
as    O
well    O
as    O
other    O
drugs    O
used    O
for    O
treating    O
patients    O
suffering    O
from    O
neurological    O
disorders    O
.    O

vinpocetine    B-Alkaloid114712692

Aporphine    B-Alkaloid114712692

Oliveroline    B-Alkaloid114712692
is    O
an    O
anti    O
-    O
cholinergic    O
aporphine    B-Alkaloid114712692
alkaloid    O
.    O

For    O
example    O
,    O
aporphine    B-Alkaloid114712692
alkaloid    O
liriodenine    B-Alkaloid114712692
produced    O
by    O
the    O
tulip    O
tree    O
protects    O
it    O
from    O
parasitic    O
mushrooms    O
.    O

Hordenine    B-Alkaloid114712692

Hordenine    B-Alkaloid114712692

Hordenine    B-Alkaloid114712692

The    O
plant    O
contains    O
bitter    O
and    O
toxic    O
alkaloids    O
such    O
as    O
hordenine    B-Alkaloid114712692
.    O

The    O
4    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
,    O
palmatine    B-Alkaloid114712692
,    O
NADPH    O
,    O
and    O
H+    O
,    O
whereas    O
its    O
3    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
,    O
corydaline    B-Alkaloid114712692
,    O
and    O
NADP+    O
.    O

The    O
rhizomes    O
of    O
"    O
Coptis    O
chinensis    O
"    O
are    O
used    O
in    O
Traditional    O
Chinese    O
Medicine    O
and    O
serve    O
as    O
a    O
source    O
for    O
the    O
isoquinoline    O
alkaloids    O
berberine    B-Alkaloid114712692
,    O
palmatine    B-Alkaloid114712692
,    O
and    O
coptisine    B-Alkaloid114712692
among    O
others    O
.    O

Pepper    O
can    O
also    O
lose    O
flavour    O
when    O
exposed    O
to    O
light    O
,    O
which    O
can    O
transform    O
piperine    O
into    O
nearly    O
tasteless    O
chavicine    B-Alkaloid114712692
.    O

Goldenseal    O
contains    O
the    O
isoquinoline    O
alkaloids    O
:    O
hydrastine    B-Alkaloid114712692
,    O
berberine    B-Alkaloid114712692
,    O
berberastine    O
,    O
hydrastinine    B-Alkaloid114712692
,    O
tetrahydroberberastine    O
,    O
canadine    O
,    O
and    O
canalidine    O
.    O

Tombozine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
found    O
in    O
"    O
Vinca    O
minor    O
"    O
.    O

Dihydroquinine    B-Alkaloid114712692

One    O
example    O
isolated    O
from    O
the    O
Okinawan    O
"    O
plakortis    O
"    O
sponges    O
,    O
plakoridine    B-Alkaloid114712692
A    I-Alkaloid114712692
,    O
has    O
shown    O
potential    O
as    O
a    O
cytotoxin    O
to    O
murine    O
lymphoma    O
cells    O
.    O

Two    O
other    O
harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
in    O
"    O
B.    O
caapi    O
"    O
,    O
harmaline    B-Alkaloid114712692
and    O
harmine    B-Alkaloid114712692
,    O
are    O
reversible    O
inhibitors    O
of    O
monoamine    O
oxidase    O
A.    O
Tetrahydroharmine    O
,    O
however    O
,    O
does    O
not    O
inhibit    O
monoamine    O
oxidase    O
B.    O

In    O
the    O
20th    O
century    O
,    O
the    O
active    O
chemical    O
constituent    O
of    O
"    O
B.    O
caapi    O
"    O
was    O
named    O
"    O
telepathine    B-Alkaloid114712692
"    O
,    O
but    O
it    O
was    O
found    O
to    O
be    O
identical    O
to    O
a    O
chemical    O
already    O
isolated    O
from    O
"    O
Peganum    O
harmala    O
"    O
and    O
was    O
given    O
the    O
name    O
harmaline    B-Alkaloid114712692
.    O

The    O
three    O
most    O
studied    O
harmala    O
alkaloids    O
in    O
the    O
"    O
B.    O
caapi    O
"    O
vine    O
are    O
harmine    B-Alkaloid114712692
,    O
harmaline    B-Alkaloid114712692
and    O
tetrahydroharmine    O
.    O

Molecular    O
structure    O
of    O
harmaline    B-Alkaloid114712692
.    O

It    O
has    O
been    O
demonstrated    O
in    O
essential    O
tremor    O
animal    O
models    O
that    O
the    O
food    O
additive    O
1-octanol    O
suppresses    O
tremors    O
induced    O
by    O
harmaline    B-Alkaloid114712692
,    O
and    O
decreases    O
the    O
amplitude    O
of    O
essential    O
tremor    O
for    O
about    O
90    O
minutes    O
.    O

Prosopine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
found    O
in    O
"    O
Prosopis    O
africana    O
"    O
.    O

Eburnamine    B-Alkaloid114712692
is    O
an    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
in    O
the    O
aspidosperma    O
group    O
.    O

Tortuosamine    B-Alkaloid114712692

Plakohypaphorines    B-Alkaloid114712692
D-F    I-Alkaloid114712692
,    O
also    O
found    O
in    O
"    O
P.    O
simplex    O
"    O
,    O
were    O
reported    O
in    O
2004    O
by    O
a    O
group    O
including    O
the    O
researchers    O
who    O
discovered    O
the    O
original    O
plakohypaphorines    O
.    O

It    O
is    O
a    O
synthetic    O
halogenated    O
derivative    O
of    O
febrifugine    B-Alkaloid114712692
,    O
a    O
natural    O
quinazolinone    O
alkaloid    O
which    O
can    O
be    O
found    O
in    O
the    O
Chinese    O
herb    O
"    O
Dichroa    O
febrifuga    O
"    O
(    O
Chang    O
Shan    O
)    O
.    O

Pseudopelletierine    B-Alkaloid114712692
is    O
the    O
main    O
alkaloid    O
derived    O
from    O
the    O
root    O
-    O
bark    O
of    O
the    O
pomegranate    O
tree    O
(    O
"    O
Punica    O
granatum    O
"    O
)    O
,    O
along    O
with    O
at    O
least    O
three    O
other    O
alkaloids    O
:    O
pelletierine    O
,    O
isopelletierine    O
,    O
and    O
methylpelleteirine    O
(    O
C9H17ON    O
)    O
,    O
which    O
yield    O
1.8    O
,    O
0.52    O
,    O
0.01    O
,    O
and    O
0.20    O
grams    O
per    O
kilogram    O
of    O
raw    O
bark    O
.    O

Eburnamenine    B-Alkaloid114712692
is    O
an    O
anticholinergic    O
alkaloid    O
.    O

Narcotoline    B-Alkaloid114712692
is    O
an    O
opiate    O
alkaloid    O
chemically    O
related    O
to    O
noscapine    B-Alkaloid114712692
.    O

Clinical    O
trials    O
have    O
found    O
that    O
the    O
first    O
generation    O
tyrosine    O
kinase    O
inhibitors    O
sorafenib    O
,    O
sunitinib    O
,    O
midostaurin    B-Alkaloid114712692
,    O
lestaurtinib    O
have    O
shown    O
some    O
promise    O
in    O
treating    O
acute    O
myelogenous    O
leukemia    O
associated    O
with    O
the    O
"    O
FLT3-TKI    O
"    O
fusion    O
gene    O
;    O
the    O
second    O
generation    O
tyrosine    O
kinase    O
inhibtors    O
quizartinib    O
and    O
crenolanib    O
which    O
are    O
highly    O
selective    O
in    O
inhibiting    O
the    O
FLT3    O
protein    O
,    O
have    O
shown    O
significant    O
promise    O
in    O
treating    O
relapsed    O
and    O
refractory    O
acute    O
myelogenous    O
leukemia    O
related    O
to    O
the    O
"    O
FLT3-TKI    O
"    O
fusion    O
gene    O
.    O

midostaurin    B-Alkaloid114712692
(    O
USAN    O
)    O

Ergine    B-Alkaloid114712692
(    O
LSA    O
)    O
,    O
isoergine    B-Alkaloid114712692
,    O
D-lysergic    B-Alkaloid114712692
acid    I-Alkaloid114712692
N-(α-hydroxyethyl)amide    I-Alkaloid114712692
and    O
lysergol    B-Alkaloid114712692
have    O
been    O
isolated    O
from    O
"    O
I.    O
tricolor    O
"    O
,    O
"    O
I.    O
violacea    O
"    O
and/or    O
purple    O
morning    O
glory    O
(    O
"    O
I.    O
purpurea    O
"    O
)    O
;    O
although    O
these    O
are    O
often    O
assumed    O
to    O
be    O
the    O
cause    O
of    O
the    O
plants    O
'    O
effects    O
,    O
this    O
is    O
not    O
supported    O
by    O
scientific    O
studies    O
,    O
which    O
show    O
although    O
they    O
are    O
psychoactive    O
,    O
they    O
are    O
not    O
notably    O
hallucinogenic    O
.    O

Ergine    B-Alkaloid114712692
(    O
D    O
-    O
lysergic    O
acid    O
amide    O
)    O
.    O

The    O
hallucinogenic    O
properties    O
of    O
the    O
seeds    O
are    O
usually    O
attributed    O
to    O
ergine    B-Alkaloid114712692
(    O
also    O
known    O
as    O
"    O
d    O
-    O
lysergic    O
acid    O
amide    O
"    O
,    O
or    O
LSA    B-Alkaloid114712692
)    O
,    O
although    O
the    O
validity    O
of    O
the    O
attribution    O
remains    O
disputed    O
.    O

One    O
of    O
the    O
alkaloids    O
in    O
the    O
seeds    O
of    O
"    O
Rivea    O
corymbosa    O
"    O
(    O
Ololiuhqui    O
)    O
,    O
"    O
Argyreia    O
nervosa    O
"    O
(    O
Hawaiian    O
Baby    O
Woodrose    O
)    O
,    O
and    O
"    O
Ipomoea    O
violacea    O
"    O
(    O
Tlitliltzin    O
)    O
are    O
ergine    B-Alkaloid114712692
(    O
LSA    O
)    O
and    O
isoergine    B-Alkaloid114712692
(    O
its    O
epimer    O
)    O
.    O

LSA    B-Alkaloid114712692

Nordihydrocapsaicin    B-Alkaloid114712692

Mayer's    B-Alkaloid114712692
reagent    I-Alkaloid114712692

Scoulerine    B-Alkaloid114712692
,    O
also    O
known    O
as    O
discretamine    B-Alkaloid114712692
and    O
aequaline    B-Alkaloid114712692
,    O
is    O
a    O
benzylisoquinoline    B-Alkaloid114712692
alkaloid    O
that    O
derives    O
from    O
reticuline    B-Alkaloid114712692
and    O
is    O
a    O
precursor    O
of    O
berberine    B-Alkaloid114712692
.    O

Sanguinarine    B-Alkaloid114712692
and    O
dihydrosanguinarine    B-Alkaloid114712692
are    O
two    O
major    O
toxic    O
alkaloids    O
of    O
argemone    O
oil    O
,    O
which    O
cause    O
widespread    O
capillary    O
dilatation    O
,    O
proliferation    O
and    O
increased    O
capillary    O
permeability    O
.    O

Skeletal    O
formula    O
of    O
retronecine    B-Alkaloid114712692
,    O
a    O
pyrrolizidine    O
alkaloid    O
found    O
in    O
the    O
Common    O
groundsel    O
(    O
"    O
Senecio    O
vulgaris    O
"    O
)    O
and    O
comfrey    O
(    O
"    O
Symphytum    O
''    O
spp    O
.    O
)    O
.    O

Pleiocarpine    B-Alkaloid114712692
is    O
an    O
anticholinergic    O
alkaloid    O
.    O

The    O
clinical    O
efficacy    O
of    O
almitrine    O
-    O
raubasine    B-Alkaloid114712692
combination    O
therapy    O
for    O
age    O
related    O
cerebral    O
disorders    O
and    O
functional    O
rehabilitation    O
after    O
stroke    O
has    O
been    O
reviewed    O
by    O
Allain    O
and    O
Bentué    O
-    O
Ferrer    O
.    O

Ajmalicine    B-Alkaloid114712692

Streptomyces    O
variegatus    O
"    O
produces    O
prodigiosin    B-Alkaloid114712692
.    O

The    O
plant    O
contains    O
isoquinoline    O
alkaloids    O
protopine    B-Alkaloid114712692
and    O
allocryptopine    B-Alkaloid114712692
.    O

Ayahuasca    B-Alkaloid114712692

Many    O
of    O
their    O
traditions    O
are    O
still    O
practiced    O
,    O
such    O
as    O
ayahuasca    B-Alkaloid114712692
shamanism    O
.    O

In    O
low    O
dosages    O
,    O
ibogaine    O
is    O
a    O
stimulant    O
and    O
aphrodisiac    O
,    O
while    O
in    O
larger    O
amounts    O
it    O
is    O
a    O
divinatory    O
medicine    O
,    O
similar    O
to    O
both    O
Ayahuasca    B-Alkaloid114712692
and    O
Peyote    O
.    O

His    O
healing    O
techniques    O
involve    O
use    O
of    O
tobacco    O
,    O
bark    O
,    O
natural    O
fragrances    O
and    O
ayahuasca    B-Alkaloid114712692
.    O

In    O
his    O
last    O
work    O
,    O
he    O
used    O
the    O
psychological    O
theory    O
of    O
Jacques    O
Lacan    O
to    O
analyze    O
the    O
ways    O
in    O
which    O
the    O
Shuar    O
use    O
the    O
hallucinogen    O
Ayahuasca    B-Alkaloid114712692
.    O

Some    O
Yala    O
towns    O
and    O
villages    O
are    O
Okuku    O
,    O
Yahe    B-Alkaloid114712692
,    O
Ugaga    O
,    O
Ijegu    O
,    O
Oloko    O
,    O
Imaje    O
,    O
Oke    O
,    O
Echumoga    O
,    O
Woda    O
,    O
Ebo    O
,    O
Igede    O
Edii    O
Nation    O
,    O
Itekpa    O
,    O
Maa    O
,    O
Wonye    O
,    O
Uchu    O
,    O
Osina    O
,    O
Mbuor    O
,    O
Aliforkpa    O
,    O
Echumofana    O
,    O
Wanihem    O
,    O
Wanikade    O
,    O
Wanikom    O
,    O
etc    O
.    O

The    O
chief    O
also    O
led    O
group    O
sessions    O
using    O
ayahuasca    B-Alkaloid114712692
.    O

In    O
a    O
clearing    O
away    O
from    O
the    O
village    O
a    O
dark    O
-    O
green    O
drink    O
was    O
made    O
mostly    O
from    O
vines    O
of    O
"    O
ayahuasca    B-Alkaloid114712692
"    O
[    O
HK    O
:    O
"    O
nixi    O
honi    O
"    O
]    O
and    O
"    O
chacruna    O
"    O
leaves    O
,    O
boiled    O
slowly    O
over    O
a    O
low    O
fire    O
.    O

Primarily    O
ayahuasca    O
,    O
but    O
either    O
of    O
these    O
two    O
plants    O
,    O
or    O
their    O
comibination    O
,    O
are    O
also    O
called    O
"    O
yagé    B-Alkaloid114712692
"    O
,    O
among    O
other    O
names    O
.    O

Ayahuasca    B-Alkaloid114712692

Harpy    O
eagle    O
,    O
in    O
sessions    O
of    O
ayahuasca    B-Alkaloid114712692
,    O
called    O
forth    O
in    O
vision    O
by    O
the    O
hawk    O
icaro    O
..    O

Hancock    O
gave    O
a    O
TEDx    O
lecture    O
titled    O
"    O
The    O
War    O
on    O
Consciousness    O
"    O
,    O
in    O
which    O
he    O
described    O
his    O
use    O
of    O
ayahuasca    B-Alkaloid114712692
,    O
an    O
amazonian    O
brew    O
containing    O
a    O
hallucinogenic    O
compound    O
DMT    B-Alkaloid114712692
,    O
and    O
argued    O
that    O
adults    O
should    O
be    O
allowed    O
to    O
responsibly    O
use    O
it    O
for    O
self    O
-    O
improvement    O
and    O
spiritual    O
growth    O
.    O

In    O
the    O
city    O
of    O
Brasiléia    O
,    O
which    O
is    O
close    O
to    O
the    O
border    O
of    O
Bolivia    O
,    O
he    O
was    O
in    O
contact    O
with    O
other    O
people    O
from    O
his    O
home    O
state    O
of    O
Maranhão    O
as    O
well    O
as    O
Bolivians    O
,    O
from    O
whom    O
he    O
learned    O
the    O
use    O
of    O
ayahuasca    B-Alkaloid114712692
.    O

"    O
Carludovica    O
divergens    O
"    O
is    O
added    O
to    O
some    O
versions    O
of    O
the    O
hallucinogenic    O
drink    O
Ayahuasca    B-Alkaloid114712692
.    O

Although    O
ritual    O
is    O
often    O
used    O
in    O
context    O
with    O
worship    O
performed    O
in    O
a    O
church    O
,    O
the    O
actual    O
relationship    O
between    O
any    O
religion    O
's    O
doctrine    O
and    O
its    O
ritual(s    O
)    O
can    O
vary    O
considerably    O
from    O
organized    O
religion    O
to    O
non    O
-    O
institutionalized    O
spirituality    O
,    O
such    O
as    O
ayahuasca    B-Alkaloid114712692
shamanism    O
as    O
practiced    O
by    O
the    O
Urarina    O
of    O
the    O
upper    O
Amazon    O
.    O

Today    O
,    O
this    O
term    O
is    O
commonly    O
used    O
to    O
describe    O
the    O
medicine    O
songs    O
performed    O
in    O
"    O
vegetal    O
"    O
ceremonies    O
,    O
especially    O
by    O
shamans    O
in    O
ayahuasca    B-Alkaloid114712692
ceremonies    O
to    O
induce    O
a    O
profound    O
state    O
of    O
healing    O
,    O
awareness    O
or    O
amazement    O
.    O

It    O
is    O
also    O
commonly    O
used    O
to    O
describe    O
a    O
traditional    O
artisanal    O
pattern    O
of    O
the    O
Shipibo    O
tribe    O
based    O
on    O
the    O
visions    O
induced    O
by    O
ayahuasca    B-Alkaloid114712692
.    O

Icaro    O
is    O
most    O
commonly    O
used    O
to    O
describe    O
the    O
medicine    O
songs    O
used    O
by    O
shamans    O
in    O
healing    O
ceremonies    O
,    O
such    O
as    O
with    O
the    O
psychedelic    O
brew    O
ayahuasca    B-Alkaloid114712692
.    O

These    O
patterns    O
,    O
usually    O
involving    O
geometric    O
shapes    O
and    O
contrasting    O
colors    O
,    O
are    O
said    O
to    O
be    O
based    O
on    O
the    O
visions    O
induced    O
by    O
ayahuasca    B-Alkaloid114712692
.    O

Artisanal    O
goods    O
with    O
these    O
patterns    O
are    O
most    O
commonly    O
found    O
in    O
Iquitos    O
,    O
Peru    O
,    O
which    O
is    O
considered    O
to    O
be    O
the    O
capital    O
of    O
the    O
world    O
for    O
ayahuasca    B-Alkaloid114712692
healing    O
,    O
and    O
is    O
home    O
to    O
many    O
remaining    O
Shipibos    O
.    O

Neurons    O
to    O
Nirvana    O
explores    O
the    O
medicinal    O
properties    O
(    O
biological    O
,    O
emotional    O
and    O
psychological    O
)    O
of    O
Cannabis    O
,    O
Psilocybin    O
,    O
MDMA    O
,    O
LSD    O
and    O
Ayahuasca    B-Alkaloid114712692
.    O

The    O
album    O
is    O
a    O
sonic    O
documentation    O
of    O
her    O
and    O
Lee    O
's    O
experiences    O
with    O
the    O
South    O
American    O
healing    O
medicine    O
,    O
Ayahuasca    B-Alkaloid114712692
.    O

Ayahuasca    B-Alkaloid114712692
,    O
psychoactive    O
concoction    O
prepared    O
from    O
the    O
Amazonian    O
vine    O
"    O
Banisteriopsis    O
caapi    O
"    O

Ayahuasca    B-Alkaloid114712692
(;    O
)    O
,    O
or    O
iowaska    O
,    O
or    O
yagé    B-Alkaloid114712692
(    O
or    O
)    O
,    O
is    O
an    O
entheogenic    O
brew    O
made    O
out    O
of    O
"    O
Banisteriopsis    O
caapi    O
"    O
vine    O
and    O
other    O
ingredients    O
.    O

Recent    O
research    O
includes    O
collaborations    O
with    O
Dr    O
Jordi    O
Riba    O
at    O
Sant    O
Pau    O
Hospital    O
on    O
ayahuasca    B-Alkaloid114712692
,    O
Professor    O
David    O
Nutt    O
at    O
Imperial    O
College    O
on    O
the    O
effects    O
of    O
psychedelics    O
on    O
cerebral    O
blood    O
flow    O
,    O
Professor    O
Valerie    O
Curran    O
at    O
University    O
College    O
London    O
on    O
the    O
effects    O
of    O
cannabis    O
on    O
the    O
brain    O
with    O
a    O
view    O
to    O
possible    O
therapeutic    O
applications    O
and    O
with    O
Professor    O
Roland    O
Griffiths    O
at    O
Johns    O
Hopkins    O
University    O
studying    O
the    O
effects    O
of    O
psilocybin    O
in    O

A    O
preliminary    O
study    O
conducted    O
within    O
the    O
framework    O
of    O
the    O
Beckley    O
-    O
Sant    O
Pau    O
Research    O
Programme    O
and    O
in    O
collaboration    O
with    O
the    O
Spanish    O
National    O
Research    O
Council    O
found    O
that    O
harmine    O
and    O
tetrahydroharmine    O
,    O
the    O
alkaloids    O
present    O
in    O
highest    O
amounts    O
in    O
ayahuasca    B-Alkaloid114712692
,    O
have    O
potent    O
neurogenic    O
properties    O
(    O
the    O
ability    O
to    O
create    O
new    O
brain    O
cells    O
)    O
.    O

Shamanic    O
ethnomedicine    O
uses    O
the    O
ayahuasca    B-Alkaloid114712692
beverage    O
and    O
a    O
newly    O
identified    O
mushroom    O
(    O
"    O
Dictyonema    O
huaorani    O
"    O
)    O
with    O
the    O
analogous    O
substance    O
of    O
Psilocybe    O
genus    O

In    O
the    O
Netherlands    O
,    O
which    O
is    O
home    O
to    O
most    O
of    O
the    O
smart    O
shops    O
in    O
Europe    O
,    O
this    O
includes    O
"    O
Salvia    O
divinorum    O
"    O
,    O
"    O
Amanita    O
muscaria    O
"    O
,    O
Peyote    O
,    O
San    O
Pedro    O
cactus    O
,    O
"    O
Tabernanthe    O
iboga    O
"    O
,    O
and    O
various    O
ingredients    O
for    O
Ayahuasca    B-Alkaloid114712692
preparations    O
.    O

The    O
mature    O
inner    O
bark    O
of    O
this    O
species    O
contains    O
the    O
compound    O
NN-Dimethyltryptamine    B-Alkaloid114712692
(    O
0.4%    O
)    O
and    O
other    O
substituted    O
tryptamines    O
that    O
are    O
components    O
of    O
the    O
South    O
American    O
visionary    O
medicine    O
Ayahuasca    B-Alkaloid114712692
.    O

Solauricine    B-Alkaloid114712692
,    O
solauricidine    B-Alkaloid114712692
,    O
and    O
solasodamine    B-Alkaloid114712692
have    O
also    O
been    O
found    O
in    O
"    O
Solanum    O
mauritianum    O
"    O
.    O

Asimilobine    B-Alkaloid114712692

Vinca    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
are    O
amines    O
produced    O
by    O
the    O
hallucinogenic    O
plant    O
"    O
Catharanthus    O
roseus    O
"    O
(    O
Madagascar    O
Periwinkle    O
)    O
.    O

The    O
vinca    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
and    O
anthracyclines    O
have    O
been    O
used    O
most    O
commonly    O
in    O
ECD    O
treatment    O
.    O

Vinorelbine    O
is    O
in    O
the    O
vinca    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
family    O
of    O
medications    O
.    O

The    O
Madagascan    O
periwinkle    O
"    O
Catharanthus    O
roseus    O
"    O
L.    O
is    O
the    O
source    O
for    O
a    O
number    O
of    O
important    O
natural    O
products    O
,    O
including    O
catharanthine    B-Alkaloid114712692
and    O
vindoline    O
and    O
the    O
vinca    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
it    O
produces    O
from    O
them    O
:    O
leurosine    O
and    O
the    O
chemotherapy    O
agents    O
vinblastine    O
and    O
vincristine    O
,    O
all    O
of    O
which    O
can    O
be    O
obtained    O
from    O
the    O
plant    O
.    O

The    O
plant    O
is    O
a    O
congeneric    O
of    O
the    O
Madagascar    O
periwinkle    O
(    O
"    O
C.    O
roseus    O
"    O
)    O
,    O
the    O
original    O
main    O
source    O
of    O
vinca    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
,    O
also    O
known    O
as    O
catharanthus    O
alkaloids    O
,    O
which    O
are    O
still    O
in    O
use    O
today    O
as    O
anticancer    O
drugs    O
.    O
"    O

There    O
are    O
also    O
at    O
least    O
86    O
alkaloids    O
whose    O
names    O
contain    O
the    O
root    O
"    O
vin    O
"    O
because    O
they    O
are    O
extracted    O
from    O
"    O
vinca    O
"    O
plants    O
such    O
as    O
"    O
Vinca    O
rosea    O
"    O
(    O
"    O
Catharanthus    O
roseus    O
"    O
)    O
;    O
these    O
are    O
called    O
"vinca"    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
.    O

He    O
was    O
the    O
first    O
to    O
synthesise    O
mescaline    O
and    O
was    O
one    O
of    O
the    O
first    O
to    O
synthesize    O
cuscohygrine    B-Alkaloid114712692
on    O
a    O
small    O
scale    O
with    O
Hans    O
Tuppy    O
.    O

Cuscohygrine    B-Alkaloid114712692

Cymserine    B-Alkaloid114712692
and    O
derivatives    O

Delsoline    B-Alkaloid114712692
is    O
a    O
hypotensive    O
alkaloid    O
isolated    O
from    O
"    O
Aconitum    O
"    O
.    O

"N"-Methylmescaline    B-Alkaloid114712692

Neoxaline    B-Alkaloid114712692
is    O
a    O
bio    O
-    O
active    O
"    O
Aspergillus    O
japonicus    O
"    O
isolate    O
.    O

Convolutindole    B-Alkaloid114712692
A    I-Alkaloid114712692

The    O
findings    O
in    O
some    O
"    O
Ranunculus    O
"    O
species    O
of    O
,    O
for    O
example    O
,    O
Protoanemonin    O
,    O
anemonin    B-Alkaloid114712692
,    O
may    O
justify    O
the    O
uses    O
of    O
these    O
species    O
against    O
fever    O
,    O
rheumatism    O
and    O
rubefacient    O
in    O
Asian    O
traditional    O
medicines    O
.    O

Four    O
quaternary    O
isoquinoline    O
alkaloids    O
,    O
dehydrocorydalmine    O
,    O
jatrorrhizine    B-Alkaloid114712692
,    O
columbamine    O
,    O
and    O
oxyberberine    O
,    O
have    O
been    O
isolated    O
from    O
the    O
whole    O
plant    O
of    O
"    O
Argemone    O
mexicana    O
"    O
.    O

"    O
Latua    O
pubiflora    O
"    O
produces    O
four    O
tropane    B-Alkaloid114712692
alkaloids    O
:    O
scopolamine    O
,    O
hyoscyamine    O
,    O
apoatropine    O
and    O
3α-cinnamoyloxitropane    O
,    O
giving    O
it    O
deliriant    O
properties    O
.    O

The    O
genus    O
is    O
a    O
valuable    O
one    O
,    O
since    O
its    O
species    O
are    O
not    O
only    O
of    O
considerable    O
medicinal    O
value    O
,    O
being    O
rich    O
in    O
tropane    B-Alkaloid114712692
alkaloids    O
,    O
but    O
also    O
of    O
ornamental    O
value    O
,    O
three    O
species    O
having    O
been    O
grown    O
for    O
the    O
purpose    O
,    O
although    O
hitherto    O
infrequently    O
outside    O
botanical    O
gardens    O
.    O

The    O
major    O
contribution    O
of    O
L    O
-    O
ornithine    O
and    O
L    O
-    O
arginine    O
as    O
a    O
precursor    O
to    O
the    O
tropane    B-Alkaloid114712692
ring    O
was    O
confirmed    O
by    O
Edward    O
Leete    O
.    O

Tropane    B-Alkaloid114712692
.    O

(    O
+    O
)    O
-Catechin    O
and    O
(    O
-)-epicatechin    O
are    O
found    O
in    O
the    O
plant    O
as    O
well    O
as    O
the    O
alkaloid    O
rhynchophylline    B-Alkaloid114712692
.    O

This    O
reaction    O
transforms    O
SAM    O
into    O
S    O
-    O
adenosylhomocysteine    O
(    O
SAH    O
)    O
,    O
and    O
gives    O
the    O
intermediate    O
product    O
"N"-methyltryptamine    B-Alkaloid114712692
(    O
NMT    O
)    O
.    O

N-Methyltryptamine    B-Alkaloid114712692
,    O
1.43%    O

"beta"-Ergosine    B-Alkaloid114712692

Many    O
other    O
different    O
structures    O
have    O
been    O
used    O
for    O
their    O
muscle    O
relaxant    O
effect    O
such    O
as    O
alcuronium    B-Alkaloid114712692
(    O
alloferin    O
)    O
,    O
anatruxonium    O
,    O
diadonium    O
,    O
fazadinium    O
(    O
AH8165    O
)    O
and    O
tropeinium    O
.    O

Alcuronium    B-Alkaloid114712692

Perakine    B-Alkaloid114712692
is    O
an    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
isolated    O
from    O
the    O
leaves    O
of    O
"    O
Rauvolfia    O
yunnanensis    O
"    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
5,8,13,13a    O
-    O
tetrahydrocolumbamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
tetrahydropalmatine    B-Alkaloid114712692
.    O

Tetrahydropalmatine    B-Alkaloid114712692

Darnel    O
can    O
be    O
infected    O
by    O
an    O
endophytic    O
fungus    O
of    O
the    O
genus    O
"    O
Neotyphodium    O
"    O
,    O
and    O
the    O
endophyte    O
-    O
produced    O
,    O
insecticidal    O
loline    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
were    O
first    O
isolated    O
from    O
this    O
plant    O
.    O

Conhydrine    B-Alkaloid114712692
is    O
a    O
poisonous    O
alkaloid    O
found    O
in    O
poison    O
hemlock    O
(    O
"    O
Conium    O
maculatum    O
"    O
)    O
in    O
small    O
quantities    O
.    O

To    O
make    O
any    O
of    O
the    O
phenyltropanes    O
requires    O
either    O
a    O
source    O
of    O
cocaine    O
,    O
or    O
extensive    O
and    O
repeated    O
separation    O
of    O
enantiomers    O
due    O
to    O
the    O
lack    O
of    O
enantioselective    O
routes    O
to    O
the    O
essential    O
intermediate    O
methylecgonidine    B-Alkaloid114712692
and    O
the    O
large    O
differences    O
in    O
potency    O
between    O
different    O
structural    O
isomers    O
of    O
the    O
final    O
product    O
.    O

Methylecgonidine    B-Alkaloid114712692
is    O
the    O
direct    O
precursor    O
to    O
this    O
compound    O
.    O

For    O
example    O
,    O
aporphine    B-Alkaloid114712692
alkaloid    O
liriodenine    B-Alkaloid114712692
produced    O
by    O
the    O
tulip    O
tree    O
protects    O
it    O
from    O
parasitic    O
mushrooms    O
.    O

Thebaine    B-Alkaloid114712692
(    O
paramorphine    O
)    O

#    O
Thebaine    B-Alkaloid114712692

The    O
psychoactive    O
compounds    O
found    O
in    O
the    O
opium    O
plant    O
include    O
morphine    O
,    O
codeine    O
,    O
and    O
thebaine    B-Alkaloid114712692
.    O

The    O
major    O
psychoactive    O
opiates    O
are    O
morphine    O
,    O
codeine    O
,    O
and    O
thebaine    B-Alkaloid114712692
.    O

Therefore    O
,    O
most    O
of    O
the    O
opiate    O
-    O
type    O
analgesics    O
in    O
use    O
today    O
are    O
either    O
extracted    O
from    O
"    O
Papaver    O
somniferum    O
"    O
or    O
synthesized    O
from    O
those    O
opiates    O
,    O
especially    O
thebaine    B-Alkaloid114712692
.    O

Synthesis    O
of    O
morphine    O
-    O
like    O
alkaloids    O
in    O
chemistry    O
describes    O
the    O
total    O
synthesis    O
of    O
the    O
natural    O
morphinan    O
class    O
of    O
alkaloids    O
that    O
includes    O
codeine    O
,    O
morphine    O
,    O
oripavine    O
,    O
and    O
thebaine    B-Alkaloid114712692
and    O
the    O
closely    O
related    O
semisynthetic    O
analogs    O
buprenorphine    O
,    O
hydrocodone    O
,    O
isocodeine    O
,    O
naltrexone    O
,    O
naloxone    O
,    O
nalbuphine    O
,    O
and    O
oxycodone    B-Alkaloid114712692
.    O

For    O
example    O
,    O
naloxone    O
,    O
an    O
opioid    O
receptor    O
antagonist    O
,    O
is    O
a    O
derivative    O
of    O
thebaine    B-Alkaloid114712692
that    O
is    O
present    O
in    O
opium    O
.    O

File    O
:    O
Thebaine    O
Thebaine    B-Alkaloid114712692

Thebaine    B-Alkaloid114712692
is    O
used    O
in    O
the    O
synthesis    O
of    O
many    O
painkillers    O
such    O
as    O
oxycodone    B-Alkaloid114712692
.    O

Ergocornine    B-Alkaloid114712692

Another    O
route    O
is    O
the    O
partial    O
reduction    O
of    O
myosmine    B-Alkaloid114712692
,    O
which    O
can    O
be    O
accomplished    O
by    O
standard    O
catalytic    O
hydrogenation    O
conditions    O
using    O
palladium    O
as    O
a    O
catalyst    O
.    O
or    O
with    O
sodium    O
borohydride    O

Noroliveroline    B-Alkaloid114712692
is    O
an    O
anticholinergic    O
alkaloid    O
.    O

Rivastigmine    B-Alkaloid114712692

Five    O
medications    O
are    O
currently    O
used    O
to    O
treat    O
the    O
cognitive    O
problems    O
of    O
AD    O
:    O
four    O
are    O
acetylcholinesterase    O
inhibitors    O
(    O
tacrine    O
,    O
rivastigmine    B-Alkaloid114712692
,    O
galantamine    B-Alkaloid114712692
and    O
donepezil    O
)    O
and    O
the    O
other    O
(    O
memantine    O
)    O
is    O
an    O
NMDA    O
receptor    O
antagonist    O
.    O

Exelon    B-Alkaloid114712692
-    O
A    O
cholinesterase    O
inhibitor    O
,    O
a    O
type    O
of    O
medicine    O
prescribed    O
for    O
people    O
in    O
the    O
early    O
or    O
middle    O
stages    O
of    O
Alzheimer    O
's    O
disease    O
.    O

PRIMUS    O
has    O
been    O
used    O
to    O
assess    O
the    O
efficacy    O
of    O
fingolimod    O
and    O
rivastigmine    B-Alkaloid114712692
.    O

7-Hydroxymitragynine    B-Alkaloid114712692

Mitragynine    B-Alkaloid114712692
pseudoindoxyl    I-Alkaloid114712692
is    O
a    O
rearrangement    O
product    O
of    O
7-hydroxymitragynine    B-Alkaloid114712692
.    O

Further    O
research    O
was    O
published    O
in    O
1960    O
,    O
when    O
Don    O
Thomes    O
MacDougall    O
reported    O
that    O
the    O
seeds    O
of    O
"    O
Ipomoea    O
tricolor    O
"    O
were    O
used    O
as    O
sacraments    O
by    O
certain    O
Zapotecs    O
,    O
sometimes    O
in    O
conjunction    O
with    O
the    O
seeds    O
of    O
"    O
Rivea    O
corymbosa    O
"    O
,    O
another    O
species    O
which    O
has    O
a    O
similar    O
chemical    O
composition    O
,    O
with    O
lysergol    B-Alkaloid114712692
instead    O
of    O
ergometrine    B-Alkaloid114712692
.    O

It    O
decomposes    O
to    O
haematopodin    B-Alkaloid114712692
under    O
the    O
influence    O
of    O
air    O
and    O
light    O
.    O

Vineridine    B-Alkaloid114712692
(    O
vineridin    O
)    O
is    O
a    O
vinca    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
.    O

When    O
patients    O
are    O
resistant    O
to    O
atropine    O
,    O
the    O
patients    O
can    O
be    O
treated    O
with    O
low    O
doses    O
of    O
anisodamine    B-Alkaloid114712692
,    O
a    O
cholinergic    O
and    O
alpha-1    O
adrenergic    O
antagonist    O
,    O
to    O
achieve    O
a    O
shorter    O
recovery    O
time    O
.    O

Setoclavine    B-Alkaloid114712692
is    O
an    O
ergot    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
.    O

Evoxine    B-Alkaloid114712692

Methylliberine    B-Alkaloid114712692
is    O
an    O
isolate    O
of    O
coffee    O
beans    O
,    O
tea    O
,    O
cola    O
nuts    O
,    O
guarana    O
,    O
cocoa    O
,    O
and    O
yerba    O
mate    O
.    O

Cinchonidine    B-Alkaloid114712692
,    O
one    O
of    O
the    O
cinchona    O
alkaloids    O
.    O

Mesembranol    B-Alkaloid114712692

N-methylephedrine    B-Alkaloid114712692
and    O
N    O
-    O
methylpseudoephedrine    O

"N"-Methylphenethylamine    B-Alkaloid114712692
(    O
endogenous    O
amphetamine    O
isomer    O
)    O

"    O
S.    O
berlandieri    O
"    O
contains    O
a    O
number    O
of    O
diverse    O
alkaloids    O
,    O
the    O
most    O
plentiful    O
of    O
which    O
are    O
"N"-methylphenethylamine    B-Alkaloid114712692
,    O
tyramine    O
,    O
and    O
phenethylamine    O
.    O

File    O
:    O
Dauricine    B-Alkaloid114712692

Lurtotecan    O
is    O
a    O
semi    O
-    O
synthetic    O
analog    O
of    O
camptothecin    B-Alkaloid114712692
with    O
antineoplastic    O
activity    O
.    O

Exatecan    O
is    O
a    O
drug    O
which    O
is    O
an    O
analogue    O
of    O
camptothecin    B-Alkaloid114712692
with    O
antineoplastic    O
activity    O
.    O

Many    O
indole    O
alkaloids    O
formed    O
from    O
strictosidine    O
synthase    O
-    O
catalyzed    O
condensation    O
are    O
important    O
precursors    O
to    O
medicinally    O
important    O
compounds    O
such    O
as    O
quinine    O
,    O
the    O
antineoplastic    O
drug    O
camptothecin    B-Alkaloid114712692
,    O
and    O
anticancer    O
drugs    O
vincristine    O
and    O
vinblastine    O
.    O
Because    O
of    O
this    O
,    O
strictosidine    O
synthase    O
is    O
widely    O
known    O
as    O
the    O
enzyme    O
of    O
choice    O
for    O
investigations    O
towards    O
chemoenzymatic    O
alkaloid    O
synthesis    O
.    O

He    O
is    O
co    O
-    O
discoverer    O
of    O
Taxol    B-Alkaloid114712692
and    O
camptothecin    B-Alkaloid114712692
,    O
two    O
anti    O
-    O
cancer    O
drugs    O
considered    O
standard    O
in    O
the    O
treatment    O
to    O
fight    O
ovarian    O
,    O
breast    O
,    O
lung    O
and    O
colon    O
cancers    O
.    O

One    O
study    O
which    O
did    O
address    O
this    O
topic    O
used    O
flow    O
cytometry    O
or    O
elutriation    O
of    O
synchronized    O
cells    O
treated    O
with    O
actinomycin    O
D1    O
,    O
camptothecin    B-Alkaloid114712692
,    O
or    O
aphidicolin    O
,    O
each    O
of    O
which    O
had    O
been    O
documented    O
to    O
exert    O
its    O
effects    O
in    O
a    O
particular    O
phase    O
of    O
the    O
cell    O
cycle    O
.    O

Hasubanonine    B-Alkaloid114712692

Vasicinone    O
has    O
also    O
been    O
studied    O
in    O
combination    O
with    O
the    O
related    O
alkaloid    O
vasicine    B-Alkaloid114712692
.    O

Matrine    B-Alkaloid114712692
and    O
matrine    B-Alkaloid114712692
oxide    I-Alkaloid114712692
,    O
quinolizidine    O
alkaloids    O
found    O
in    O
the    O
roots    O

The    O
putative    O
anti    O
-    O
inflammatory    O
properties    O
of    O
iporuru    O
are    O
attributed    O
to    O
a    O
group    O
of    O
alkaloids    O
,    O
including    O
one    O
called    O
alchorneine    B-Alkaloid114712692
,    O
which    O
are    O
found    O
in    O
the    O
bark    O
of    O
iporuru    O
as    O
well    O
as    O
several    O
other    O
species    O
of    O
"    O
Alchornea    O
"    O
.    O

Brevianamides    B-Alkaloid114712692
are    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
that    O
belong    O
to    O
a    O
class    O
of    O
naturally    O
occurring    O
2,5-diketopiperazines    O
produced    O
as    O
secondary    O
metabolites    O
of    O
fungi    O
in    O
the    O
genus    O
"    O
Penicillium    O
"    O
and    O
"    O
Aspergillus    O
"    O
.    O

The    O
San    O
Pedro    O
cactus    O
contains    O
a    O
number    O
of    O
alkaloids    O
,    O
including    O
the    O
well    O
-    O
studied    O
chemical    O
mescaline    O
(    O
0.21–1.8%    O
)    O
,    O
and    O
also    O
3,4-dimethoxyphenethylamine    B-Alkaloid114712692
,    O
3-Methoxytyramine    O
,    O
4-hydroxy-3-methoxyphenethylamine    O
,    O
4-hydroxy-3,5-dimethoxyphenethylamine    O
,    O
anhalonidine    B-Alkaloid114712692
,    O
anhalinine    O
,    O
hordenine    B-Alkaloid114712692
,    O
tyramine    O
,    O
and    O
3-methoxytyramine    O
.    O

Littorine    B-Alkaloid114712692
is    O
a    O
tropane    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
found    O
in    O
a    O
variety    O
of    O
plants    O
including    O
"    O
Datura    O
"    O
and    O
"    O
Atropa    O
belladonna    O
"    O
.    O

Tetrahydroharmine    O
(    O
THH    O
)    O
is    O
a    O
fluorescent    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
that    O
occurs    O
in    O
the    O
tropical    O
liana    O
species    O
"    O
Banisteriopsis    O
caapi    O
"    O
.    O

Brevianamides    B-Alkaloid114712692
are    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
that    O
belong    O
to    O
a    O
class    O
of    O
naturally    O
occurring    O
2,5-diketopiperazines    O
produced    O
as    O
secondary    O
metabolites    O
of    O
fungi    O
in    O
the    O
genus    O
"    O
Penicillium    O
"    O
and    O
"    O
Aspergillus    O
"    O
.    O

Eburnamine    B-Alkaloid114712692
is    O
an    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
in    O
the    O
aspidosperma    O
group    O
.    O

This    O
enzyme    O
is    O
a    O
part    O
of    O
the    O
pathway    O
of    O
indole    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
biosynthesis    O
.    O

The    O
plant    O
has    O
been    O
reported    O
to    O
contain    O
a    O
variety    O
of    O
alkaloids    O
,    O
including    O
,    O
in    O
the    O
bark    O
of    O
the    O
stem    O
and    O
root    O
including    O
tabernaemontanine    O
,    O
coronarine    O
,    O
coronaridine    B-Alkaloid114712692
,    O
and    O
dregamine    O
.    O

Coronaridine    B-Alkaloid114712692

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
1-O    O
-    O
sinapoyl    O
-    O
beta    O
-    O
D    O
-    O
glucose    O
and    O
choline    O
,    O
whereas    O
its    O
two    O
products    O
are    O
D    O
-    O
glucose    O
and    O
sinapoylcholine    B-Alkaloid114712692
(    O
sinapine    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
sinapoylcholine    B-Alkaloid114712692
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
sinapate    O
and    O
choline    O
.    O

Ajmalicine    O
is    O
structurally    O
related    O
to    O
yohimbine    O
,    O
rauwolscine    O
,    O
and    O
other    O
yohimban    B-Alkaloid114712692
derivatives    O
.    O

TAN-1057    B-Alkaloid114712692
C    I-Alkaloid114712692
and    O
TAN-1057    B-Alkaloid114712692
D    I-Alkaloid114712692
are    O
organic    O
compounds    O
found    O
in    O
the    O
"    O
Flexibacter    O
sp    O
.    O

The    O
San    O
Pedro    O
cactus    O
contains    O
a    O
number    O
of    O
alkaloids    O
,    O
including    O
the    O
well    O
-    O
studied    O
chemical    O
mescaline    O
(    O
0.21–1.8%    O
)    O
,    O
and    O
also    O
3,4-dimethoxyphenethylamine    B-Alkaloid114712692
,    O
3-Methoxytyramine    O
,    O
4-hydroxy-3-methoxyphenethylamine    O
,    O
4-hydroxy-3,5-dimethoxyphenethylamine    O
,    O
anhalonidine    B-Alkaloid114712692
,    O
anhalinine    O
,    O
hordenine    B-Alkaloid114712692
,    O
tyramine    O
,    O
and    O
3-methoxytyramine    O
.    O

Solauricine    B-Alkaloid114712692
,    O
solauricidine    B-Alkaloid114712692
,    O
and    O
solasodamine    B-Alkaloid114712692
have    O
also    O
been    O
found    O
in    O
"    O
Solanum    O
mauritianum    O
"    O
.    O

Vomilenine    B-Alkaloid114712692
is    O
an    O
intermediate    O
chemical    O
in    O
the    O
biosynthesis    O
of    O
ajmaline    B-Alkaloid114712692
.    O

#    O
4-Hydroxyamfetamine    B-Alkaloid114712692

Norpholedrine    B-Alkaloid114712692

In    O
a    O
recent    O
study    O
,    O
researchers    O
identified    O
thirty    O
-    O
one    O
alkaloids    O
in    O
samples    O
of    O
plant    O
foliage    O
,    O
including    O
trace    O
amounts    O
of    O
four    O
amphetamines    O
previously    O
known    O
only    O
from    O
laboratory    O
synthesis    O
:    O
amphetamine    O
,    O
methamphetamine    O
,    O
"para"-hydroxyamphetamine    B-Alkaloid114712692
and    O
"    O
para    O
"-    O
methoxyamphetamine    O
.    O

N-Acetylserotonin    B-Alkaloid114712692

Harmaline    O
forces    O
the    O
anabolic    O
metabolism    O
of    O
serotonin    O
into    O
normelatonin    B-Alkaloid114712692
or    O
n-acetylserotonin    B-Alkaloid114712692
,    O
and    O
then    O
to    O
melatonin    O
,    O
the    O
body    O
's    O
principle    O
sleep    O
-    O
regulating    O
hormone    O
and    O
a    O
powerful    O
antioxidant    O
.    O

SNAT    O
catalyzes    O
the    O
anabolic    O
metabolism    O
of    O
serotonin    O
into    O
"N"-acetylserotonin    B-Alkaloid114712692
,    O
another    O
neuromodulator    O
(    O
specifically    O
a    O
neurotrophic    O
factor    O
via    O
TrkB    O
agonism    O
)    O
and    O
the    O
immediate    O
precursor    O
for    O
melatonin    O
.    O

Lobivine    B-Alkaloid114712692
is    O
a    O
phenethylamine    O
alkaloid    O
found    O
in    O
"    O
Lophophora    O
williamsii    O
"    O
.    O

Lennoxamine    B-Alkaloid114712692
is    O
an    O
isoindolobenzazepine    O
alkaloid    O
,    O
originally    O
isolated    O
from    O
the    O
Chilean    O
barberry    O
,    O
"    O
Berberis    O
darwinii    O
"    O
.    O

Glaucine    B-Alkaloid114712692
is    O
the    O
main    O
alkaloid    O
component    O
in    O
"    O
Glaucium    O
flavum    O
"    O
.    O

Glaucine    B-Alkaloid114712692
has    O
bronchodilator    O
and    O
antiinflammatory    O
effects    O
,    O
acting    O
as    O
a    O
PDE4    O
inhibitor    O
and    O
calcium    O
channel    O
blocker    O
,    O
and    O
is    O
used    O
medically    O
as    O
an    O
antitussive    O
in    O
some    O
countries    O
.    O

The    O
plant    O
is    O
deer    O
-    O
resistant    O
due    O
to    O
the    O
presence    O
of    O
the    O
bitter    O
-    O
tasting    O
alkaloid    O
toxins    O
anagyrine    O
and    O
lupinine    B-Alkaloid114712692
.    O

Berberine    B-Alkaloid114712692
is    O
a    O
quaternary    O
ammonium    O
salt    O
from    O
the    O
protoberberine    O
group    O
of    O
benzylisoquinoline    B-Alkaloid114712692
alkaloids    O
.    O

Benzylisoquinoline    B-Alkaloid114712692

Scoulerine    B-Alkaloid114712692
,    O
also    O
known    O
as    O
discretamine    B-Alkaloid114712692
and    O
aequaline    B-Alkaloid114712692
,    O
is    O
a    O
benzylisoquinoline    B-Alkaloid114712692
alkaloid    O
that    O
derives    O
from    O
reticuline    B-Alkaloid114712692
and    O
is    O
a    O
precursor    O
of    O
berberine    B-Alkaloid114712692
.    O

Leonurine    B-Alkaloid114712692
,    O
a    O
psychoactive    O
alkaloid    O
found    O
in    O
"    O
L.    O
artemisia    O
"    O
.    O

#    O
Leonuramine    O
and    O
Leonurine    B-Alkaloid114712692
.    O

This    O
method    O
has    O
been    O
used    O
in    O
natural    O
product    O
synthesis    O
of    O
Taxol    B-Alkaloid114712692
by    O
Danishefsky    O
and    O
Cortistatin    B-Alkaloid114712692
A    I-Alkaloid114712692
by    O
Shair    O
.    O

Ergonovine    B-Alkaloid114712692
(    O
ergometrine    O
)    O
.    O

Further    O
research    O
was    O
published    O
in    O
1960    O
,    O
when    O
Don    O
Thomes    O
MacDougall    O
reported    O
that    O
the    O
seeds    O
of    O
"    O
Ipomoea    O
tricolor    O
"    O
were    O
used    O
as    O
sacraments    O
by    O
certain    O
Zapotecs    O
,    O
sometimes    O
in    O
conjunction    O
with    O
the    O
seeds    O
of    O
"    O
Rivea    O
corymbosa    O
"    O
,    O
another    O
species    O
which    O
has    O
a    O
similar    O
chemical    O
composition    O
,    O
with    O
lysergol    B-Alkaloid114712692
instead    O
of    O
ergometrine    B-Alkaloid114712692
.    O

Lysergic    B-Alkaloid114712692
acid    I-Alkaloid114712692
hydroxyethylamide    I-Alkaloid114712692
and    O
ergonovine    B-Alkaloid114712692
are    O
also    O
considered    O
to    O
be    O
contributing    O
psychedelic    O
alkaloids    O
in    O
the    O
plant    O
.    O

ergometrine    B-Alkaloid114712692

ergocristine    B-Alkaloid114712692
,    O
ergonovine    B-Alkaloid114712692
and    O
ergotamine    O

Penniclavine    B-Alkaloid114712692

"    O
Psilocybe    O
pelliculosa    O
"    O
contains    O
the    O
psychoactive    O
compounds    O
psilocybin    O
and    O
baeocystin    B-Alkaloid114712692
,    O
and    O
is    O
used    O
as    O
a    O
recreational    O
drug    O
.    O

Mildly    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
and    O
baeocystin    B-Alkaloid114712692
.    O

"    O
Pholiotina    O
cyanopus    O
"    O
is    O
hallucinogenic    O
,    O
containing    O
psilocin    O
,    O
psilocybin    O
,    O
baeocystin    B-Alkaloid114712692
,    O
norbaeocystin    B-Alkaloid114712692
and    O
aeruginascin    B-Alkaloid114712692
.    O

A    O
variety    O
of    O
modifications    O
to    O
the    O
basic    O
ergoline    O
are    O
seen    O
in    O
nature    O
,    O
for    O
example    O
agroclavine    B-Alkaloid114712692
,    O
elymoclavine    B-Alkaloid114712692
,    O
lysergol    B-Alkaloid114712692
.    O

BZP    O
is    O
a    O
piperazine    O
derivative    O
which    O
comes    O
as    O
either    O
the    O
hydrochloride    O
salt    O
or    O
a    O
free    B-Alkaloid114712692
base    I-Alkaloid114712692
.    O

Black    O
cocaine    O
,    O
also    O
known    O
as    O
Coca    O
Negra    O
,    O
is    O
a    O
mixture    O
of    O
regular    O
cocaine    O
base    B-Alkaloid114712692
or    O
cocaine    O
hydrochloride    O
with    O
various    O
other    O
substances    O
.    O

The    O
chemical    O
name    O
of    O
butriptyline    O
is    O
3-(10,11-dihydro-5"H    O
"-    O
dibenzo["a","d"]cycloheptene-5-yl)-"N","N",2-trimethylpropan-1-amine    O
and    O
its    O
free    B-Alkaloid114712692
base    I-Alkaloid114712692
form    O
has    O
a    O
chemical    O
formula    O
of    O
C21H27N    O
with    O
a    O
molecular    O
weight    O
of    O
293.446    O
g    O
/    O
mol    O
.    O

The    O
chemical    O
name    O
of    O
lofepramine    O
is    O
"    O
N"-(4-chlorobenzoylmethyl)-3-(10,11-dihydro-5"H    O
"-    O
dibenzo["b","f"]azepin-5-yl)-N    O
-    O
methylpropan-1-amine    O
and    O
its    O
free    B-Alkaloid114712692
base    I-Alkaloid114712692
form    O
has    O
a    O
chemical    O
formula    O
of    O
C26H27ClN2O    O
with    O
a    O
molecular    O
weight    O
of    O
418.958    O
g    O
/    O
mol    O
.    O

The    O
chemical    O
name    O
of    O
protriptyline    O
is    O
3-(5"H    O
"-    O
dibenzo["a","d"][7]annulen-5-yl)-"N    O
"-    O
methylpropan-1-amine    O
and    O
its    O
free    B-Alkaloid114712692
base    I-Alkaloid114712692
form    O
has    O
a    O
chemical    O
formula    O
of    O
C19H21N1    O
with    O
a    O
molecular    O
weight    O
of    O
263.377    O
g    O
/    O
mol    O
.    O

The    O
chemical    O
name    O
of    O
iprindole    O
is    O
3-(6,7,8,9,10,11-hexahydro-5"H    O
"-    O
cycloocta["b"]indol-5-yl)-"N","N    O
"-    O
dimethylpropan-1-amine    O
and    O
its    O
free    B-Alkaloid114712692
base    I-Alkaloid114712692
form    O
has    O
a    O
chemical    O
formula    O
of    O
C19H28N2    O
with    O
a    O
molecular    O
weight    O
of    O
284.439    O
g    O
/    O
mol    O
.    O

Steinberg    O
departed    O
and    O
returned    O
several    O
times    O
,    O
sometimes    O
freebasing    B-Alkaloid114712692
cocaine    O
.    O

Free    B-Alkaloid114712692
base    I-Alkaloid114712692
or    O
freebase    O
,    O
the    O
pure    O
basic    O
form    O
of    O
an    O
amine    O
,    O
as    O
opposed    O
to    O
its    O
salt    O
form    O

User    O
-    O
specific    O
products    O
include    O
glass    O
hashish    O
pipes    O
,    O
crack    O
cocaine    O
pipes    O
,    O
smoking    O
masks    O
,    O
hashish    O
bongs    O
,    O
cocaine    B-Alkaloid114712692
freebase    I-Alkaloid114712692
kits    O
,    O
syringes    O
,    O
roach    O
clips    O
for    O
holding    O
the    O
burning    O
end    O
of    O
a    O
marijuana    O
joint    O
.    O

Vincoline    B-Alkaloid114712692
is    O
an    O
alkaloid    O
isolated    O
from    O
"    O
Catharanthus    O
roseus    O
"    O
.    O

Also    O
present    O
are    O
:    O
dimethyltetradine    O
iodide    O
,    O
cyclanoline    O
,    O
menisine    O
,    O
menisidine    O
,    O
oxofangchirine    O
,    O
stephenanthrine    O
,    O
stepholidine    B-Alkaloid114712692
and    O
bisbenzylisoquinoline    O
.    O

Stepholidine    B-Alkaloid114712692

In    O
formation    O
of    O
tropinone    B-Alkaloid114712692
from    O
racemic    O
ethyl    O
[    O
2,3    O
-    O
13C2]4(Nmethyl-    O

It    O
is    O
a    O
homolog    O
of    O
tropinone    B-Alkaloid114712692
,    O
and    O
can    O
be    O
synthesized    O
in    O
a    O
manner    O
analogous    O
to    O
the    O
classical    O
Robinson    O
tropinone    O
synthesis    O
,    O
using    O
glutaraldehyde    O
(    O
rather    O
than    O
succinaldehyde    O
)    O
,    O
acetonedicarboxylic    O
acid    O
,    O
and    O
methylammonium    O
chloride    O
.    O

Two    O
selected    O
methods    O
for    O
the    O
synthesis    O
of    O
tropone    O
are    O
by    O
selenium    O
dioxide    O
oxidation    O
of    O
cycloheptatriene    O
and    O
indirectly    O
from    O
tropinone    B-Alkaloid114712692
by    O
a    O
Hofmann    O
elimination    O
and    O
a    O
bromination    O
.    O

The    O
earliest    O
generally    O
cited    O
example    O
of    O
a    O
biomimetic    O
synthesis    O
is    O
Robinson    O
's    O
organic    O
synthesis    O
of    O
the    O
alkaloid    O
tropinone    B-Alkaloid114712692
.    O

Agonists    O
/    O
positive    O
allosteric    O
modulators    O
:    O
alcohol    O
(    O
ethanol    O
)    O
,    O
barbiturates    O
,    O
benzodiazepines    O
,    O
carisoprodol    O
,    O
chloral    O
hydrate    O
,    O
etaqualone    O
,    O
etomidate    O
,    O
glutethimide    O
,    O
kava    O
,    O
methaqualone    O
,    O
muscimol    B-Alkaloid114712692
,    O
neuroactive    O
steroids    O
,    O
z    O
-    O
drugs    O
,    O
propofol    O
,    O
skullcap    O
,    O
valerian    O
,    O
theanine    O
,    O
volatile    O
/    O
inhaled    O
anaesthetics    O
.    O

Toxicity    O
is    O
suspected    O
to    O
be    O
due    O
to    O
the    O
presence    O
of    O
muscimol    B-Alkaloid114712692
and    O
ibonetic    B-Alkaloid114712692
acid    I-Alkaloid114712692
.    O

"    O
Amanita    O
muscaria    O
"    O
var    O
.    O
"    O
guessowii    O
"    O
contains    O
ibotenic    O
acid    O
and    O
muscimol    B-Alkaloid114712692
.    O

This    O
species    O
contains    O
variable    O
amounts    O
of    O
the    O
neuroactive    O
compounds    O
ibotenic    O
acid    O
and    O
muscimol    B-Alkaloid114712692
.    O

Fos    O
-    O
labeled    O
cell    O
analysis    O
showed    O
that    O
the    O
PMDvl    O
is    O
the    O
most    O
activated    O
structure    O
in    O
the    O
hypothalamus    O
,    O
and    O
inactivation    O
with    O
muscimol    B-Alkaloid114712692
prior    O
to    O
exposure    O
to    O
the    O
context    O
abolishes    O
the    O
defensive    O
behavior    O
.    O

In    O
addition    O
,    O
on    O
the    O
basis    O
of    O
these    O
findings    O
,    O
the    O
drug    O
has    O
been    O
characterized    O
as    O
a    O
hallucinogen    O
similarly    O
to    O
the    O
potent    O
GABAA    O
receptor    O
full    O
agonist    O
muscimol    B-Alkaloid114712692
(    O
a    O
constituent    O
of    O
the    O
hallucinogenic    O
"    O
Amanita    O
muscaria    O
"    O
(    O
fly    O
agaric    O
)    O
mushrooms    O
)    O
.    O

Substances    O
with    O
dissociative    O
properties    O
include    O
ketamine    O
,    O
nitrous    O
oxide    O
,    O
alcohol    O
,    O
tiletamine    O
,    O
amphetamine    O
,    O
dextromethorphan    O
,    O
MK-801    O
,    O
PCP    O
,    O
methoxetamine    O
,    O
salvia    O
,    O
muscimol    B-Alkaloid114712692
,    O
atropine    O
,    O
and    O
ibogaine    B-Alkaloid114712692
.    O

Muscimol    B-Alkaloid114712692

Xylopine    B-Alkaloid114712692

Two    O
other    O
harmala    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
in    O
"    O
B.    O
caapi    O
"    O
,    O
harmaline    B-Alkaloid114712692
and    O
harmine    B-Alkaloid114712692
,    O
are    O
reversible    O
inhibitors    O
of    O
monoamine    O
oxidase    O
A.    O
Tetrahydroharmine    O
,    O
however    O
,    O
does    O
not    O
inhibit    O
monoamine    O
oxidase    O
B.    O

In    O
the    O
20th    O
century    O
,    O
the    O
active    O
chemical    O
constituent    O
of    O
"    O
B.    O
caapi    O
"    O
was    O
named    O
"    O
telepathine    B-Alkaloid114712692
"    O
,    O
but    O
it    O
was    O
found    O
to    O
be    O
identical    O
to    O
a    O
chemical    O
already    O
isolated    O
from    O
"    O
Peganum    O
harmala    O
"    O
and    O
was    O
given    O
the    O
name    O
harmaline    B-Alkaloid114712692
.    O

The    O
three    O
most    O
studied    O
harmala    O
alkaloids    O
in    O
the    O
"    O
B.    O
caapi    O
"    O
vine    O
are    O
harmine    B-Alkaloid114712692
,    O
harmaline    B-Alkaloid114712692
and    O
tetrahydroharmine    O
.    O

Molecular    O
structure    O
of    O
harmine    B-Alkaloid114712692
.    O

Thesinine    B-Alkaloid114712692
is    O
a    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
first    O
isolated    O
from    O
"    O
Thesium    O
minkwitzianum    O
"    O
from    O
which    O
it    O
derives    O
its    O
name    O
.    O

Overman    O
has    O
also    O
worked    O
extensively    O
on    O
the    O
aza    O
-    O
Cope    O
-    O
Mannich    O
reaction    O
,    O
originally    O
designed    O
to    O
solve    O
a    O
stereoelectronic    O
problem    O
in    O
the    O
total    O
synthesis    O
of    O
gephyrotoxin    B-Alkaloid114712692
.    O

cocaine    O
(    O
methyl    O
ester    O
of    O
benzoylecgonine    B-Alkaloid114712692
)    O
—    O
an    O
alkaloid    O
found    O
in    O
coca    O
leaves    O
or    O
prepared    O
by    O
synthesis    O
from    O
ecgonine    O

In    O
November    O
2007    O
,    O
Hingis    O
called    O
a    O
press    O
conference    O
to    O
announce    O
that    O
she    O
was    O
under    O
investigation    O
for    O
testing    O
positive    O
for    O
benzoylecgonine    B-Alkaloid114712692
,    O
a    O
metabolite    O
of    O
cocaine    O
,    O
during    O
a    O
urine    O
test    O
taken    O
by    O
players    O
at    O
Wimbledon    O
.    O

The    O
official    O
autopsy    O
report    O
lists    O
also    O
a    O
second    O
cause    O
of    O
death    O
as    O
“    O
acute    O
mixed    O
drug    O
ingestion    O
”    O
,    O
listing    O
alprazolam    O
,    O
methadone    O
,    O
benzoylecgonine    B-Alkaloid114712692
(    O
a    O
metabolite    O
of    O
cocaine    O
)    O
and    O
traces    O
of    O
methamphetamine    O
as    O
the    O
drugs    O
found    O
in    O
Andy    O
's    O
body    O
at    O
the    O
time    O
of    O
his    O
death    O
.    O

While    O
playing    O
for    O
Volta    O
Redonda    O
in    O
the    O
Campeonato    O
Carioca    O
in    O
2010    O
,    O
Paulinho    O
tested    O
positive    O
for    O
Benzoylecgonine    B-Alkaloid114712692
,    O
a    O
metabolised    O
version    O
of    O
cocaine    O
.    O

It    O
contains    O
large    O
quantities    O
of    O
the    O
extremely    O
toxic    O
alkaloid    O
pseudaconitine    B-Alkaloid114712692
(    O
also    O
known    O
as    O
nepaline    O
,    O
after    O
Nepal    O
)    O
and    O
is    O
considered    O
to    O
be    O
the    O
most    O
poisonous    O
plant    O
found    O
in    O
the    O
Himalaya    O
and    O
one    O
of    O
the    O
most    O
poisonous    O
in    O
the    O
world    O
.    O

Aspergillus    O
brevipes    O
"    O
produces    O
roquefortine    O
C    O
,    O
meleagrin    B-Alkaloid114712692
and    O
viriditoxin    O
.    O

In    O
the    O
next    O
step    O
,    O
the    O
pyrrolium    O
cation    O
condenses    O
with    O
acetoacetic    O
acid    O
yielding    O
hygrine    B-Alkaloid114712692
.    O

Senecionine    B-Alkaloid114712692
,    O
a    O
closely    O
related    O
pyrrolizidine    B-Alkaloid114712692
alkaloid    O

Akuammicine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
found    O
in    O
"    O
Vinca    O
minor    O
"    O
and    O
"    O
Aspidosperma    O
"    O
.    O

Including    O
;    O
catuabine    B-Alkaloid114712692
,    O
convolamine    O
of    O
the    O
"    O
convolvulaceae    O
"    O
&    O
phyllalbine    O
of    O
"    O
euphorbiaceae    O
"    O
(    O
"    O
Phyllanthus    O
discoïdes    O
"    O
)    O
families    O
.    O

Penicillium    O
commune    O
"    O
produces    O
the    O
mycotoxins    O
cyclopiazonic    O
acid    O
,    O
rugulovasine    B-Alkaloid114712692
,    O
viridicatin    O
,    O
penitrem    O
A    O
,    O
roquefortine    O
comazaphilone    O
A    O
,    O
comazaphilone    O
B    O
,    O
comazaphilone    O
C    O
,    O
comazaphilone    O
D    O
,    O
comazaphilone    O
E    O
and    O
comazaphilone    O
F    O

In    O
addition    O
,    O
the    O
nootropic    O
agent    O
vincamine    B-Alkaloid114712692
is    O
derived    O
from    O
"    O
Vinca    O
minor    O
"    O
.    O

Alkaloids    O
have    O
a    O
wide    O
range    O
of    O
pharmacological    O
activities    O
including    O
antimalarial    O
(    O
"    O
e.g.    O
"    O
quinine    O
)    O
,    O
antiasthma    O
(    O
"    O
e.g.    O
"    O
ephedrine    O
)    O
,    O
anticancer    O
(    O
"    O
e.g.    O
"    O
homoharringtonine    B-Alkaloid114712692
)    O
,    O
cholinomimetic    O
(    O
"    O
e.g.    O
"    O
galantamine    B-Alkaloid114712692
)    O
,    O
vasodilatory    O
(    O
"    O
e.g.    O
"    O
vincamine    B-Alkaloid114712692
)    O
,    O
antiarrhythmic    O
(    O
"    O
e.g.    O
"    O
quinidine    O
)    O
,    O
analgesic    O
(    O
"    O
e.g.    O
"    O
morphine    O
)    O
,    O
antibacterial    O
(    O
"    O
e.g.    O
"    O
chelerythrine    B-Alkaloid114712692
)    O
,    O
and    O
antihyperglycemic    O
activities    O
(    O
"    O
e.g.    O
"    O
piperine    O
)    O
.    O

Lobelanine    B-Alkaloid114712692

Hamayne    B-Alkaloid114712692
,    O
an    O
alkaloid    O

Omacetaxine    B-Alkaloid114712692
,    O
a    O
substance    O
derived    O
from    O
the    O
leaves    O
of    O
this    O
plant    O
,    O
is    O
a    O
novel    O
(    O
as    O
of    O
2008    O
)    O
anti    O
-    O
leukemia    O
drug    O
.    O

Alkaloids    O
have    O
a    O
wide    O
range    O
of    O
pharmacological    O
activities    O
including    O
antimalarial    O
(    O
"    O
e.g.    O
"    O
quinine    O
)    O
,    O
antiasthma    O
(    O
"    O
e.g.    O
"    O
ephedrine    O
)    O
,    O
anticancer    O
(    O
"    O
e.g.    O
"    O
homoharringtonine    B-Alkaloid114712692
)    O
,    O
cholinomimetic    O
(    O
"    O
e.g.    O
"    O
galantamine    B-Alkaloid114712692
)    O
,    O
vasodilatory    O
(    O
"    O
e.g.    O
"    O
vincamine    B-Alkaloid114712692
)    O
,    O
antiarrhythmic    O
(    O
"    O
e.g.    O
"    O
quinidine    O
)    O
,    O
analgesic    O
(    O
"    O
e.g.    O
"    O
morphine    O
)    O
,    O
antibacterial    O
(    O
"    O
e.g.    O
"    O
chelerythrine    B-Alkaloid114712692
)    O
,    O
and    O
antihyperglycemic    O
activities    O
(    O
"    O
e.g.    O
"    O
piperine    O
)    O
.    O

Toxic    O
metabolite    O
called    O
laudanosine    B-Alkaloid114712692
,    O
greater    O
accumulation    O
in    O
individuals    O
with    O
renal    O
failure    O

There    O
are    O
other    O
recent    O
examples    O
of    O
the    O
use    O
of    O
aryl    O
iodides    O
for    O
the    O
preparation    O
of    O
intermediates    O
under    O
typical    O
Sonogashira    O
conditions    O
,    O
which    O
,    O
after    O
cyclization    O
,    O
yield    O
natural    O
products    O
such    O
as    O
benzylisoquinoline    O
or    O
indole    O
alkaloids    O
An    O
example    O
is    O
the    O
synthesis    O
of    O
the    O
benzylisoquinoline    B-Alkaloid114712692
alkaloids    O
(    O
+    O
)    O
laudanosine    B-Alkaloid114712692
and    O
(    O
–)-(S)-xylopinine    O
.    O

Heyneanine    B-Alkaloid114712692

Norzoanthamine    B-Alkaloid114712692

The    O
novel    O
alkaloid    O
yuehchukene    B-Alkaloid114712692
was    O
found    O
in    O
"    O
M.    O
paniculata    O
"    O
,    O
and    O
it    O
has    O
since    O
been    O
isolated    O
from    O
other    O
"    O
Murraya    O
"    O
.    O

Vincaminol    B-Alkaloid114712692

Pumiliotoxin    B-Alkaloid114712692

Kibayashi    O
and    O
coworkers    O
utilized    O
the    O
Negishi    O
coupling    O
in    O
the    O
total    O
synthesis    O
of    O
Pumiliotoxin    B-Alkaloid114712692
B.    O
Pumiliotoxin    O
B    O
is    O
one    O
of    O
the    O
major    O
toxic    O
alkaloids    O
isolated    O
from    O
Dendrobates    O
pumilio    O
,    O
a    O
Panamanian    O
poison    O
frog    O
.    O

However    O
,    O
it    O
can    O
be    O
prepared    O
either    O
from    O
vindoline    O
and    O
catharanthine    O
or    O
from    O
leurosine    O
,    O
in    O
both    O
cases    O
by    O
synthesis    O
of    O
anhydrovinblastine    B-Alkaloid114712692
.    O

Amongst    O
his    O
discoveries    O
are    O
:    O
vinorelbine    B-Alkaloid114712692
(    O
from    O
the    O
Catharanthus    O
roseus    O
)    O
and    O
Docetaxel    B-Alkaloid114712692
(    O
from    O
Taxus    O
baccata    O
)    O
.    O

The    O
newer    O
semi    O
-    O
synthetic    O
chemotherapeutic    O
agent    O
vinorelbine    B-Alkaloid114712692
is    O
used    O
in    O
the    O
treatment    O
of    O
non    O
-    O
small    O
-    O
cell    O
lung    O
cancer    O
.    O

It    O
is    O
another    O
derivative    O
dimer    O
of    O
vindoline    O
and    O
catharanthine    O
and    O
is    O
synthesised    O
from    O
anhydrovinblastine    B-Alkaloid114712692
,    O
starting    O
either    O
from    O
leurosine    O
or    O
the    O
monomers    O
themselves    O
.    O

Tryptoline    B-Alkaloid114712692

"    O
Gelsemium    O
"    O
roots    O
contain    O
the    O
highly    O
toxic    O
alkaloid    O
gelsemine    B-Alkaloid114712692
,    O
which    O
acts    O
as    O
a    O
paralytic    O
and    O
often    O
results    O
in    O
death    O
.    O

Lobelanidine    B-Alkaloid114712692

Broad    O
beans    O
,    O
e.g.    O
,    O
fava    O
beans    O
,    O
contain    O
high    O
levels    O
of    O
vicine    B-Alkaloid114712692
,    O
divicine    O
,    O
convicine    O
and    O
isouramil    O
,    O
all    O
of    O
which    O
create    O
oxidants    O
.    O

Nitidine    B-Alkaloid114712692
is    O
a    O
benzophenanthridine    O
alkaloid    O
found    O
in    O
species    O
of    O
the    O
genus    O
"    O
Zanthoxylum    O
"    O
,    O
notably    O
in    O
"    O
Zanthoxylum    O
nitidum    O
"    O
.    O

The    O
ripe    O
fruit    O
also    O
contains    O
0.3–0.45%    O
solasonine    B-Alkaloid114712692
,    O
and    O
acetylcholine    O
,    O
and    O
has    O
a    O
cholinesterase    O
-    O
inhibiting    O
effect    O
on    O
human    O
plasma    O
.    O

Lycorine    B-Alkaloid114712692
is    O
toxic    O
in    O
sufficient    O
quantities    O
,    O
particularly    O
in    O
pets    O
and    O
small    O
children    O
.    O

Lycorine    B-Alkaloid114712692
is    O
a    O
toxic    O
crystalline    O
alkaloid    O
found    O
in    O
various    O
Amaryllidaceae    O
species    O
,    O
such    O
as    O
the    O
cultivated    O
bush    O
lily    O
(    O
"    O
Clivia    O
miniata    O
"    O
)    O
,    O
surprise    O
lilies    O
(    O
"    O
Lycoris    O
"    O
)    O
,    O
and    O
daffodils    O
(    O
"    O
Narcissus    O
"    O
)    O
.    O

Aconites    O
have    O
been    O
used    O
more    O
recently    O
in    O
murder    O
plots    O
;    O
they    O
contain    O
the    O
chemical    O
alkaloids    O
aconitine    B-Alkaloid114712692
,    O
mesaconitine    O
,    O
hypaconitine    O
and    O
jesaconitine    O
,    O
which    O
are    O
highly    O
toxic    O
.    O

It    O
combines    O
7    O
drugs    O
:    O
7/10    O
of    O
a    O
bushel    O
of    O
hemp    O
-    O
seeds    O
,    O
7    O
ounces    O
of    O
"    O
Smilax    O
"    O
,    O
6    O
ounces    O
of    O
"    O
Rehmannia    O
glutinosa    O
"    O
,    O
5    O
ounces    O
of    O
aconite    B-Alkaloid114712692
,    O
5    O
ounces    O
of    O
cloud    O
-    O
shaped    O
agaric    O
mushrooms    O
,    O
4    O
ounces    O
of    O
cinnamon    O
,    O
and    O
a    O
7-inch    O
long    O
"    O
Zanthoxylum    O
"    O
root    O
.    O

Aconitine    B-Alkaloid114712692

aconitine    B-Alkaloid114712692

Extracts    O
from    O
plants    O
containing    O
toxic    O
alkaloids    O
,    O
such    O
as    O
aconitine    B-Alkaloid114712692
and    O
tubocurarine    B-Alkaloid114712692
,    O
were    O
used    O
since    O
antiquity    O
for    O
poisoning    O
arrows    O
.    O

Aconitine    B-Alkaloid114712692
:    O
Raw    O
Fu    O
Zi    O
,    O
0.004%    O
;    O
prepared    O
Fu    O
Zi    O
,    O
trace    O
/    O
none    O
.    O

It    O
was    O
developed    O
as    O
a    O
less    O
toxic    O
analogue    O
of    O
the    O
potent    O
poison    O
dart    O
frog    O
-    O
derived    O
compound    O
epibatidine    B-Alkaloid114712692
,    O
which    O
is    O
some    O
200x    O
stronger    O
than    O
morphine    O
as    O
an    O
analgesic    O
but    O
produces    O
extremely    O
dangerous    O
toxic    O
side    O
effects    O
.    O

It    O
was    O
developed    O
as    O
a    O
less    O
toxic    O
analogue    O
of    O
the    O
potent    O
frog    O
-    O
derived    O
alkaloid    O
epibatidine    B-Alkaloid114712692
,    O
which    O
is    O
around    O
200    O
times    O
stronger    O
than    O
morphine    O
as    O
an    O
analgesic    O
but    O
produces    O
extremely    O
dangerous    O
toxic    O
nicotinic    O
side    O
effects    O
.    O

Intraocular    O
injections    O
of    O
epibatidine    B-Alkaloid114712692
,    O
a    O
cholinergic    O
agonist    O
,    O
can    O
be    O
used    O
to    O
block    O
spontaneous    O
firing    O
in    O
half    O
of    O
all    O
retinal    O
ganglion    O
cells    O
and    O
cause    O
uncorrelated    O
firing    O
in    O
the    O
remaining    O
half    O
.    O

The    O
fire    O
salamander    O
's    O
primary    O
alkaloid    O
toxin    O
,    O
Samandarin    B-Alkaloid114712692
,    O
causes    O
strong    O
muscle    O
convulsions    O
and    O
hypertension    O
combined    O
with    O
hyperventilation    O
in    O
all    O
vertebrates    O
.    O

"O"-Acetylpsilocin    B-Alkaloid114712692
(    O
4-AcO    O
-    O
DMT    O
)    O
is    O
an    O
acetylated    O
analog    O
of    O
psilocin    O
.    O

O-Acetylpsilocin    B-Alkaloid114712692

Opioid    B-Alkaloid114712692
peptide    I-Alkaloid114712692

Opioid    B-Alkaloid114712692
peptide    I-Alkaloid114712692

Opioid    B-Alkaloid114712692
peptides    I-Alkaloid114712692
are    O
peptides    O
that    O
bind    O
to    O
opioid    O
receptors    O
in    O
the    O
brain    O
;    O
opiates    O
and    O
opioids    O
mimic    O
the    O
effect    O
of    O
these    O
peptides    O
.    O

The    O
rubiscolins    O
are    O
a    O
group    O
of    O
opioid    B-Alkaloid114712692
peptide    I-Alkaloid114712692
that    O
are    O
formed    O
during    O
digestion    O
of    O
the    O
ribulose    O
bisphosphate    O
carboxylase    O
/    O
oxygenase    O
(    O
Rubisco    O
)    O
protein    O
from    O
spinach    O
leaves    O
.    O

Casokefamide    O
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
β-casomorphin    O
4027    O
(    O
β-CM-4027    O
)    O
and    O
[    O
D    O
-    O
Ala2,4,Tyr5]-β-casomorphin-5-amide    O
,    O
is    O
a    O
peripherally    O
-    O
specific    O
,    O
synthetic    O
opioid    B-Alkaloid114712692
pentapeptide    I-Alkaloid114712692
with    O
the    O
amino    O
acid    O
sequence    O
Tyr    O
-    O
D    O
-    O
Ala    O
-    O
Phe    O
-    O
D    O
-    O
Ala    O
-    O
Tyr    O
-    O
NH2    O
.    O

Frakefamide    O
(    O
INN    O
)    O
is    O
a    O
synthetic    O
,    O
fluorinated    O
opioid    B-Alkaloid114712692
tetrapeptide    I-Alkaloid114712692
with    O
the    O
amino    O
acid    O
sequence    O
Tyr    O
-    O
D    O
-    O
Ala-("p    O
"-    O
F)Phe    O
-    O
Phe    O
-    O
NH2    O
which    O
acts    O
as    O
a    O
peripherally    O
-    O
specific    O
,    O
selective    O
μ-opioid    O
receptor    O
agonist    O
.    O

Metkefamide    O
(    O
INN    O
;    O
LY-127,623    O
)    O
,    O
or    O
metkephamid    O
acetate    O
(    O
USAN    O
)    O
,    O
but    O
most    O
frequently    O
referred    O
to    O
simply    O
as    O
metkephamid    O
,    O
is    O
a    O
synthetic    O
opioid    B-Alkaloid114712692
pentapeptide    I-Alkaloid114712692
and    O
derivative    O
of    O
[    O
[    O
met    O
-    O
enkephalin|[Met]enkephalin    O
]    O
]    O
with    O
the    O
amino    O
acid    O
sequence    O
Tyr    O
-    O
D    O
-    O
Ala    O
-    O
Gly    O
-    O
Phe-("N    O
"-    O
Me)-Met    O
-    O
NH2    O
.    O

Exercise    O
is    O
known    O
to    O
affect    O
dopamine    O
signaling    O
in    O
the    O
nucleus    O
accumbens    O
,    O
producing    O
euphoria    O
as    O
a    O
result    O
,    O
through    O
increased    O
biosynthesis    O
of    O
three    O
particular    O
neurochemicals    O
:    O
anandamide    B-Alkaloid114712692
(    O
an    O
endocannabinoid    O
)    O
,    O
β-endorphin    O
(    O
an    O
endogenous    B-Alkaloid114712692
opioid    I-Alkaloid114712692
)    O
,    O
and    O
phenethylamine    O
(    O
a    O
trace    O
amine    O
and    O
amphetamine    O
analog    O
)    O
.    O

Therefore    O
,    O
investigators    O
have    O
explored    O
the    O
effects    O
of    O
genetic    O
variation    O
in    O
the    O
endogenous    B-Alkaloid114712692
opioid    I-Alkaloid114712692
system    O
and    O
the    O
GABAergic    O
system    O
on    O
SR    O
.    O

Lofexidine    O
inhibits    O
the    O
release    O
of    O
norepinephrine    O
in    O
the    O
central    O
and    O
peripheral    O
nervous    O
system    O
,    O
thereby    O
reducing    O
some    O
of    O
the    O
withdrawal    O
symptoms    O
,    O
but    O
it    O
has    O
no    O
documented    O
effect    O
on    O
drug    O
craving    O
and    O
endogenous    B-Alkaloid114712692
opioid    I-Alkaloid114712692
levels    O
.    O

Castoramine    B-Alkaloid114712692
,    O
an    O
alkaloid    O
found    O
in    O
castoreum    O

In    O
Australia    O
it    O
is    O
covered    O
by    O
the    O
Pharmaceutical    O
Benefits    O
Scheme    O
when    O
being    O
used    O
to    O
treat    O
castration    O
-    O
resistant    O
prostate    O
cancer    O
and    O
given    O
in    O
combination    O
with    O
prednisone    O
/    O
prednisolone    O
(    O
subject    O
to    O
the    O
conditions    O
that    O
the    O
patient    O
is    O
not    O
currently    O
receiving    O
chemotherapy    O
,    O
is    O
either    O
resistant    O
or    O
intolerant    O
of    O
docetaxel    B-Alkaloid114712692
,    O
has    O
a    O
WHO    O
performance    O
status    O
of    O
Adverse    O
effects    O
by    O
frequency    O
:    O
'    O
"    O

Examples    O
of    O
mitotic    O
inhibitors    O
frequently    O
used    O
in    O
the    O
treatment    O
of    O
cancer    O
include    O
paclitaxel    B-Alkaloid114712692
,    O
docetaxel    B-Alkaloid114712692
,    O
vinblastine    O
,    O
vincristine    O
,    O
and    O
vinorelbine    B-Alkaloid114712692
.    O

Docetaxel    B-Alkaloid114712692
—    O
used    O
to    O
treat    O
breast    O
,    O
ovarian    O
,    O
and    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
.    O

While    O
in    O
hospital    O
,    O
Megrahi    O
underwent    O
chemotherapy    O
treatment    O
,    O
receiving    O
the    O
drug    O
Docetaxel    B-Alkaloid114712692
.    O

This    O
effect    O
has    O
been    O
observed    O
with    O
dexamethasone    O
,    O
the    O
anti    O
-    O
cancer    O
drugs    O
docetaxel    B-Alkaloid114712692
and    O
etoposide    O
,    O
and    O
to    O
a    O
minor    O
(    O
not    O
clinically    O
significant    O
)    O
extent    O
with    O
levonorgestrel    O
,    O
erythromycin    O
and    O
midazolam    O
.    O

2012    O
–    O
Perjeta    O
(    O
pertuzumab    O
)    O
:    O
For    O
use    O
in    O
combination    O
with    O
Herceptin    O
(    O
trastuzumab    O
)    O
and    O
docetaxel    B-Alkaloid114712692
chemotherapy    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
previously    O
untreated    O
HER2-positive    O
metastatic    O
breast    O
cancer    O
.    O

Phyton    O
Biotech    O
uses    O
plant    O
cell    O
culture    O
systems    O
to    O
manufacture    O
active    O
pharmaceutical    O
ingredients    O
based    O
on    O
taxanes    O
,    O
including    O
paclitaxel    B-Alkaloid114712692
and    O
docetaxel    B-Alkaloid114712692

Certain    O
plant    O
-    O
derived    O
anticancer    O
chemotherapeutic    O
agents    O
,    O
such    O
as    O
docetaxel    B-Alkaloid114712692
,    O
cause    O
anasarca    O
through    O
a    O
poorly    O
understood    O
capillary    O
leak    O
syndrome    O
.    O

taxol    B-Alkaloid114712692
and    O
Docetaxel    B-Alkaloid114712692
both    O
are    O
still    O
used    O
in    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
ovarian    O
cancer    O
and    O
other    O
types    O
of    O
epithelial    O
cancer    O
.    O

Siltuximab    O
was    O
also    O
tested    O
in    O
the    O
phase    O
I    O
/    O
II    O
study    O
for    O
therapy    O
of    O
patients    O
with    O
metastatic    O
castration    O
-    O
associated    O
prostate    O
cancer    O
in    O
combination    O
with    O
docetaxel    B-Alkaloid114712692
and    O
in    O
renal    O
cell    O
carcinoma    O
;    O
phase    O
II    O
trials    O
in    O
ovarian    O
cancer    O
resulted    O
in    O
39%    O
of    O
patients    O
showed    O
disease    O
stabilization    O
via    O
IL-6-regulated    O
downregulation    O
of    O
CCL2    O
,    O
CXCL12    O
and    O
VEGF    O
.    O

Amongst    O
his    O
discoveries    O
are    O
:    O
vinorelbine    B-Alkaloid114712692
(    O
from    O
the    O
Catharanthus    O
roseus    O
)    O
and    O
Docetaxel    B-Alkaloid114712692
(    O
from    O
Taxus    O
baccata    O
)    O
.    O

More    O
commonly    O
,    O
it    O
is    O
used    O
in    O
combination    O
with    O
two    O
similar    O
compounds    O
,    O
dihydroergocornine    B-Alkaloid114712692
and    O
dihydroergocristine    B-Alkaloid114712692
.    O

,    O
produced    O
incapacitating    O
"    O
curariform    O
"    O
(    O
i.e.    O
,    O
resembling    O
the    O
effects    O
of    O
tubocurarine    B-Alkaloid114712692
)    O
paralysis    O
of    O
the    O
skeletal    O
muscles    O
,    O
as    O
well    O
as    O
marked    O
drowsiness    O
.    O

Tubocurarine    B-Alkaloid114712692

The    O
total    O
synthesis    O
of    O
a    O
number    O
of    O
natural    O
alkaloids    O
–    O
pilocarpine    O
,    O
pilozinin    O
,    O
alkaloids    O
of    O
propane    O
series    O
(    O
tropine    O
,    O
cocaine    O
)    O
,    O
arecoline    B-Alkaloid114712692
,    O
eserine    O
,    O
emetine    O
,    O
psyhotrine    O
,    O
emataliine    O
,    O
cinchonamine    O
,    O
tubocurarine    B-Alkaloid114712692
and    O
other    O
alkaloids    O
of    O
curare    O
(    O
magnolin    O
,    O
magnolamine    O
,    O
dauricine    B-Alkaloid114712692
)    O
.    O

Tubocurarine    B-Alkaloid114712692
-    O
Nondepolarizing    O
skeletal    O
muscular    O
relaxant    O

Alkaloids    O
can    O
be    O
toxic    O
too    O
(    O
"    O
e.g.    O
"    O
atropine    O
,    O
tubocurarine    B-Alkaloid114712692
)    O
.    O

Extracts    O
from    O
plants    O
containing    O
toxic    O
alkaloids    O
,    O
such    O
as    O
aconitine    B-Alkaloid114712692
and    O
tubocurarine    B-Alkaloid114712692
,    O
were    O
used    O
since    O
antiquity    O
for    O
poisoning    O
arrows    O
.    O

File    O
:    O
Tubocurarine    B-Alkaloid114712692

Ethacridine    O
lactate    O
(    O
ethacridine    O
monolactate    O
monohydrate    O
,    O
acrinol    O
,    O
trade    O
name    O
Rivanol    O
)    O
is    O
an    O
aromatic    O
organic    O
compound    O
based    O
on    O
acridine    B-Alkaloid114712692
.    O

Where    O
two    O
of    O
the    O
aryl    O
groups    O
are    O
bridged    O
by    O
a    O
heteroatom    O
,    O
these    O
triarylmethane    O
compounds    O
may    O
be    O
further    O
categorized    O
into    O
acridine    B-Alkaloid114712692
(    O
nitrogen    O
-    O
bridged    O
)    O
,    O
xanthenes    O
(    O
oxygen    O
-    O
bridged    O
)    O
,    O
and    O
thioxanthenes    O
(    O
sulfur    O
-    O
bridged    O
)    O
.    O

Acridine    B-Alkaloid114712692
derivatives    O
:    O
proflavin    O
,    O
acridine    O
orange    O
,    O
acridine    O
yellow    O
,    O
etc    O
.    O

The    O
Skraup    O
synthesis    O
is    O
a    O
chemical    O
reaction    O
used    O
to    O
synthesize    O
quinoline    B-Alkaloid114712692
.    O

"    O
Rhodococcus    O
"    O
sp    O
.    O
strain    O
Q1    O
(    O
American    O
Type    O
Culture    O
Collection    O
strain    O
number    O
49988    O
)    O
,    O
isolated    O
from    O
soil    O
and    O
paper    O
mill    O
sludge    O
,    O
is    O
able    O
to    O
degrade    O
quinoline    B-Alkaloid114712692
,    O
various    O
pyridine    O
derivatives    O
,    O
catechol    O
,    O
benzoate    O
,    O
and    O
protocatechuic    O
acid    O
.    O

The    O
Gould    O
–    O
Jacobs    O
reaction    O
is    O
an    O
organic    O
synthesis    O
for    O
the    O
preparation    O
of    O
quinoline    B-Alkaloid114712692
(    O
more    O
specifically    O
,    O
a    O
4-quinolinol    O
)    O
.    O

In    O
a    O
standard    O
quinoline    B-Alkaloid114712692
reaction    O
,    O
this    O
amine    O
is    O
then    O
used    O
to    O
displace    O
the    O
more    O
reactive    O
fluorine    O
at    O
the    O
7-position    O
in    O
Ethyl    O
1-(2,4-difluorophenyl)-6,7-difluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate    O
(    O
9    O
)    O
.    O

With    O
pyridine    O
as    O
solvent    O
(    O
basic    O
)    O
,    O
the    O
reaction    O
gives    O
a    O
quinoline    B-Alkaloid114712692
which    O
can    O
be    O
degraded    O
to    O
a    O
dihydroquinoline    O
.    O

An    O
aromatic    O
imine    O
reacts    O
with    O
an    O
enol    O
ether    O
to    O
a    O
quinoline    B-Alkaloid114712692
in    O
the    O
Povarov    O
reaction    O
.    O

Typical    O
examples    O
of    O
basic    O
aromatic    O
rings    O
are    O
pyridine    O
or    O
quinoline    B-Alkaloid114712692
.    O

Roquinimex    O
(    O
Linomide    O
)    O
is    O
a    O
quinoline    B-Alkaloid114712692
derivative    O
immunostimulant    O
which    O
increases    O
NK    O
cell    O
activity    O
and    O
macrophage    O
cytotoxicity    O
.    O

Two    O
systems    O
exist    O
for    O
the    O
asymmetric    O
hydrogenation    O
of    O
2-substituted    O
quinolines    B-Alkaloid114712692
with    O
isolated    O
yields    O
generally    O
greater    O
than    O
80%    O
and    O
ee    O
values    O
generally    O
greater    O
than    O
90%    O
.    O

Much    O
of    O
the    O
asymmetric    O
hydrogenation    O
chemistry    O
of    O
quinoxalines    O
is    O
closely    O
related    O
to    O
that    O
of    O
the    O
structurally    O
similar    O
quinolines    B-Alkaloid114712692
.    O

It    O
is    O
a    O
derivative    O
of    O
the    O
heterocycle    O
quinoline    B-Alkaloid114712692
,    O
substituted    O
in    O
the    O
8-position    O
with    O
a    O
thiol    O
group    O
.    O

The    O
Knorr    O
quinoline    O
synthesis    O
is    O
an    O
intramolecular    O
organic    O
reaction    O
converting    O
a    O
β-ketoanilide    O
to    O
a    O
2-hydroxyquinoline    B-Alkaloid114712692
using    O
sulfuric    O
acid    O
.    O

Bosutinib    O
's    O
structure    O
is    O
based    O
on    O
a    O
quinoline    B-Alkaloid114712692
scaffold    O
and    O
is    O
structurally    O
related    O
to    O
the    O
AstraZeneca    O
quinazoline    O
template    O
.    O

Quinaldine    O
or    O
2-methylquinoline    O
is    O
an    O
organic    O
compound    O
with    O
the    O
formula    O
CH3C9H6N.    O
It    O
is    O
one    O
of    O
the    O
methyl    O
derivative    O
of    O
a    O
heterocyclic    O
compound    O
quinoline    B-Alkaloid114712692
.    O

quinoline    B-Alkaloid114712692

Investigations    O
into    O
anatoxin-"a"    B-Alkaloid114712692
,    O
also    O
known    O
as    O
"    O
Very    O
Fast    O
Death    O
Factor    O
"    O
,    O
began    O
in    O
1961    O
following    O
the    O
deaths    O
of    O
cows    O
that    O
drank    O
from    O
a    O
lake    O
containing    O
an    O
algal    O
bloom    O
in    O
Saskatchewan    O
,    O
Canada    O
.    O

Anatoxin-"a"    B-Alkaloid114712692
.    O

Skatole    B-Alkaloid114712692
(    O
3-methylindole    O
)    O

Single    O
synthetic    O
compounds    O
are    O
commonly    O
used    O
as    O
bait    O
to    O
attract    O
and    O
collect    O
males    O
for    O
study    O
,    O
and    O
include    O
many    O
familiar    O
flavorings    O
and    O
odors    O
considered    O
appealing    O
to    O
humans    O
(    O
e.g.    O
,    O
methyl    O
salicylate    O
,    O
eugenol    O
,    O
cineole    O
,    O
benzyl    O
acetate    O
,    O
methyl    O
benzoate    O
,    O
methyl    O
cinnamate    O
)    O
,    O
and    O
others    O
which    O
are    O
not    O
(    O
e.g.    O
,    O
skatole    B-Alkaloid114712692
)    O
.    O

The    O
animal    O
scent    O
is    O
reinforced    O
by    O
the    O
presence    O
of    O
smaller    O
amounts    O
of    O
indole    O
and    O
skatole    B-Alkaloid114712692
,    O
which    O
in    O
African    O
civet    O
are    O
present    O
at    O
a    O
concentration    O
of    O
about    O
1    O
percent    O
.    O

skatole    B-Alkaloid114712692

Trigonelline    B-Alkaloid114712692
(    O
"    O
N    O
"-    O
methyl    O
-    O
nicotinate    O
)    O
is    O
a    O
derivative    O
of    O
vitamin    O
B6    O
that    O
is    O
not    O
as    O
bitter    O
as    O
caffeine    O
.    O

Anhalamine    B-Alkaloid114712692

ergocristine    B-Alkaloid114712692
,    O
ergonovine    B-Alkaloid114712692
and    O
ergotamine    O

The    O
use    O
of    O
endocannabinoids    O
such    O
as    O
anandamide    B-Alkaloid114712692
and    O
2-arachidonoyl    O
glycerol    O
in    O
this    O
method    O
of    O
signalling    O
is    O
quite    O
logical    O
,    O
since    O
both    O
molecules    O
can    O
be    O
synthesized    O
relatively    O
easily    O
from    O
lipids    O
in    O
the    O
plasma    O
membrane    O
,    O
a    O
fundamental    O
constituent    O
of    O
all    O
cells    O
.    O

Interestingly    O
,    O
some    O
work    O
has    O
shown    O
that    O
anandamide    B-Alkaloid114712692
can    O
bind    O
to    O
the    O
vannilloid    O
receptor    O
VR1    O
,    O
the    O
receptor    O
responsible    O
for    O
mediating    O
the    O
effects    O
of    O
capsaicin    O
.    O

O    O
"-    O
Arachidonoyl    O
ethanolamine    O
is    O
arachidonic    O
acid    O
and    O
ethanolamine    O
joined    O
by    O
an    O
ester    O
linkage    O
,    O
the    O
opposite    O
of    O
the    O
amide    O
linkage    O
found    O
in    O
anandamide    B-Alkaloid114712692
.    O

Concentrations    O
of    O
virodhamine    O
in    O
the    O
human    O
hippocampus    O
are    O
similar    O
to    O
those    O
of    O
anandamide    B-Alkaloid114712692
,    O
but    O
they    O
are    O
2-    O
to    O
9-fold    O
higher    O
in    O
peripheral    O
tissues    O
that    O
express    O
CB2    O
.    O

Anandamide    B-Alkaloid114712692

It    O
displays    O
high    O
selectivity    O
for    O
MAGL    O
over    O
other    O
brain    O
serine    O
hydrolases    O
,    O
including    O
the    O
anandamide    B-Alkaloid114712692
-    O
degrading    O
enzyme    O
fatty    O
acid    O
amide    O
hydrolase    O
(    O
FAAH    O
)    O
,    O
thereby    O
making    O
it    O
a    O
useful    O
tool    O
for    O
studying    O
the    O
effects    O
of    O
endogenous    O
2-AG    O
signaling    O
,    O
"    O
in    O
vivo    O
"    O
.    O

AM404    O
was    O
originally    O
reported    O
to    O
be    O
an    O
endogenous    O
cannabinoid    O
reuptake    O
inhibitor    O
,    O
preventing    O
the    O
transport    O
of    O
anandamide    B-Alkaloid114712692
and    O
other    O
related    O
compounds    O
back    O
from    O
the    O
synaptic    O
cleft    O
,    O
much    O
in    O
the    O
same    O
way    O
that    O
common    O
selective    O
serotonin    O
reuptake    O
inhibitor    O
(    O
SSRI    O
)    O
antidepressants    O
prevent    O
the    O
reuptake    O
of    O
serotonin    O
.    O

Earlier    O
work    O
on    O
the    O
mechanism    O
of    O
AM404    O
suggested    O
that    O
the    O
inhibition    O
of    O
fatty    O
acid    O
amide    O
hydrolase    O
(    O
FAAH    O
)    O
by    O
AM404    O
was    O
responsible    O
for    O
all    O
of    O
its    O
attributed    O
reuptake    O
properties    O
,    O
since    O
intracellular    O
FAAH    O
hydrolysis    O
of    O
anandamide    B-Alkaloid114712692
changes    O
the    O
intra    O
/    O
extracellular    O
anandamide    O
equilibrium    O
.    O

Insulin    O
is    O
a    O
major    O
regulator    O
of    O
endocannabinoid    O
(    O
EC    O
)    O
metabolism    O
and    O
insulin    O
treatment    O
has    O
been    O
shown    O
to    O
reduce    O
intracellular    O
ECs    O
,    O
the    O
2-arachidonylglycerol    O
(    O
2-AG    O
)    O
and    O
anandamide    B-Alkaloid114712692
(    O
AEA    O
)    O
,    O
which    O
correspond    O
with    O
insulin    O
-    O
sensitive    O
expression    O
changes    O
in    O
enzymes    O
of    O
EC    O
metabolism    O
.    O

It    O
has    O
been    O
shown    O
that    O
the    O
actions    O
of    O
abnormal    O
cannabidiol    O
are    O
mediated    O
through    O
a    O
site    O
separate    O
from    O
the    O
CB1    O
and    O
CB2    O
receptors    O
,    O
which    O
responds    O
to    O
abnormal    O
cannabidiol    O
,    O
O-1602    O
,    O
and    O
the    O
endogenous    O
ligands    O
:    O
anandamide    B-Alkaloid114712692
(    O
AEA    O
)    O
,    O
N    O
-    O
arachidonoyl    O
glycine    O
(    O
NAGly    O
)    O
and    O
N    O
-    O
arachidonoyl    O
L    O
-    O
serine    O
.    O

counteracting    O
the    O
effects    O
of    O
anandamide    B-Alkaloid114712692
,    O
another    O
potent    O
hunger    O
promoter    O
that    O
binds    O
to    O
the    O
same    O
receptors    O
as    O
THC    O

It    O
is    O
found    O
that    O
truffles    O
contain    O
the    O
endocannabinoid    O
anandamide    B-Alkaloid114712692
(    O
AEA    O
)    O
and    O
the    O
major    O
metabolic    O
enzymes    O
of    O
the    O
endocannabinoid    O
system    O
ECS    O
,    O
and    O
the    O
anandamide    O
content    O
increases    O
in    O
the    O
late    O
stages    O
of    O
truffles’    O
development    O
.    O

Exercise    O
is    O
known    O
to    O
affect    O
dopamine    O
signaling    O
in    O
the    O
nucleus    O
accumbens    O
,    O
producing    O
euphoria    O
as    O
a    O
result    O
,    O
through    O
increased    O
biosynthesis    O
of    O
three    O
particular    O
neurochemicals    O
:    O
anandamide    B-Alkaloid114712692
(    O
an    O
endocannabinoid    O
)    O
,    O
β-endorphin    O
(    O
an    O
endogenous    B-Alkaloid114712692
opioid    I-Alkaloid114712692
)    O
,    O
and    O
phenethylamine    O
(    O
a    O
trace    O
amine    O
and    O
amphetamine    O
analog    O
)    O
.    O

Cannabinoid    O
receptor    O
1    O
agonists    O
are    O
a    O
group    O
of    O
euphoriants    O
that    O
includes    O
certain    O
plant    O
-    O
based    O
cannabinoids    O
(    O
e.g.    O
,    O
THC    O
from    O
the    O
cannabis    O
plant    O
)    O
,    O
endogenous    O
cannabinoids    O
(    O
e.g.    O
,    O
anandamide    B-Alkaloid114712692
)    O
,    O
and    O
synthetic    O
cannabinoids    O
.    O

The    O
endocannabinoids    O
(    O
anandamide    B-Alkaloid114712692
,    O
AEA    O
,    O
and    O
2-arachidonoylglycerol    O
,    O
2-AG    O
)    O
on    O
the    O
other    O
hand    O
,    O
are    O
non    O
-    O
charged    O
lipids    O
that    O
readily    O
cross    O
lipid    O
membranes    O
.    O

Pellotine    B-Alkaloid114712692

While    O
at    O
Merck    O
,    O
Dr    O
Köllisch    O
was    O
involved    O
in    O
investigating    O
syntheses    O
for    O
methylhydrastinine    O
and    O
hydrastinine    B-Alkaloid114712692
.    O

with    O
noscapine    B-Alkaloid114712692
as    O
Tussisedal    O
;    O
and    O

The    O
discovery    O
of    O
a    O
10    O
gene    O
cluster    O
responsible    O
for    O
the    O
production    O
of    O
the    O
anti    O
-    O
cancer    O
compound    O
noscapine    B-Alkaloid114712692
in    O
opium    O
poppy    O
provided    O
the    O
tools    O
for    O
molecular    O
breeding    O
of    O
new    O
commercial    O
varieties    O
.    O

Papaverine    O
is    O
also    O
present    O
in    O
combinations    O
of    O
opium    O
alkaloid    O
salts    O
such    O
as    O
papaveretum    O
(    O
Omnopon    O
,    O
Pantopon    O
)    O
and    O
others    O
,    O
along    O
with    O
morphine    O
,    O
codeine    O
,    O
and    O
in    O
some    O
cases    O
noscapine    B-Alkaloid114712692
and    O
others    O
in    O
a    O
percentage    O
similar    O
to    O
that    O
in    O
opium    O
,    O
or    O
modified    O
for    O
a    O
given    O
application    O
.    O

Noscapine    B-Alkaloid114712692

Berberine    B-Alkaloid114712692
,    O
the    O
active    O
ingredient    O
in    O
barberry    O
,    O
inhibits    O
the    O
growth    O
of    O
bacteria    O
and    O
has    O
antioxidant    O
properties    O
"    O
in    O
vitro    O
"    O
.    O

Traditional    O
Chinese    O
herbal    O
medicines    O
,    O
like    O
berberine    B-Alkaloid114712692
downregulate    O
E    O
-    O
selectin    O
.    O

Berberine    B-Alkaloid114712692
is    O
a    O
quaternary    O
ammonium    O
salt    O
from    O
the    O
protoberberine    O
group    O
of    O
benzylisoquinoline    B-Alkaloid114712692
alkaloids    O
.    O

Canadine    O
is    O
a    O
berberine    B-Alkaloid114712692
alkaloid    O
which    O
can    O
act    O
as    O
a    O
calcium    O
channel    O
blocker    O
.    O

This    O
argemone    O
resin    O
contains    O
berberine    B-Alkaloid114712692
and    O
protopine    B-Alkaloid114712692
.    O

The    O
rhizomes    O
of    O
"    O
Coptis    O
chinensis    O
"    O
are    O
used    O
in    O
Traditional    O
Chinese    O
Medicine    O
and    O
serve    O
as    O
a    O
source    O
for    O
the    O
isoquinoline    O
alkaloids    O
berberine    B-Alkaloid114712692
,    O
palmatine    B-Alkaloid114712692
,    O
and    O
coptisine    B-Alkaloid114712692
among    O
others    O
.    O

Because    O
of    O
the    O
strong    O
coloring    O
quality    O
of    O
berberine    B-Alkaloid114712692
,    O
it    O
has    O
been    O
traditionally    O
used    O
as    O
a    O
dye    O
,    O
especially    O
for    O
wool    O
and    O
other    O
fibers    O
.    O

Some    O
alkaloids    O
are    O
colored    O
,    O
like    O
berberine    B-Alkaloid114712692
(    O
yellow    O
)    O
and    O
sanguinarine    B-Alkaloid114712692
(    O
orange    O
)    O
.    O

Scoulerine    B-Alkaloid114712692
,    O
also    O
known    O
as    O
discretamine    B-Alkaloid114712692
and    O
aequaline    B-Alkaloid114712692
,    O
is    O
a    O
benzylisoquinoline    B-Alkaloid114712692
alkaloid    O
that    O
derives    O
from    O
reticuline    B-Alkaloid114712692
and    O
is    O
a    O
precursor    O
of    O
berberine    B-Alkaloid114712692
.    O

Reaction    O
with    O
diazomethane    O
at    O
the    O
conjugated    O
double    O
bond    O
at    O
16    O
gives    O
first    O
the    O
pyrazole    B-Alkaloid114712692
(    O
6    O
)    O
.    O

Compounds    O
containing    O
two    O
or    O
three    O
adjacent    O
ring    O
N    O
atoms    O
(    O
pyridazine    O
,    O
pyrazole    B-Alkaloid114712692
,    O
indazole    O
)    O
tend    O
to    O
have    O
a    O
significantly    O
higher    O
inhibition    O
effect    O
than    O
compounds    O
containing    O
non    O
-    O
adjacent    O
N    O
atoms    O
or    O
singular    O
ring    O
N    O
atoms    O
(    O
pyridine    O
,    O
pyrrole    O
)    O
.    O

Typical    O
"    O
easy    O
"    O
substrates    O
contain    O
O    O
-    O
H    O
,    O
N    O
-    O
H    O
,    O
S    O
-    O
H    O
bonds    O
,    O
including    O
alcohols    O
,    O
phenols    O
,    O
pyrazole    B-Alkaloid114712692
,    O
and    O
thiols    O
.    O

Chemistry    O
involving    O
nickel    O
catalysis    O
of    O
Suzuki    O
reactions    O
was    O
greatly    O
affected    O
by    O
pyrazole    B-Alkaloid114712692
and    O
pyrazolates    O
acting    O
as    O
coplanar    O
ligand    O
.    O

The    O
π    O
interactions    O
tied    O
multiple    O
pyrazole    B-Alkaloid114712692
and    O
pyrazolates    O
together    O
around    O
the    O
nickel    O
metal    O
to    O
cause    O
reaction    O
results    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
O3-acetyl    O
-    O
L    O
-    O
serine    O
and    O
pyrazole    B-Alkaloid114712692
,    O
whereas    O
its    O
two    O
products    O
are    O
3-(pyrazol-1-yl)-L    O
-    O
alanine    O
and    O
acetate    O
.    O

Pyrazole    B-Alkaloid114712692

dehydroemetine    B-Alkaloid114712692
(    O
INN    O
)    O

The    O
patient    O
was    O
treated    O
with    O
dehydroemetine    B-Alkaloid114712692
and    O
chloroquine    O
.    O

Tetrahydroharman    B-Alkaloid114712692

Solanidine    B-Alkaloid114712692
is    O
a    O
poisonous    O
steroidal    O
alkaloid    O
chemical    O
compound    O
that    O
occurs    O
in    O
plants    O
of    O
the    O
Solanaceae    O
family    O
,    O
such    O
as    O
potato    O
and    O
"    O
Solanum    O
americanum    O
"    O
.    O

Rhoeadine    B-Alkaloid114712692
(    O
rheadine    B-Alkaloid114712692
)    O
is    O
an    O
alkaloid    O
derived    O
from    O
the    O
flowers    O
of    O
the    O
corn    O
poppy    O
(    O
"    O
Papaver    O
rhoeas    O
"    O
)    O
.    O

The    O
"    O
beta    O
"    O
differs    O
from    O
the    O
"    O
alpha    O
"    O
form    O
only    O
in    O
the    O
position    O
of    O
a    O
single    O
methyl    O
group    O
,    O
which    O
is    O
a    O
consequence    O
of    O
the    O
biosynthesis    O
of    O
the    O
parent    O
compound    O
ergocryptine    B-Alkaloid114712692
,    O
in    O
which    O
the    O
proteinogenic    O
amino    O
acid    O
leucine    O
is    O
replaced    O
by    O
isoleucine    O
.    O

cathine    B-Alkaloid114712692

Buphedrone    O
is    O
a    O
beta    O
-    O
ketone    O
and    O
is    O
related    O
to    O
the    O
naturally    O
occurring    O
compounds    O
,    O
cathinone    B-Alkaloid114712692
and    O
cathine    B-Alkaloid114712692
.    O

He    O
received    O
a    O
temporary    O
suspension    O
or    O
a    O
one    O
-    O
month    O
ban    O
from    O
FINA    O
after    O
testing    O
positive    O
for    O
the    O
banned    O
stimulants    O
pseudophedrine    O
and    O
cathine    B-Alkaloid114712692
at    O
the    O
Short    O
Course    O
World    O
Championships    O
in    O
Hong    O
Kong    O
.    O

The    O
technical    O
chemistry    O
names    O
cathine    B-Alkaloid114712692
and    O
cathinone    B-Alkaloid114712692
are    O
20th    O
century    O
from    O
"    O
Catha    O
"    O
.    O

Ephedra    O
was    O
used    O
5000    O
years    O
ago    O
in    O
China    O
as    O
a    O
medicinal    O
plant    O
;    O
its    O
active    O
ingredients    O
are    O
alkaloids    O
ephedrine    O
,    O
pseudoephedrine    O
,    O
norephedrine    O
(    O
phenylpropanolamine    O
)    O
and    O
norpseudoephedrine    B-Alkaloid114712692
(    O
cathine    B-Alkaloid114712692
)    O
.    O

Scholarine    B-Alkaloid114712692
is    O
an    O
alkaloid    O
isolated    O
from    O
the    O
West    O
African    O
tree    O
"    O
Alstonia    O
boonei    O
"    O
.    O

Hydroxytropacocaine    B-Alkaloid114712692
:    O

Candicine    B-Alkaloid114712692

Lysergic    B-Alkaloid114712692
acid    I-Alkaloid114712692
methyl    I-Alkaloid114712692
ester    I-Alkaloid114712692
is    O
an    O
analogue    O
of    O
lysergic    O
acid    O
diethylamide    O
(    O
LSD    O
)    O
.    O

Darienine    B-Alkaloid114712692
ia    O
an    O
anti    O
-    O
cholinergic    O
alkaloid    O
.    O

Solauricine    B-Alkaloid114712692
,    O
solauricidine    B-Alkaloid114712692
,    O
and    O
solasodamine    B-Alkaloid114712692
have    O
also    O
been    O
found    O
in    O
"    O
Solanum    O
mauritianum    O
"    O
.    O

I.    O
lacera    O
"    O
is    O
known    O
to    O
be    O
poisonous    O
,    O
containing    O
quantities    O
of    O
the    O
toxic    O
compound    O
muscarine    B-Alkaloid114712692
.    O

It    O
is    O
a    O
toxic    O
mushroom    O
that    O
has    O
muscarine    B-Alkaloid114712692
,    O
the    O
same    O
toxin    O
as    O
Amanita    O
muscaria    O
and    O
Amanita    O
pantherina    O
as    O
well    O
as    O
many    O
species    O
in    O
the    O
Clitocybe    O
and    O
Inocybe    O
genera    O
.    O

"    O
Inocybe    O
erubescens    O
"    O
contains    O
the    O
toxin    O
muscarine    B-Alkaloid114712692
,    O
in    O
much    O
higher    O
doses    O
than    O
"    O
Amanita    O
muscaria    O
"    O
,    O
and    O
has    O
been    O
known    O
to    O
cause    O
death    O
,    O
unlike    O
the    O
latter    O
mushroom    O
.    O

He    O
discovers    O
accidentally    O
that    O
muscarine    B-Alkaloid114712692
-    O
the    O
poison    O
that    O
killed    O
Harrison    O
-    O
can    O
exist    O
in    O
a    O
natural    O
or    O
a    O
synthetic    O
form    O
.    O

Muscarine    B-Alkaloid114712692

He    O
conducted    O
extensive    O
studies    O
on    O
the    O
actions    O
of    O
digitalis    O
,    O
muscarine    B-Alkaloid114712692
(    O
a    O
product    O
of    O
certain    O
mushrooms    O
)    O
,    O
choline    O
and    O
curare    O
.    O

The    O
fruit    O
bodies    O
are    O
suspected    O
to    O
be    O
toxic    O
,    O
as    O
they    O
contain    O
muscarine    B-Alkaloid114712692
.    O

Symptoms    O
are    O
predominantly    O
gastrointestinal    O
in    O
nature    O
,    O
though    O
muscarine    B-Alkaloid114712692
,    O
muscaridine    O
,    O
and    O
choline    O
have    O
been    O
isolated    O
as    O
toxic    O
agents    O
.    O

On    O
January    O
31    O
,    O
2006    O
,    O
Jason    O
Sears    O
died    O
due    O
to    O
complications    O
while    O
undergoing    O
a    O
detox    O
treatment    O
involving    O
ibogaine    B-Alkaloid114712692
in    O
Tijuana    O
,    O
Mexico    O
.    O

Ibogaine    B-Alkaloid114712692

He    O
underwent    O
a    O
treatment    O
using    O
ibogaine    B-Alkaloid114712692
,    O
a    O
potent    O
hallucinogenic    O
drug    O
.    O

Western    O
gorillas    O
inhabiting    O
Gabon    O
have    O
been    O
observed    O
consuming    O
the    O
fruit    O
,    O
stems    O
,    O
and    O
roots    O
of    O
Tabernanthe    O
iboga    O
,    O
which    O
,    O
due    O
to    O
the    O
compound    O
ibogaine    B-Alkaloid114712692
in    O
it    O
,    O
acts    O
on    O
the    O
central    O
nervous    O
system    O
,    O
producing    O
hallucinogenic    O
effects    O
.    O

Ibogaine    B-Alkaloid114712692

In    O
November    O
2014    O
,    O
a    O
naturopath    O
who    O
treated    O
clients    O
with    O
ibogaine    B-Alkaloid114712692
,    O
which    O
resulted    O
in    O
one    O
client    O
's    O
death    O
and    O
another    O
client    O
's    O
blindness    O
,    O
was    O
sentenced    O
to    O
141    O
days    O
imprisonment    O
.    O

Emery    O
and    O
his    O
staff    O
offered    O
free    O
ibogaine    O
therapy    O
to    O
volunteer    O
heroin    O
and    O
cocaine    O
addicts    O
with    O
a    O
plant    O
-    O
based    O
alkaloid    O
called    O
ibogaine    B-Alkaloid114712692
,    O
which    O
eliminates    O
withdrawal    O
symptoms    O
and    O
helps    O
produce    O
the    O
mental    O
change    O
needed    O
to    O
quit    O
using    O
.    O

"    O
Tabernaemontana    O
undulata    O
"    O
contains    O
iboga    B-Alkaloid114712692
alkaloids    I-Alkaloid114712692
,    O
naturally    O
occurring    O
psychoactive    O
compounds    O
.    O

Author    O
and    O
Rolling    O
Stone    O
journalist    O
Hunter    O
S.    O
Thompson    O
is    O
credited    O
for    O
starting    O
a    O
rumor    O
that    O
Muskie    O
was    O
addicted    O
to    O
a    O
drug    O
called    O
Ibogaine    B-Alkaloid114712692
,    O
which    O
dealt    O
a    O
surprising    O
amount    O
of    O
damage    O
to    O
Muskie    O
's    O
reputation    O
.    O

When    O
it    O
looks    O
like    O
Brody    O
's    O
heroin    O
withdrawals    O
will    O
take    O
too    O
long    O
,    O
Dar    O
Adal    O
endorses    O
the    O
use    O
of    O
ibogaine    B-Alkaloid114712692
,    O
a    O
drug    O
which    O
speeds    O
up    O
the    O
withdrawal    O
process    O
but    O
also    O
induces    O
severe    O
,    O
violent    O
hallucinations    O
;    O
Adal    O
implies    O
that    O
he    O
's    O
used    O
the    O
drug    O
for    O
that    O
purpose    O
.    O

Substances    O
with    O
dissociative    O
properties    O
include    O
ketamine    O
,    O
nitrous    O
oxide    O
,    O
alcohol    O
,    O
tiletamine    O
,    O
amphetamine    O
,    O
dextromethorphan    O
,    O
MK-801    O
,    O
PCP    O
,    O
methoxetamine    O
,    O
salvia    O
,    O
muscimol    B-Alkaloid114712692
,    O
atropine    O
,    O
and    O
ibogaine    B-Alkaloid114712692
.    O

Mescaline    O
and    O
many    O
of    O
indole    O
alkaloids    O
(    O
such    O
as    O
psilocybin    O
,    O
dimethyltryptamine    B-Alkaloid114712692
and    O
ibogaine    B-Alkaloid114712692
)    O
have    O
hallucinogenic    O
effect    O
.    O
Morphine    O
and    O
codeine    O
are    O
strong    O
narcotic    O
pain    O
killers    O
.    O

The    O
frogs    O
produce    O
the    O
toxin    O
by    O
modifying    O
the    O
original    O
version    O
,    O
pumiliotoxin    B-Alkaloid114712692
251D    I-Alkaloid114712692
It    O
has    O
been    O
tested    O
on    O
mice    O
and    O
found    O
to    O
be    O
five    O
times    O
more    O
potent    O
than    O
the    O
former    O
version    O
.    O

Kynurenic    B-Alkaloid114712692
acid    I-Alkaloid114712692

kynurenic    B-Alkaloid114712692
acid    I-Alkaloid114712692

Kynurenic    B-Alkaloid114712692
acid    I-Alkaloid114712692

Dysfunctional    O
states    O
of    O
distinct    O
steps    O
of    O
the    O
kynurenine    O
pathway    O
(    O
e.g.    O
kynurenine    O
,    O
kynurenic    B-Alkaloid114712692
acid    I-Alkaloid114712692
,    O
quinolinic    O
acid    O
,    O
anthranilic    O
acid    O
,    O
3    O
-Hydroxykynurenine    O
)    O
have    O
been    O
described    O
for    O
a    O
number    O
of    O
disorders    O
,    O
e.g.    O
:    O

This    O
is    O
one    O
of    O
several    O
"    O
Solanum    O
"    O
species    O
that    O
contain    O
solasodine    B-Alkaloid114712692
.    O

Solasodine    B-Alkaloid114712692

Palau'amine    B-Alkaloid114712692

Muscazone    B-Alkaloid114712692
is    O
another    O
compound    O
that    O
has    O
more    O
recently    O
been    O
isolated    O
from    O
European    O
specimens    O
of    O
the    O
fly    O
agaric    O
.    O

A.    O
flavus    O
"    O
also    O
produces    O
other    O
toxic    O
compounds    O
including    O
sterigmatocystin    O
,    O
cyclopiazonic    O
acid    O
,    O
kojic    O
acid    O
,    O
β-nitropropionic    O
acid    O
,    O
aspertoxin    O
,    O
aflatrem    O
,    O
gliotoxin    B-Alkaloid114712692
,    O
and    O
aspergillic    O
acid    O
.    O

Gliotoxin    B-Alkaloid114712692
is    O
a    O
sulfur    O
-    O
containing    O
mycotoxin    O
produced    O
by    O
several    O
species    O
of    O
fungi    O
under    O
investigation    O
as    O
an    O
antiviral    O
agent    O
.    O

Sanguinarine    B-Alkaloid114712692
and    O
dihydrosanguinarine    B-Alkaloid114712692
are    O
two    O
major    O
toxic    O
alkaloids    O
of    O
argemone    O
oil    O
,    O
which    O
cause    O
widespread    O
capillary    O
dilatation    O
,    O
proliferation    O
and    O
increased    O
capillary    O
permeability    O
.    O

Some    O
alkaloids    O
are    O
colored    O
,    O
like    O
berberine    B-Alkaloid114712692
(    O
yellow    O
)    O
and    O
sanguinarine    B-Alkaloid114712692
(    O
orange    O
)    O
.    O

The    O
Madagascan    O
periwinkle    O
"    O
Catharanthus    O
roseus    O
"    O
L.    O
is    O
the    O
source    O
for    O
a    O
number    O
of    O
important    O
natural    O
products    O
,    O
including    O
catharanthine    B-Alkaloid114712692
and    O
vindoline    O
and    O
the    O
vinca    B-Alkaloid114712692
alkaloid    I-Alkaloid114712692
it    O
produces    O
from    O
them    O
:    O
leurosine    O
and    O
the    O
chemotherapy    O
agents    O
vinblastine    O
and    O
vincristine    O
,    O
all    O
of    O
which    O
can    O
be    O
obtained    O
from    O
the    O
plant    O
.    O

There    O
are    O
also    O
dimeric    O
alkaloids    O
formed    O
from    O
two    O
distinct    O
monomers    O
,    O
such    O
as    O
the    O
"    O
vinca    O
"    O
alkaloids    O
vinblastine    O
and    O
vincristine    O
,    O
which    O
are    O
formed    O
from    O
the    O
coupling    O
of    O
catharanthine    B-Alkaloid114712692
and    O
vindoline    O
.    O

Imperialin    B-Alkaloid114712692
(    O
imperialine    B-Alkaloid114712692
or    O
peiminine    B-Alkaloid114712692
)    O
is    O
an    O
alkaloid    O
found    O
in    O
the    O
bulbs    O
of    O
species    O
of    O
the    O
genus    O
"    O
Fritillaria    O
"    O
,    O
where    O
it    O
occurs    O
to    O
the    O
extent    O
of    O
0.1    O
-    O
2.0%    O
.    O

Huperzine    B-Alkaloid114712692
A    I-Alkaloid114712692
while    O
promising    O
,    O
requires    O
further    O
evidence    O
before    O
its    O
use    O
can    O
be    O
recommended    O
.    O

Drugs    O
containing    O
Huperzine    B-Alkaloid114712692
A    I-Alkaloid114712692
and    O
Donepezil    O

Its    O
ingredient    O
michellamine    B-Alkaloid114712692
B    O
,    O
an    O
acetogenic    O
napthyl    O
isoquinoline    O
alkaloid    O
,    O
contained    O
in    O
mature    O
leaves    O
,    O
is    O
the    O
active    O
principle    O
.    O

Pelargonic    B-Alkaloid114712692
acid    I-Alkaloid114712692
vanillylamide    I-Alkaloid114712692
or    O
Nonivamide    O

Despite    O
being    O
armed    O
,    O
AFOs    O
carry    O
the    O
standard    O
issue    O
telescopic    O
or    O
rigid    O
baton    O
,    O
CS    O
/    O
PAVA    B-Alkaloid114712692
incapacitant    O
spray    O
,    O
and    O
Speedcuffs    O
on    O
the    O
duty    O
belt    O
.    O

Common    O
lachrymators    O
include    O
pepper    O
spray    O
(    O
OC    O
gas    O
)    O
,    O
PAVA    O
spray    O
(    O
nonivamide    B-Alkaloid114712692
)    O
,    O
CS    O
gas    O
,    O
CR    O
gas    O
,    O
CN    O
gas    O
(    O
phenacyl    O
chloride    O
)    O
,    O
bromoacetone    O
,    O
xylyl    O
bromide    O
,    O
syn    O
-    O
propanethial    O
-    O
S    O
-    O
oxide    O
(    O
from    O
onions    O
)    O
,    O
and    O
Mace    O
(    O
a    O
branded    O
mixture    O
)    O
.    O

Sinomenine    B-Alkaloid114712692

"    O
Veratrum    O
"    O
species    O
contain    O
highly    O
toxic    O
steroidal    O
alkaloids    O
(    O
e.g.    O
veratridine    B-Alkaloid114712692
)    O
that    O
activate    O
sodium    O
ion    O
channels    O
and    O
cause    O
rapid    O
cardiac    O
failure    O
and    O
death    O
if    O
ingested    O
.    O

veratridine    B-Alkaloid114712692

Flow    O
-    O
FISH    O
was    O
first    O
published    O
in    O
1998    O
by    O
Rufer    O
et    O
al    O
.    O
as    O
a    O
modification    O
of    O
another    O
technique    O
for    O
analyzing    O
telomere    O
length    O
,    O
Q    O
-    O
FISH    O
,    O
that    O
employs    O
peptide    O
nucleic    O
acid    O
probes    O
of    O
a    O
3'-CCCTAACCCTAACCCTAA-5    O
'    O
sequence    O
labeled    O
with    O
a    O
fluorescin    O
fluorophore    O
to    O
stain    O
telomeric    O
repeats    O
on    O
prepared    O
metaphase    O
spreads    O
of    O
cells    O
that    O
have    O
been    O
treated    O
with    O
colcemid    B-Alkaloid114712692
,    O
hypotonic    O
shock    O
,    O
and    O
fixation    O
to    O
slides    O
via    O
methanol    O
/    O
acetic    O
acid    O
treatment    O
(    O
protocol    O
available    O
online    O
)    O
.    O

Ecgonidine    O
(    O
anhydroecgonine    O
)    O
is    O
an    O
alkaloid    O
related    O
to    O
ecgonine    B-Alkaloid114712692
and    O
cocaine    O
.    O

#    O
Ecgonine    B-Alkaloid114712692

ecgonine    B-Alkaloid114712692
—    O
its    O
esters    O
and    O
derivatives    O
which    O
are    O
convertible    O
to    O
ecgonine    O
and    O
cocaine    O

Methylecgonine    B-Alkaloid114712692
cinnamate    I-Alkaloid114712692
,    O
an    O
alkaloid    O
widely    O
considered    O
inactive    O
in    O
its    O
own    O
right    O
,    O
but    O
postulated    O
to    O
be    O
active    O
under    O
pyrolysis    O
.    O

Penicillium    O
paxilli    O
is    O
an    O
anamorph    O
,    O
saprophytic    O
species    O
of    O
the    O
genus    O
of    O
"    O
Penicillium    O
"    O
which    O
produces    O
paxilline    B-Alkaloid114712692
,    O
paxisterol    O
,    O
penicillone    O
,    O
pyrenocine    O
A    O
,    O
paspaline    O
B    O
and    O
verruculogene    O
.    O
"    O

Cylindrospermopsin    B-Alkaloid114712692
(    O
abbreviated    O
to    O
CYN    O
or    O
CYL    O
)    O
was    O
first    O
discovered    O
after    O
an    O
outbreak    O
of    O
a    O
mystery    O
disease    O
on    O
Palm    O
Island    O
in    O
Australia    O
.    O

Cylindrospermopsin    B-Alkaloid114712692
.    O

Amides    O
of    O
lysergic    O
acid    O
,    O
lysergamides    B-Alkaloid114712692
,    O
are    O
widely    O
used    O
as    O
pharmaceuticals    O
and    O
as    O
psychedelic    O
drugs    O
(    O
LSD    O
)    O
.    O

Lysergamides    B-Alkaloid114712692

Ergoline    B-Alkaloid114712692
derivatives    O
(    O
lysergamides    B-Alkaloid114712692
)    O
are    O
probably    O
responsible    O
for    O
the    O
entheogenic    O
activity    O
.    O

Norcodeine    B-Alkaloid114712692

#    O
Norcodeine    B-Alkaloid114712692

Oxpheneridine    O
(    O
Carbamethidine    O
)    O
is    O
a    O
piperidine    B-Alkaloid114712692
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    O
(    O
meperidine    O
)    O
.    O

It    O
may    O
be    O
cleaved    O
by    O
bases    O
,    O
typically    O
a    O
solution    O
of    O
piperidine    B-Alkaloid114712692
:    O

20%    O
Piperidine    B-Alkaloid114712692
in    O
dimethylformamide    O
(    O
Fmoc    O
Group    O
has    O
an    O
approximate    O
half    O
life    O
of    O
6    O
seconds    O
in    O
this    O
solution    O
)    O

Sameridine    O
is    O
a    O
piperidine    B-Alkaloid114712692
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    O
(    O
meperidine    O
)    O
.    O

Pethidine    O
intermediate    O
A    O
is    O
a    O
piperidine    B-Alkaloid114712692
derivative    O
that    O
is    O
a    O
precursor    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    O
(    O
meperidine    O
)    O
.    O

Two    O
polymeric    O
structures    O
are    O
possible    O
when    O
polymerizing    O
DADMAC    O
:    O
"    O
N    O
"-    O
substituted    O
piperidine    B-Alkaloid114712692
structure    O
or    O
"    O
N    O
"-    O
substituted    O
pyrrolidine    O
structure    O
.    O

HDEP-28    O
or    O
ethylnaphthidate    O
is    O
a    O
piperidine    B-Alkaloid114712692
based    O
stimulant    O
drug    O
,    O
closely    O
related    O
to    O
ethylphenidate    O
,    O
but    O
with    O
the    O
benzene    O
ring    O
replaced    O
by    O
naphthalene    O
.    O

piperidine    B-Alkaloid114712692

piperidine    B-Alkaloid114712692

The    O
synthesis    O
of    O
physiologically    O
active    O
derivatives    O
of    O
piperidine    B-Alkaloid114712692
(    O
anesthetics    O
,    O
analgesics    O
,    O
and    O
other    O
drugs    O
)    O
,    O
technology    O
development    O
and    O
industrial    O
development    O
of    O
high    O
-    O
output    O
painkiller    O
"    O
promedol    O
"    O
;    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
(    O
E    O
,    O
E)-piperoyl    O
-    O
CoA    O
and    O
piperidine    B-Alkaloid114712692
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
[    O
[    O
N-[(E    O
,    O
E)-piperoyl]-piperidine    O
]    O
]    O
.    O

Of    O
these    O
three    O
piperidine    B-Alkaloid114712692
,    O
desoxypipradrol    O
has    O
the    O
longest    O
elimination    O
half    O
-    O
life    O
,    O
as    O
it    O
is    O
a    O
highly    O
lipophilic    O
molecule    O
lacking    O
polar    O
functional    O
groups    O
that    O
are    O
typically    O
targeted    O
by    O
metabolic    O
enzymes    O
,    O
giving    O
it    O
an    O
extremely    O
long    O
duration    O
of    O
action    O
when    O
compared    O
to    O
most    O
psychostimulants    O
.    O

:    O
(    O
iii    O
)    O
by    O
substitution    O
in    O
the    O
piperidine    B-Alkaloid114712692
ring    O
with    O
alkyl    O
or    O
alkenyl    O
groups    O
;    O

It    O
is    O
closely    O
related    O
to    O
the    O
drug    O
prodine    O
,    O
the    O
only    O
difference    O
being    O
that    O
meprodine    O
has    O
an    O
ethyl    O
group    O
rather    O
than    O
a    O
methyl    O
at    O
the    O
3-position    O
of    O
the    O
piperidine    B-Alkaloid114712692
ring    O
.    O

Examples    O
of    O
cyclic    O
amines    O
include    O
the    O
3-membered    O
ring    O
aziridine    O
and    O
the    O
six    O
-    O
membered    O
ring    O
piperidine    B-Alkaloid114712692
.    O

With    O
other    O
amines    O
such    O
as    O
piperidine    B-Alkaloid114712692
the    O
ring    O
-    O
opened    O
compound    O
after    O
loss    O
of    O
hydrogen    O
bromide    O
to    O
the    O
nitrile    O
is    O
also    O
the    O
isolated    O
reaction    O
product    O
:    O

Piperidine    B-Alkaloid114712692
(    O
hexahydropyridine    O
)    O


